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Abstract
Classical receptor theory is largely built on assumptions of monomeric receptors. In this
thesis, we contribute to receptor theory by considering the now widely accepted cases of
dimeric receptors. The implications of dimerisation for drug discovery and therapeutics
remain unclear. Therefore, a theoretical consideration of ligand binding and signalling
via receptor dimers is warranted. Here, we develop mathematical models for ligand bind-
ing at dimerised and dimerising receptors. A key factor in developing these theoretical
models is cooperativity across the dimer, whereby binding of a ligand to one protomer
affects the binding of a ligand to the other protomer. The effects of cooperativity on
binding dynamics are a primary point of interest.
The first models we present focus on G protein-coupled receptors, where we assume
that all receptors are pre-dimerised. Ligand binding models give linear systems of differ-
ential equations which we use to analyse time course behaviours. At equilibrium, these
models may exhibit multi-phasic log dose response curves, critically depending on co-
operativity factors. When considering receptor activation, we see dose response curves
that are indicative of non-standard ligand-receptor interactions, giving a quantitative
and qualitative platform for analysing and interpreting data when dimers are suspected.
A ligand induced model for vascular endothelial growth factor receptors is developed,
whereby receptors exist constitutively as monomers and dimerise in response to ligand
binding. The resulting nonlinear system of differential equations is investigated using
numerical computations and perturbation methods. We see an excellent fit to published
data, validating the model.
The utility of our models in parameter estimation is explored theoretically using
structural identifiability analysis. This determines which parameters can be theoretically
estimated from fitting. This analysis is valuable but often overlooked when fitting to
ligand-receptor interaction models. We explore the identifiability of some canonical lig-
and binding models, and our dimer binding models, providing a tutorial and results to
contribute to the receptor theory toolbox.
Acknowledgements
First and foremost I am extremely grateful to my supervisors, Dr Gibin Powathil, Dr
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1.2.1 Cell signalling: Ligand binding initiates a signalling cascade that results
in a cellular response.
1.2.2 Drugs can be classified depending on how they affect the cell’s response.
Agonists increase the response and can be full or partial, antagonists pro-
duce no response and inverse agonists reduce the response. Response is
considered as a percentage of the maximal response.
1.2.3 Ligand dissociation is observed by removing the ligand as it dissociates
from receptors.
1.3.1 The GPCR is made up of a N-terminus, C-terminus and 7 membrane
spanning domains [72].
1.3.2 The G protein cycle [138].
1.5.1 The first two-state model. A ligand A binds a receptor R creating the
complex AR. Binding causes the receptor to activate, creating AR∗ and
the signal is altered [76].
1.5.2 The modified two-state model [94]. A modification of the original two-
state model, a receptor can now also activate in the absence of ligand,
represented by R∗. Cooperativity factor α represents intrinsic efficacy of
the ligand.
1.5.3 Schematic: The ternary complex model [31]. Ligands or G proteins can
bind a free receptor, creating AR and RG, or both can bind, creating
ARG. Cooperativity factor in this model is γ.
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1.5.4 Schematic: The extended ternary complex model [68]. Receptors, in this
model, can bind a ligand (AR), activate (R∗ and AR∗), though G proteins
can only bind activate receptors (R∗G and AR∗G). This model contans
both cooperativity factors α (from the two-state model) and γ (from the
first ternary complex model).
1.5.5 Schematic: The cubic ternary complex model [133]. All combinations of
bound receptors, active receptors and receptors with G proteins attached
are possible. Along with the two existing cooperativity factors α and γ,
two new cooperativity factors, β and δ, are introduced.
1.6.1 Schematic for a competition binding scenario. Labelled ligand, A, com-
petes with unlabelled ligand, B, for receptor R.
1.6.2 Concentration of u and v (equations (1.43)) are plotted on a log-log scale to
highlight the time course dynamics on the different timescales. Parameters
used for the plot are λ = 3.4, κ = 6.7, ε = 1e− 2.
1.6.3 The numerical solution (to equations (1.42))is plotted together with the
inner and outer approximated solutions. The approximations in each re-
gion show a good approximation to the curves. Parameters used for the
plot are λ = 3.4, κ = 6.7, ε = 1e− 2.
1.6.4 Plotting the concentration curves for all species individually, for a com-
petition binding with monomeric receptor model, using three different pa-
rameter sets. Although all curves have the same measured output (concen-
tration of [AR]) curve, non-identifiability can be seen from the differences
in the different species curves.
2.1.1 Schematic: A ligand A binds to one side of a dimer, R, creating AR. A
second ligand subsequently binds this complex, creating ARA.
2.1.2 LogDR curves (plotted using equation (2.9)) for α ranging from extreme
negative to extreme positive cooperativity. We see that extra inflections
appear in Abound when we have extreme low cooperativity.
2.1.3 The binding of ligand A to a pre-dimerised receptor results in slight peaks
in [AR], while positive cooperativity leads to all dimers becoming dual
bound. The plot shows a numerical solution to the system in equations
(2.1). We use a ligand concentration of [A] = 10−8M while the cooperativ-
ity factors were set at α+ = 2 and α− = 0.01 giving positive cooperativity.
2.1.4 Plot shows a numerical solution to equations (2.1) for a varying ligand
concentration. With high levels of [A] in the system we no longer see
peaks in [AR]. Cooperativity values are fixed at α+ = 2 and α− = 0.01.
2.1.5 Plot shows a numerical solution to equations (2.1) for a varying forward
cooperativity factor. As we move from positive to negative cooperativity
we see a more pronounced peak in [AR] with Abound tending to lower con-
centrations. Ligand concentration for the plot is [A] = 10−8M .The value
α− = 1 was fixed so that cooperativity depends solely on α+.
2.2.1 Schematic: Two ligands, A and B compete for binding sites on dimer R.
2.2.2 Schematic of the two-ligand dimer model presented by May et al. in [83].
2.2.3 Plotting logDR curves, using equation (2.39), for varying α shows extra
inflections when we have low A-A cooperativity regardless of [B]. Other
cooperativity factors are fixed at β = γ = 1.
2.2.4 Individual species plots (equations (2.35)) for a varying α help to under-
stand the effects of cooperativity on the dose response curves. Competition
ligand concentration is fixed at B = 10−8M , while β = γ = 1.
2.2.5 Plotting logDR curves, using equation (2.39), for varying β shows extra
inflections appear when we have both low B-B cooperativity and low [B].
Other cooperativity factors are fixed at α = γ = 1.
2.2.6 Individual species plots for a varying β help to understand the effects of co-
operativity on the dose response curves. Competition ligand concentration
is fixed at B = 10−5M , while α = γ = 1.
2.2.7 Plotting logDR curves, using equation (2.39), for varying γ shows extra
inflections when we have high A-B cooperativity as well as low [B]. Other
cooperativity factors are fixed at β = γ = 1.
2.2.8 Individual species plots for a varying γ help to understand the effects of co-
operativity on the dose response curves. Competition ligand concentration
is fixed at B = 10−8M , while β = γ = 1.
2.2.9 In the time course plot, we have a numerical solution to the system in
equations (2.28), where we see peaks in both [AR] and [BR]. Cooperativity
values are α+ = β+ = γ+ = 2, α− = β− = γ− = 0.01, while ligand
concentrations used are [A] = 10−8M , [B] = 2× 10−8M .
2.2.10Plotting the numerical solution to equations (2.28) with a varying α+ while
all other cooperativity factors equal 1. Increasing α+ results in increases
in [ARA]. Ligand concentrations are [A] = 10−8M , [B] = 2× 10−8M .
2.2.11Plotting the numerical solution to equations (2.28) with a varying β+ while
all other cooperativity factors equal 1. Increasing β+ results in increases
in [BRB]. Ligand concentrations are [A] = 10−8M , [B] = 2× 10−8M .
2.2.12Plotting the numerical solution to equations (2.28) with a varying γ+ while
all other cooperativity factors equal 1. Increasing γ+ results in increases
in [ARB]. Ligand concentrations are [A] = 10−8M , [B] = 2× 10−8M .
2.3.1 Schematic: the binding of a single ligand to a pre-formed heterodimer.
2.3.2 Plotting logDR curves, using equation (2.54), for varying α show extra
inflections appear for heterodimers, similar to those in the homodimer
binding curves.
2.3.3 Plotting the numerical solution to equations (2.44) shows peaks appearing
in the time course curves for [AR1-R2] and [R1-R2A]. Cooperativity values
used for the plot are α+ = 2 and α− = 0.01, while ligand concentration is
[A] = 10−8M .
2.3.4 Plotting the numerical solution to equations (2.44) for a range of both
cooperativity factors (α+ and α−) result in peaks appearing in some of the
[AR1-R2] and [R1-R2A] curves. Ligand concentration used is [A] = 10
−8M .
3.1.1 The binding of a ligand A, and activation of pre-dimerised receptors show
a spherical schematic describing interactions with ten dimer complexes.
Binding is determined by KA, while activation Kact. Cooperativity factors
α, λ, ν and ξ describe crosstalk and the more complex interactions.
3.3.1 The logDR Abound curve for this activation model (equation (3.8)) is plot-
ted alongside the logDR Abound curve for the binding model (Section 2.1,
equation (3.9)). With equal binding parameters we see that the curves
appear to be the equal.
3.3.2 Plotting a logDR curve (equation (3.12)) for a range of values for binding
cooperativity factor α. While all signal curves have a bell shape, increasing
α decreases the peak size.
3.3.3 Plotting a logDR curve (equation (3.18)) for a range of values for activation
cooperativity factor λ. Increasing λ increases the signal for all concentra-
tion of [A].
3.3.4 Plotting a logDR curve (equation (3.26)) for a range of values for efficacy
parameter ν. This parameter determines whether the ligand acts as an
agonist (when ν > 1), or inverse agonist (ν < 1), while ν = 1 shows a
curve with a small peak.
3.3.5 We plot the signal curve (equation (3.26)) for values of ν close to one,
showing the smoothing out of the peak.
3.3.6 Plotting two sets of logDR curve (equation (3.33)), with ν = 100, ξ = 0.1
and also ν = 0.1, ξ = 100. The symmetry in the model sphere means that,
although the curves of [R∗AR] and [RAR
∗] change with varying ν and ξ,
their sum, as well as all other concentrations, is equal.
3.3.7 Plotting a logDR curve (equation (3.6)) for a range of values for weighting
parameter ω, with all cooperativity factors fixed at one. Increasing ω
increases the contribution symmetric dimers have to the signal, which then
increases the signal.
3.4.1 We fix ξ = 1 and vary λ on each row, ν in each column and α within
each subplot (using equation (3.6)). We see effects such as inflections and
overshoots in some of the curves.
3.4.2 We plot dose response curves (equation (3.6)) for α = 10−4, ν = 10 and
λ = 0.1, as well as for these each being set individually.
3.4.3 We fix ξ = ν and vary λ on each row, ν in each column and α within each
subplot. We see some extra inflections but now no overshoots in the curve.
4.1.1 Ligand binding and dimerisation is a two step process whereby a two poled
ligand (in red) first binds a monomeric receptor (blue) before then binding
a second and instantaneously dimerising the monomers.
4.1.2 Schematic representing the reactions resulting from the binding of a two
poled ligand to two monomeric receptors.
4.2.1 LogDR curves for varying cooperativity factor, ψ. The plots show the over-
all signal as well as concentrations of R (equation (4.7a)), AR (equation
(4.7b)) and RAR (equation (4.7c)).
4.3.1 A numerical investigation into the effects of cooperativity factors ψ+ and
ψ−. The columns show the overall signal as well as individual species
(equations 4.1) while in each row we fix the ψ+ value. Each plot then shows
a varied ψ−. Plots are created with ligand concentration [A] = 10
−10M .
4.5.1 Both the solution to the full system in equations (4.32) is plotted along
side the solution of the reduced, approximated system (equations (4.34))
in red. Conservation of receptors is used to show the approximation for q.
Parameters used to create plots are α = β = 1 and γ = ε = 0.001.
4.5.2 Numerical solutions of the full system (equation (4.35)), on a log-log scale.
Plot created with α = 6.8, β = 1/ε, γ = 1.4 with ε = 10−4.
4.5.3 Plotting the numerical solution of equation (4.35) with inner (equation
(4.40))), intermediate (equation (4.65)) and outer (equations (4.52) and
(4.55)) solutions. The intermediate solution matches both the inner and
outer solution, creating a full approximation to the numerical solution.
Conservation of receptors is used to show the approximation for q. Plot
created with α = 6.8, γ = 1.4 and β = ε = 10−4.
4.5.4 Numerical solutions of the full system in equation (4.70) on a log-log scale.
Plot created with α=6.8, β=1, γ = ε = 10−4.
4.5.5 Plotting the numerical solution of equation (4.70) with asymptotic solu-
tions (4.88) and (4.108) show good agreement in both regions. Parameters
used to create plot are α=6.8, β=1, ε=1e-4.
4.6.1 Data published in [101] is used to estimate the model parameters. Exper-
iments were performed using five concentrations of three different VEGF
isoforms (VEGF 165a-TMR, VEGF 165b-TMR and VEGF 121a-TMR) and
are scaled with respect to Rtot. An excellent fit to the data is seen from
fitting to all data sets simultaneously. Parameter values returned can be
seen in Table 4.2.
4.6.2 Individual species curves using the estimated parameters show peaks some
of the [RAR] curves.
5.2.1 An algorithm for using the transfer function method to determine identi-
fiability.
5.2.2 An algorithm for using the Taylor series method to determine identifiabil-
ity.
5.2.3 An algorithm for using the similarity transformation method to determine
identifiability.
5.3.1 Three sets of parameters are used to plot the system given in equations
(5.23). All three parameter sets give the same measured output curve,
Abound. However, non-identifiability can be seen in the individual species
curves. Each set of plots is created using the values in Table 5.1 together
with [A] = 10−8M .
5.3.2 Three sets of parameters are used to plot the system given in equations
(5.45). All three parameter sets give the same measured output curve,
Abound. However, non-identifiability can be seen in the individual species
curves. Each set of plots is created using the values in Table 5.2 together
with [A] = 10−8M .
5.3.3 Three sets of parameters are used to plot the system given in equations
(5.90). All three parameter sets give the same measured output curve,
Abound. However, non-identifiability can be seen in the individual species
curves. Each set of plots is created using the values in Table 5.3 together
with [A] = 10−8M .
5.3.4 Three sets of parameters are used to plot the system given in equations
(5.125). All three parameter sets give the same measured output curve,
Abound. However, non-identifiability can be seen in the individual species
curves. Each set of plots is created using the values in Table 5.4 together
with [A] = 10−8M .
5.3.5 The STRIKE-GOLDD toolbox [129] confirms the identifiability of the pa-





In the pursuit of drug discovery and therapeutics, pharmacological analysis is required to
understand the interactions of drug/ligand molecules and cell surface receptors. Classical
pharmacological receptor theory falls short of analysing the dynamics of the range of these
interactions, despite an increased recognition of their importance. In this thesis, we will
develop new mathematical models to investigate ligand-cell interactions when receptor
dimerisation is suspected, and use mathematical techniques to analyse these models in
order to give important insights into the pharmacological impacts. In this chapter, we
review the underlying pharmacology as well as some of the mathematical techniques used
throughout the thesis.
1.2 Basic pharmacology principles
Pharmacology is a branch of medical science that studies the actions of ligands. Not
only is pharmacology essential in discovering new ligands and improving the effectiveness
of existing ligands, whilst reducing unwanted side effects, but is also used to help in
understanding why some ligands are effective for some people but not others. Although
pharmacology has been studied for over a century the underlying concepts remain the
same, and these begin with the ligand. A ligand is a substance that is either man-
made, natural or endogenous molecule that binds to a protein and causes a physiology or
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psychology effect on the body [66]. A detailed history of the development of pharmacology
can be found in [69].
1.2.1 Pharmacokinetics/pharmacodynamics
Pharmacology can be divided into two broad categories: pharmacokinetics and pharma-
codynamics. Pharmacokinetics describes the effect the body has on the ligand as it moves
through the body. This includes processes such as absorption, distribution, metabolism
and elimination [64]. Pharmacodynamics focuses on the effect the ligand has on the body
once it reaches the site of action, and so dose-dependent issues such as toxicity and effi-
cacy are considered. Pharmacodynamics is also used to determine what the appropriate
use for the ligand is and what disease or symptom it will target. In this thesis, we focus
on receptor theory, which falls under pharmacodynamics.
1.2.2 Cell surface receptors
A cell surface receptor is a protein that lies on the surface of a cell, and is the component
that interacts with the ligand and initiates the reactions that lead to an observed effect
[66]. There are many types of receptors in human cells, but the most well characterised
are G-protein coupled receptors (GPCRs), enzyme-linked receptors and ligand-gated ion
channels.
A ligand is a molecule that binds with a specific receptor and can be a drug or endoge-
nous molecules such as hormones [118]. When a ligand molecule is in close proximity to a
relevant receptor they bind together, by means of a chemical bond, setting off a chain of
reactions that alter the activities of the cell on which the receptor resides. For binding to
occur the ligand molecule must be the same shape as the receptor’s binding site, so that
these fit together in a lock and key style manner [64, 107]. The ‘strength’ with which a
ligand binds to a receptor is an important concept, known as affinity.
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1.2.3 Cell signalling
To elicit a response a signal needs to be transmitted into the interior of the cell. In Figure
1.2.1 we see an example of how ligand-receptor binding leads to a physiological response.
Ligands can act as agonists, antagonists or inverse agonists (see Section 1.2.6) based on
their effect on a cell’s signal. Upon an agonist binding, a receptor becomes activated,
which initiates a conformational change in the receptor, allowing for the binding of other
molecules or proteins. This subsequently initiates a chain of biochemical reactions within
the cell, which ultimately leads to a cellular response, that is, a change in the cell’s
behaviour or characteristic. This is known as a signal transduction pathway. Examples
of signalling pathways for GPCRs can be seen in Section 1.3.2.
Figure 1.2.1: Cell signalling: Ligand binding initiates a signalling cascade that results in
a cellular response.
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1.2.4 Ligand binding assays
A ligand-binding assay is an experiment that assesses or measures ligand binding, and is
used to characterise ligand-receptor interactions. There is a range of types of ligand bind-
ing assays, but most common methods are based on radioligand binding or fluorescence
detection [107, 69]. Radioligand binding requires the ligand molecules to be radiolabelled
and then radioactive decay is observed. Fluorescent detection techniques utilise molecules
that increase in fluorescence when in close proximity to a receptor. However, all methods
are based on being able to discern bound molecules from unbound ones. Ligand bind-
ing experiments can be categorised as either saturation, competition or kinetic binding
experiments [66, 57].
1.2.5 Saturation binding assays and dose-response curves
Saturation binding experiments measure the amount of ligand bound once equilibrium
(or steady-state) is reached, for a range of ligand concentrations. The primary aim of
these experiments is to estimate the total number of receptors as well as the equilibrium
binding rate of the ligand, that is, to determine the affinity of the ligand for the receptor
[66]. A common way to analyse this data is a Scatchard plot, where ‘bound ligand‘ is
plotted against ‘bound ligand divided by the number of free receptors’. However, this
method has limitations. As the concentration of bound ligand appears on both the x
and y axis, the effect of any experimental errors is compounded. Furthermore, nonlinear
plots are difficult to interpret. For these reasons we do not use Scatchard plots in our
analysis, however more information on these can be found in [69].
An alternative way to analyse the data is a dose-response curve, (as can be seen in
Figure 1.2.2) that is, a plot relating the ligand concentration to the amount of ligand
bound, or output response of a cell. We note that, we use term dose-response to also
encompass concentration-response. While these curves can be used to study the affinity
of a ligand, they are also used in experiments where a cell’s response is measured, as
opposed to ligand bound. In this case, it is a ligand’s efficacy, that is, a ligand’s ability to
activate receptors and produce a response, and potency that is analysed, as opposed to
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affinity [107]. A common measurement that is considered in dose-response curves is the
EC50, that is defined as the concentration of a drug that gives half-maximal response.
1.2.6 Agonists and antagonists
Ligands are classified as agonists, antagonists (also referred to as neutral agonist) or in-
verse agonists, depending on how they affect the activation of a receptor and therefore
the resulting response [64]. We can see how each of these affect the dose-response rela-
tionship in Figure 1.2.2. Once bound an agonist increases the chances of the receptor
activating, and therefore, as the ligand concentration increases so does the response, until
the maximal response is reached. Agonists can be either full or partial agonists, with a
full agonist able to increase the response to 100% of the maximum possible response,
whereas a partial agonist can only achieve a partial response, regardless of the amount of
ligand present. Antagonists bind a receptor but have no effect on the response [66, 64].
These are most commonly used in competition binding to block or reduce the activity
of an agonist. Thus if we consider the dose-response relationship of an agonist with an
antagonist present, it will require a higher concentration of agonist to reach maximal ef-
fect than if the antagonist wasn’t present. Many receptors exist in a state of spontaneous
equilibrium; a number of receptors within a cell will activate without any outside factors
affecting them [78]. GPCRs, in particular, are known to behave in this way. An inverse
agonist binds a receptor and forces it to become inactive, thus reducing the constitutive
activity, and as such the basal receptor-induced response from the cell.
1.2.7 Competition binding assays
Competition binding experiments (sometimes referred to as displacement binding exper-
iments) measure the binding of a single concentration of a labelled ligand whilst in the
presence of a second, unlabelled ligand [95]. Ligands bind to, and therefore compete for,
the same domain on the receptors. Usually, the experiment is performed for a range of
concentrations of the unlabelled ligand, and measurements are taken once equilibrium
is reached. For each of the unlabelled ligand concentrations, the observation of interest
is, how much the binding of the labelled ligand is displaced or otherwise affected [66].
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Figure 1.2.2: Drugs can be classified depending on how they affect the cell’s response.
Agonists increase the response and can be full or partial, antagonists produce no response
and inverse agonists reduce the response. Response is considered as a percentage of the
maximal response.
For each of these experiments, the IC50 is determined. This is the amount of unlabelled
ligand that inhibits the response by 50%. This is the equivalent to the EC50, where the
IC50 relates to an antagonist ligand as opposed to an agonist.
Competition binding assays have a number of significant uses. Firstly, they are a fast
and efficient way to determine whether a ligand binds to a receptor. Also, results from
direct binding assays can be validated via competition binding. When competing with
a ligand where the potencies are known, this can validate that the correct receptor has
been identified. Finally, they are used to investigate the interactions of a ligand that has
a low affinity for the receptor, as these can be difficult to observe in direct binding assays
[86].
1.2.8 Kinetic binding assays
New technological developments, specifically fluorescence-based methods, have allowed
for real-time observations of ligand binding in living cells [70]. This has lead to a rise
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in kinetic binding studies, as more time-dependent data is available. These studies are
advantageous when compared to saturation and competition assays as they provide in-
formation about the rates at which a ligand binds to and dissociates from a receptor
individually, as opposed to only equilibrium values. This gives a more detailed view of
the ligand-receptor interactions and can aid in determining ligand safety levels. However,
kinetic binding methods can be more costly than saturation methods [51].
There are two general types of kinetic binding assays: association experiments and
dissociation (or washout) experiments. In an association binding experiment, all receptors
on the cell begin in an unbound form and binding is observed once the ligand is added.
This is useful, not only for determining the rate of association but also how long it takes
for equilibrium to be reached. Dissociation binding experiments are often performed
following association experiments, that is once the system is in equilibrium. At this point
the free ligand is removed by repeated washing, ensuring that no further ligand associates
with the receptors and the rate of decrease of effect is then observed. An example time
course of an association followed by dissociation curve can be seen in Figure 1.2.3. The
total number of receptors can be ascertained from dissociation experiments, as well as
the rate of dissociation [120].
1.3 G protein-coupled receptors
GPCRs are one of the largest families of cell surface receptors and one of the most
diverse. They mediate most of our cellular responses to hormones, neurotransmitters
and environmental stimulants, and are targets for up to approximately 50% of current
ligands [14]. GPCRs can be classified into four main families, rhodopsin (family A),
secretin (family B), glutamate (family C), adhesion and Frizzled/Taste2, although all
have a similar structure [126, 122]. This structure consists of an extracellular N-terminus,
an intracellular C-terminus and a middle section containing seven membrane-spanning
helices that pass through the cell membrane seven times in a serpentine pattern, with
three loops extending into the extracellular region [72]. This has led to them also being
referred to as seven-transmembrane domain receptors (7TM) receptors. This structure
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Figure 1.2.3: Ligand dissociation is observed by removing the ligand as it dissociates from
receptors.
can be seen in Figure 1.3.1. Ligand binding can occur on either the N-terminus or on any
of the extracellular loops [126]. Upon binding of an agonist, a conformational change in
the 7TM domain is initiated, activating the C-terminus which allows for the binding of
a G-protein.




G-proteins are heterotrimeric proteins, in that they consist of three subunits, namely α,
β and γ. These are each encoded with a unique gene. There are at least 20 types of α
subunits, and can be divided into four classes: Gs, Gq, Gi and Gt with each stimulating
or inhibiting different enzymes [138]. Whilst in an inactive state a molecule of guanine
diphosphate (GDP) is bound to the α subunit. When the GPCR becomes ligand bound
and, therefore, activated, the G-protein is able to bind to the receptor creating a tempo-
rary complex. This causes the GDP molecule to dissociate from the G-protein, leaving
the G-protein in an ‘empty’ state. In this form either a GDP molecule can rebind, or
instead a molecule of guanosine triphosphate (GTP) is able to bind [122].
The binding of GTP forces the G-protein to dissociate from the receptor and a further
conformational change is initiated. Upon dissociation, the G-protein splits into two parts,
with the α subunit breaking away from the G-protein. The β and γ subunits remain
bound together. The G-protein is now said to be active and the two parts are now
referred to as Gα and Gβγ [52]. Once in this form, the Gα and Gβγ units act as effector
molecules causing the release of second messengers. Deactivation occurs once the Gα unit
hydrolyses the GTP molecule, that is, one phosphate molecule is removed, back into a
GDP molecule. This allows for the reassociation of the Gα and Gβγ. This G-protein cycle
can be seen in Figure 1.3.2 and is also explained in [138] and [137].
1.3.2 Signalling pathways
There are two primary pathways that are activated by G-proteins, namely the cyclic-
adenosine monophosphate (cAMP) pathway and the phosphatidylinositol signalling path-
way [52, 122]. Both Gα and Gβγ subunits activate second messengers and subsequently,
these pathways. However, while the Gα pathways have been well researched, the signal
elicited from the Gβγ unit has been considered less important, hence, there is still much
unknown about their role in GPCR signalling [52]. Gα subclasses Gα(s) and Gα(i) regulate
production the second messenger of cyclic-adenosine monophosphate (cAMP), with Gα(s)
stimulating and Gα(i/o) inhibiting production of cAMP. Whereas subtypes Gα(o) and Gα(q)
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Figure 1.3.2: The G protein cycle [138].
activate phosphoinositol phospholipase C enzyme (PLC) [52].
1.3.3 Dimerised receptors
It has recently become accepted that GPCRs may exist as dimers or higher oligomers
[91, 92]. An oligomer is formed by the joining of multiple receptors by molecular bonds,
creating a single unit. A dimer is a special case of an oligomer consisting of two receptors.
Single receptors are often referred to as monomers. A dimer can be made up of two
identical monomers, then known as a homodimer, or similar but not identical monomers,
creating a heterodimer. Theoretical models for GPCR binding and signalling are based
on assumptions that receptors are all monomeric [138, 14]. When one site of the dimer
becomes bound, this has an effect on the binding characteristics of the other sites. This
is termed cooperativity, and the effect of cooperativity and cross-talk within the dimer is
something that is yet to be fully explored. Understanding cooperativity and the resulting
effects on ligand binding and signalling, as well as how these can be exploited for ligand
development purposes, is one of the the main aims for this thesis.
10
1.4 Vascular endothelial growth factors
The vascular endothelial growth factor (VEGF) family consists of five members, VEGF-A,
-B, -C, -D and placenta growth factor (PIGF), and is a sub-family of growth factors (GFs).
Similar to most GFs, VEGF is a multivalent ligand, in that each molecule possesses more
than one binding site, therefore, it can bind with as many receptors as there are sites
[3]. Many aspects of cellular function, including survival, proliferation, migration and
differentiation are regulated by VEGF [47, 99, 119]. VEGF binds to three VEGF receptors
(VEGFRs), namely VEGFR-1, -2 and -3. These are receptor tyrosine kinases that are
expressed predominately on endothelial cells and regulated by the VEGF ligand [99].
Like most other receptor tyrosine kinases (RTK), activation occurs upon dimerisation
[80, 3, 119]. It is thought that VEGFRs diffuse across the cell membrane as monomeric
receptors, although there is recent evidence suggesting that a percentage may exist as
dimers [82] (also see references within). Binding of a ligand to the extracellular domain
of the receptor triggers dimerisation with adjacent receptors, which leads to the receptors
becoming activated, then leading to trans-autophosphorylation of the receptors. This
provides a docking site for downstream signalling proteins, which results in the activation
of signalling pathways, and ultimately a response [99, 82, 80].
1.5 Mathematical modelling
Quantitative systems pharmacology (QSP) is a novel discipline within biomedical re-
search that uses mathematical and computational modelling techniques to address cur-
rent problems in the discovery and the development of therapies. QSP studies aim to
combine mechanistic modelling frameworks with clinical data to predict ligand efficacy
and toxicity and give insights into ligand action [116]. In turn this can help guide further
experiments to yield more meaningful results. The field of QSP has made many advances
in the past decade, with even the United States Food and Drug Administration (FDA)
accepting modelling and simulation results in evaluating ligand proposals [103, 104]. The
term mathematical pharmacology was officially coined by Van der Graaf [125] to describe
the recent emergence of the use of mathematical approaches to further understand phar-
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macological processes, and can be seen as a sub-discipline of QSP. In this section we
will review some key models, but first we present some of the underlying mathematical
techniques used in ligand modelling.
1.5.1 The law of mass action
The law of mass action was was first proposed by Guldberg and Waage over the period
1864-79 [79] and is the basis of all ligand- receptor modelling [69], although it was initially
derived to model only chemical reactions. Given two chemicals, the law of mass action
describes the rate at which these collide to form a new chemical complex. For example,
given chemicals A and B, with
A + B
k AB, (1.1)
then mass action, in its simplest form, states that the rate of the reaction is proportional
to the product of the concentrations of A and B. The parameter k is the rate constant
of the reaction. If we consider the reaction with respect to time we can say that the rate
of change of each concentration is
d [AB]
dt
= k [A] [B] , (1.2)
d [A]
dt
= −k [A] [B] , (1.3)
d [B]
dt
= −k [A] [B] , (1.4)
where the square brackets represent chemical concentrations. A concentration of ligand
is the number of moles of solute per litre of solution has units molar (M). It is important
to mention however, that the law of mass action is not a law in the sense that it holds
in any situation, for example, when dealing with particularly high or low concentrations
[65]. Reactions that do follow the law are described as elementary reactions.
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The reaction in (1.1) was used to demonstrate the law of mass action, however, many





This leads to the system of differential equations becoming
d [AB]
dt
= k+ [A] [B]− k−[AB], (1.6)
d [A]
dt
= −k+ [A] [B] + k−[AB], (1.7)
d [B]
dt
= −k+ [A] [B] + k−[AB], (1.8)
we can see that [AB] increases by consuming molecules of A and B but now also decreases
proportionally to the existing concentration of AB. Once the system reaches equilibrium,
thermodynamic principles (see Section 1.5.4) state that the rate of the forward reaction
is equal to the rate of the backward reaction. Hence at equilibrium
k+ [A] [B] = k− [AB] , (1.9)








where KD is generally called the equilibrium dissociation constant of the reaction. So far







In the forward reaction, two molecules of A are used, as opposed to one, to create the
complex AB. As the rate of reaction is proportional to the product of each concentration
the equation for A becomes
d [A]
dt
= −2k+ [A]2 [B] + k− [AB] . (1.12)
As every reaction uses two molecules of A but only one molecule of B to create a single














1.5.2 The Langmuir isotherm, occupancy theory and the Hill
equation
The first model of ligand binding was based on ‘The Langmuir adsorption isotherm’
[73], published by Irving Langmuir, although originally this was designed to describe
chemicals binding to metal surfaces [66]. These ideas were extended by Clark [29] to
describe agonist-receptor binding, and are encapsulated by what is currently known as












where KD = k−/k+. However, Langmuir proposed that we instead consider the amount
of ligand bound as a fraction of the total number of receptors. Defining ρA as the fraction
of bound receptors, we then have 1−ρA as the fraction of unbound, or available, receptors.
Langmuir’s isotherm model asserts that the amount of ligand binding is proportional to
the fraction of available receptors, the forward reaction rate and the ligand concentration,
that is
k+[A](1− ρA). (1.16)
Similarly, the amount of ligand unbinding is proportional to the amount of ligand bound
to receptors and the reverse reaction rate, that is
k−ρA. (1.17)
At equilibrium it is assumed that these are in balance, so set
k+[A](1− ρA) = k−ρA. (1.18)









as the fraction of bound receptors. This gives a basic measurement and quantification
of a ligand’s affinity [66]. The Hill-Langmuir equation is an extension of this. If we












This n is known as the Hill coefficient [106].
In 1968, Wagner [130] proposed that there is a relationship between the concentration







where E is the effect (or response), Emax is the maximal response and EC50 is the ligand
concentration that gives half maximal response. This Hill equation is most commonly
used in pharmacology for fitting to equilibrium data. The n in this equation is still re-
ferred to as the Hill coefficient, however, where in equation (1.21) it had a mechanistic,
biological representation, in this case the n is more empirical. With the equation in this
form, the Hill coefficient is used to measure cooperativity, with n > 1 giving positive
cooperativity, that is, once a receptor is bound by a single molecule the affinity for ligand
binding on that receptor is increased. Conversely, with n ≤ 1, the affinity for binding
is decreased once a receptor has bound one ligand molecule. These are concepts we use
throughout this thesis, though in a slightly different context. Further background on the
different forms and origins of the Hill equations can be found in [43].
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Following the work of Clark, the occupancy model was built on by a number of au-
thors. Ariëns [5] noticed a limitation of Clark’s model was that it described only binding
and did not consider the response elicited from binding. To overcome this Ariëns intro-
duced a new parameter representing intrinsic activity and proposed that a theoretical
response should be composed of this new parameter as well as the affinity parameter [110].
Both the models given by Clark and Ariëns are based on the assumption that the
percentage of the maximal response is equal to the percentage of bound receptors, that
is, 50 percent of receptors being bound leads to 50 percent of the maximal response being
elicited [110]. This was later shown by Stephenson [117], Furchgott [42] and Nickerson
[97] to not always be true. Stephenson [117] proposed that ligands have varying capa-
bilities to elicit a response. Hence, some ligands are able to elicit the maximal response
with only a small proportion of receptors bound. This became known as efficacy. Fur-
thermore, he introduced the idea of a partial agonist, whereby a ligand is only able to
elicit a fraction of the maximal response, even at maximal binding.
There were many modifications of these models, with one of the most notable being by
Furchgott [42] who proposed that efficacy is the product of the intrinsic efficacy parameter
(as defined by Ariëns [5]) and the concentration of active receptors [110]. This was a
particularly important development as it highlighted the dependence of the response on
the properties of both the ligand and the tissue. Mathematically, it can be stated that







where f is a (usually hyperbolic) function relating receptor occupancy and response, ε
represents intrinsic efficacy and Rtot is the total concentration of receptors [67, 69].
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1.5.3 The operational model of agonism
The operational model of agonism was developed by Black and Leff [11] and is an exten-
sion to the occupancy models. It was designed to overcome the limitations of existing
occupancy models, such as the reliance on the parameter ε which does not correlate to
any chemical identity. To derive their model they assumed a simple reversible reaction
between a agonist, A and receptor R, creating the complex AR, that follows the law of





where KD is the dissociation constant and Rtot is the total receptor concentration. This
function is a hyperbolic function (in fact, is a rectangular hyperbolic function). Black
and Leff assumed that the relationship between [AR] and the response must also be





where Emax is the maximal effect and KE is the value of [AR] that elicits half maximal
effect. Combining equations (1.24) and (1.25), we have
E =
[A]RtotEmax
KDKE + (Rtot +KE)[A]
, (1.26)







as a constant that characterises the operational efficacy [12], that is, the propensity of
the agonist to elicit a response [69], and substituting this in to equation (1.26) gives
E =
[A]τEmax
KD + (τ + 1)[A]
, (1.28)
This is extended to include non-hyperbolic curves so as to encompass possible receptor
cooperativity by the reintroduction of the Hill coefficient, as
E =
[A]nτnEmax
(KD + [A])n + τn[A]n
. (1.29)
This model is canonical in receptor theory and is still widely accepted and used in much
of the pharmacology community [67]. However, there are still areas requiring further
exploration. While the operational model allows for an agonist that can elicit either a
full or partial response, it cannot account for ligands that have no effect on the given
signal, or ligands that decrease the signal below the basal level. Furthermore, it is useful
only for equilibrium studies, although Hoare et al [54] make some steps towards extending
it to include kinetics.
1.5.4 The two state model
In 1957, del Castillo and Katz [21], and later Katz and Thesleff [63], proposed the con-
cept of receptor activation, although originally it was applied to only ligand-gated ion
channels. They proposed that receptors undergo a conformational change and can exist
in two states, a resting state and an active one [76], and the response is elicited only from
receptors that are active.
In their first model, del Castillo and Katz proposed that receptors remain in an in-
active form, in the absence of ligand, and activation only occurs upon ligand binding.
A schematic of the model can be seen in Figure 1.5.1. The model assumes a ligand A,
binds a free receptor R which creates the complex AR. Activation occurs subsequently
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to binding, and so AR∗ represents the receptor in a bound-activated state. Parameters






Figure 1.5.1: The first two-state model. A ligand A binds a receptor R creating the
complex AR. Binding causes the receptor to activate, creating AR∗ and the signal is
altered [76].
This simple model was later modified by Monod, Wyman and Changeux [94] who
suggested that receptors also undergo a conformational change and become activated in
the absence of ligand. This modified model allows for a basal response, coming from
constitutive activity of the receptor, in the absence of ligand, and assumes that ligand
binding changes the ratio of active to inactive receptors and, therefore, the functional
response. The schematic of this model is presented in Figure 1.5.2, where α is introduced











Figure 1.5.2: The modified two-state model [94]. A modification of the original two-state
model, a receptor can now also activate in the absence of ligand, represented by R∗.
Cooperativity factor α represents intrinsic efficacy of the ligand.
The advantage of this model is that it allows for a ligand to act as an antagonist or
inverse agonist, as well as a full or partial agonist. While an agonist will more likely bind
and stabilise an active receptor, an inverse agonist would act preferentially to an inactive
receptor. An antagonist would show no preference to either conformation [56].
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Detailed balance
The modified two-state model also includes the introduction of the new parameter α,
which multiplies the binding/activation rates of the second reactions. This parameter
must appear in both secondary reaction due to a concept called detailed balance, that
was introduced by Lewis [77] in 1925. Based upon the assumption that each elementary
reaction is reversible and should respect thermodynamics[48], detailed balance states that:
“Corresponding to every individual process there is a reverse process, and in a state
of equilibrium the average rate of every process is equal to the average rate of its reverse
process” [77]
In the model given in Figure 1.5.2, the parameter α represents the intrinsic efficacy of
the ligand and accounts for the change in propensity for receptor activation when ligand
is bound as well as change in affinity of the ligand for active receptors over inactive
receptors.
1.5.5 The ternary complex model
The first attempt to incorporate the G protein into receptor theory models was the ternary
complex model. developed by De Lean, Stadel and Lefkowitz[31] in 1980. They proposed
two models to describe the interactions between ligand, receptor, and G-protein. The
first assumes that the binding of a membrane component, such as a G protein, occurs se-
quentially to ligand binding (as we saw in Figure 1.3.2). The second, and more generally
accepted, is outlined schematically in Figure 1.5.3 and allows for the spontaneous binding
of a G protein in the absence of ligand. In this model, a ligand A or G protein, can bind
a free receptor R, creating the complexes AR and RG (with equilibrium binding rates
KA and KG) respectively. Furthermore, ligands and G proteins can bind a receptor that
is already bound by the alternate molecule, for example, a ligand can bind an already
formed RG complex, thus creating ARG. A signal is then assumed to be given from any













Figure 1.5.3: Schematic: The ternary complex model [31]. Ligands or G proteins can bind
a free receptor, creating AR and RG, or both can bind, creating ARG. Cooperativity
factor in this model is γ.
The model appears similar to the modified two-state model, with a signal being elicited
from an active receptor in the two-state model, or a bound G protein complex in the
ternary complex model. However, there is one key difference: in the two-state model the
efficacy of an agonist depends receptor density, while in the ternary model, the amount
of available G proteins also has a role in how sensitive the system is to an agonist [68].
1.5.6 The extended ternary complex model
The extended ternary complex model was developed in response to findings that showed
that GPCRs were able to spontaneously activate, and thus, activate G proteins, without
any ligand present [68]. The schematic of this model can be seen in Figure 1.5.4. This
model essentially combines the original ternary complex model and the two-state model.
In this model, a receptor can become active spontaneously, represented by R∗, or can be
induced upon ligand binding, AR∗. Similarly, a G protein can bind any active receptor.
It is assumed that a response is produced from active, G protein bound species, that is
R∗G and AR∗G [69]. The equilibrium constant for G protein binding is KG.
The cooperativity (or efficacy) parameters α and γ determine if a ligand acts as an
agonist/inverse agonist. If α > 1 and γ > 1, the ligand stabilises activation and G protein
binding, thus the ligand has positive efficacy and is considered an agonist. Conversely,
if α < 1, the inactive receptor state is stabilised, or γ < 1, the affinity of the G protein
for the receptor is reduced for the active receptor state, then the signal will be reduced












Figure 1.5.4: Schematic: The extended ternary complex model [68]. Receptors, in this
model, can bind a ligand (AR), activate (R∗ and AR∗), though G proteins can only bind
activate receptors (R∗G and AR∗G). This model contans both cooperativity factors α
(from the two-state model) and γ (from the first ternary complex model).
agonist. Although it is important to note that this only holds for systems that have a
basal level of activity. While this model is an improvement in terms of representing the
GPCR signalling mechanisms, the model is incomplete as interactions between inactive
receptors and G proteins are not represented.
1.5.7 The cubic ternary complex model
The cubic ternary complex model is the thermodynamically complete version of the ex-
tended ternary complex model which allows for interaction between the G protein and
inactive form of the receptor [133]. The model schematic can be seen in Figure 1.5.5.
Equilibrium rates KA, Kact and KG determine the equilibrium ratios of ligand binding,
receptor activation and G protein binding respectively. There are now four cooperativity
factors. While α and γ are defined as in the previous section when detailing the extended
ternary complex model, we also have the addition of two new cooperativity factors, β
and δ. In summary the effect of these parameters is as follows:
− The parameter α is the effect of ligand binding on activation and vice versa.
− The parameter β represents the effect of receptor activation on the coupling of a G
protein and vice versa.
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− The parameter γ is the effect ligand binding has on the coupling of a G protein and
vice versa.
− The parameter δ represents the effect of any two of ligand binding, receptor activa-














Figure 1.5.5: Schematic: The cubic ternary complex model [133]. All combinations of
bound receptors, active receptors and receptors with G proteins attached are possible.
Along with the two existing cooperativity factors α and γ, two new cooperativity factors,
β and δ, are introduced.
These ternary complex models have formed the basis of much GPCR modelling work
done in recent decades. In particular, they underpin the work by Woodroffe et al [138, 137]
who have extended these models to include the full G protein cycle that was seen in Figure
1.3.2.
1.6 Mathematical methods
Throughout this thesis, we use a number of mathematical techniques, such as solving
systems of ordinary differential equations (ODEs) and asymptotic analysis. In this section
we will use relevant ligand binding models to explain the steps taken in these methods.
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1.6.1 Solving a linear system of ODEs
While there are multiple methods to solve systems of ODEs, we use the method of unde-
termined coefficients. In order to detail the steps in this method we use the competition
binding model presented by Motulsky and Mahan in [95], as this model also underlies
some of our later work, in Chapter 2. In [95] the authors develop a model that represents
a competition binding scenario with GPCRs. A labelled ligand, A, competes with an
unlabelled ligand, B, for the same binding site on a receptor, denoted R. Association
and dissociation rates for ligand A are ka+ and ka− respectively, and kb+ and kb− for








Figure 1.6.1: Schematic for a competition binding scenario. Labelled ligand, A, competes
with unlabelled ligand, B, for receptor R.
The law of mass action gives the system of ODEs that govern the dynamics as
d[R]
dt
= −(ka+[A] + kb+[B])[R] + ka−[AR] + kb−[BR], (1.30a)
d[AR]
dt
= ka+[A][R]− ka−[AR], (1.30b)
d[BR]
dt
= kb+[B][R]− kb−[BR], (1.30c)
which, together with the initial conditions
[R](0) = Rtot, [AR](0) = 0, [BR](0) = 0, (1.30d)
where Rtot is the total receptor concentration, form the initial value problem describing
the kinetics of the system. We notice that
[R]′ + [AR]′ + [BR]′ = 0, (1.31)
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hence, the total number of receptors, that is Rtot, must be a conserved quantity, and so
we have
[R] + [AR] + [BR] = Rtot. (1.32)
This can be rearranged to give an expression for [R], which we substitute in to the system
of ODEs, leaving the reduced system of ODEs, in the form X′ = MX + f, as
M =
−(ka+[A] + ka−) −ka+[A]
−kb+[B] −(ka+[B] + kb−)
 , f =
ka+[A]
kb+[B]












(Tr(M))2 − 4 det(M)
)
, (1.34)
where Tr(M) is the trace of M and det(M) is the determinant of M . We note that
det(M) > 0 and Tr(M) < 0, hence we must have two real, negative eigenvalues. As such,
a solution to the system will be of the form
X(t) = c1v1e
λ1t + c2v2e
λ2t + Xp(t), (1.35)
where v1,v2 are the eigenvectors corresponding to eigenvalues λ1,2. The coefficients c1, c2
are arbitrary constants which account for the initial conditions, and Xp(t) is a particular
solution that shows the equilibrium concentrations. In this case we have
v1 =
kb+[B] + kb− + λ1
kb+[B]
 , v2 =
















ka−kb+[B]− ka+kb−[A] + ka−kb− + ka−λ2
ka+kb−[A]− ka−kb+[B]− ka−kb− − ka−λ1
 . (1.38)
The expressions for c1 and c2 can then be substituted back into (1.35), to give analytical
solutions for the concentration of labelled and unlabelled ligands. Solutions can then
be used to plot species curves as well as total ligand bound, under various parameter
regimes. This can give insights into possible system behaviours.
1.6.2 Perturbation analysis
In Chapter 4, we use perturbation analysis (or asymptotic analysis) to analyse a system
of ODEs with different parameter values. Perturbation analysis is useful when analysing
the complexities in the dynamics of biological systems. It allows for asymptotic solutions
of nonlinear problems dependent on a small parameter and is useful for problems requir-
ing a separation of timescales. Perturbation analysis is particularly advantageous over
other methods as it provides insights into the biological system as opposed to relying on
observations. It is also used to analyse models for GPCR signalling in [138] and [137].
To illustrate the method we use the canonical model, first published by Michaelis and
Menten [87, 60] in 1913, of the interactions of enzymes and substrates. The reactions in
this model are known as enzymatic catalytic, where it is assumed that the concentration
of substrate is greater than the concentration of enzyme. A more detailed analysis is
given in [96]. The schematic of the model is given as








the complex ES. This complex then dissociates into a product P and enzyme E. It is
generally assumed that there are very low concentrations of E and so the rate at which the
product can be created is limited, and the product P is removed by the body continually
by some other process. Applying the law of mass action and defining s = [S], e = [E],




=− k1es+ k−1c, (1.39a)
de
dt
=− k1es+ (k−1 + k2)c, (1.39b)
dc
dt




with initial conditions initial conditions
s(0) = s0, e(0) = e0, c(0) = 0, p(0) = 0. (1.39e)







and so we can conclude that the concentration of enzymes is conserved, hence we have
e+ c = e0, (1.41)
which can be used to reduce the system by one equation. Also, as p does not appear
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explicitly in any of the equations, we can solve this individually once we have a solution
for c. This leaves the two equations to solve, as
ds
dt
=− k1e0s+ (k1s+ k−1)c, (1.42a)
dc
dt
=k1e0s− (k1s+ k−1 + k2)c, (1.42b)
s(0) =s0, c(0) = 0. (1.42c)
In order to analyse the system, we first nondimensionalise the system by setting

















This gives the dimensionless system as
du
dτ




= u− (u+ κ)v, (1.43b)
u(0) =1, v(0) = 0, (1.43c)
noting that κ− λ > 0 and 0 < ε 1, hence ε is the required small parameter.
We first determine the type of perturbation problem we have. If having small, nonzero
values of ε gives qualitatively the same system as having a zero ε, we have a regular pertur-
bation problem. However, if this is not the case, and the problem cannot be approximated
by setting ε = 0, then we say we have a singular perturbation problem. Typically, this
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is when the small parameter is multiplying the highest derivative. Singular perturbation
problems usually indicate that a problem is evolving on multiple timescales.
The general method of perturbation analysis involves representing each variable by
a power series expansion about the small parameter, so for a variable x = (x1...xn) and





In equations (1.43), we have ε multiplying the highest derivative in the second equa-
tion and so we have a singular perturbation problem. This can also be seen in Figure
1.6.2 where we plot each concentration on a log-log scale to highlight the dynamics in the
different timescales. In this, we see how we have growth in the concentration of v on a
much lower timescale than the concentration of u curves. For singular perturbation prob-



































Figure 1.6.2: Concentration of u and v (equations (1.43)) are plotted on a log-log scale
to highlight the time course dynamics on the different timescales. Parameters used for
the plot are λ = 3.4, κ = 6.7, ε = 1e− 2.
lems such as this we seek solutions to the two timescales individually, these are known as
the inner (or boundary) solution, covering the time scale where changes are rapid, and
outer solution for the slower part of the dynamics.
Outer Solution
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We first consider what happens in the outer region. We make use of big O notation to
describe the timescale that the curve is evolving on. Big O notation describes the growth
rate of a variable or function. For this outer solution, we have time increasing at O(1).
We first assume asymptotic approximations
u ≈ u0 + εu1 + ε2u2 + ..., v ≈ v0 + εv1 + ε2v2 + ..., (1.45)
where u0  εu1  ε2u2  ... and v0  εv1  ε2v2  .... Substituting these into
equations (1.43) and collecting the leading order terms (that is the largest terms), gives
du0
dτ
=− u0 + (u0 + κ− λ)v0, (1.46a)
0 = u0 − (u0 + κ)v0. (1.46b)
The initial conditions for the outer system are unknown and will be determined later by











which solves to give the implicit solution for u0(τ) as
u0 + κ log(u0) = c1 + λτ, (1.49)










= c1 + λτ. (1.50)
Inner Solution
As neglecting the term εdv/dτ in the previous solution means that the initial condition
v(0) = 0 cannot be satisfied by the outer solution so we rescale variables
τ = εT, U(T ) = u(τ), V (T ) = v(τ), (1.51)
to magnify the neighbourhood around τ = 0. Substituting these into equation (1.43), we
have the system of equations governing the dynamics in this inner region as
dU
dT
= ε(−U + (U + κ− λ)V ), (1.52a)
dV
dT
= U − (U + κ)V, (1.52b)
U(0) = 1, V (0) = 0. (1.52c)
Assuming asymptotic approximations
U ≈ U0 + εU1 + ε2U2 + ..., V ≈ V0 + εV1 + ε2V2 + ..., (1.53)








= U0 − (U0 + κ)V0, (1.54b)
U0(0) =1, V0(0) = 0. (1.54c)
which solves to give




This clearly demonstrates how only the concentration of v is changing on this timescale.
Matching
In order to determine the constant, c1 that appears in the outer region solutions
(equations (1.49) and (1.50)) we use matching, where we require the inner and outer
solutions to match in some intermediate timescale. As the inner solution is only valid
whilst time is O(ε), and the outer solution valid for time O(1), there must exist some










V (T ). (1.57)
From the first condition, we take the limits of equations (1.49) and (1.55), giving
c1 = 1, (1.58)
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whilst calculation of each of the limits in the second condition (equations (1.50) and
(1.55)) confirms that this also matches. In Figure 1.6.3 we plot the approximations in
both regions against the numerical solution, where the agreement between them is clear,
hence we have good approximations for each region.






































Figure 1.6.3: The numerical solution (to equations (1.42))is plotted together with the
inner and outer approximated solutions. The approximations in each region show a good
approximation to the curves. Parameters used for the plot are λ = 3.4, κ = 6.7, ε = 1e−2.
1.6.3 Structural identifiability analysis
We previously discussed how ligand binding assays are used to observe ligand-receptor
interactions. Mathematical models of pharmacodynamics systems have become key in
understanding these interactions, between ligands and living cells, and as such play a
significant role in the development of new therapeutic medicines. These models are of-
ten comprised of ODEs that have many mechanistic parameters that represent biological
processes and are largely unknown [28]. An essential step in using these models requires
establishing the values of these parameters [129] by fitting to experimental data from
ligand binding assays. This helps to quantify ligand-receptor interactions. Parameter
estimation for biological systems often involves global search or optimisation algorithms
[36]. However, these fitting routines can result in inaccurate and unreliable estimates
[89, 36].
Identifiability analysis is the process of assessing whether it is theoretically possible
to estimate a set of parameters from experimental observations and the dynamic equa-
tions [46, 129]. This is therefore needed to determine the reliability of these estimates.
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In particular, structural identifiability analysis (SIA) uses the model structure, together
with observed outputs, to determine whether parameters can be returned successfully,
given perfect, noiseless and bias-free observations [128, 8].






















































































Figure 1.6.4: Plotting the concentration curves for all species individually, for a com-
petition binding with monomeric receptor model, using three different parameter sets.
Although all curves have the same measured output (concentration of [AR]) curve, non-
identifiability can be seen from the differences in the different species curves.
An example of a system with non-identifiable parameters can be seen in Figure 1.6.4,
where we plot time courses for the competition binding model that we described in Section
1.6.1. We assume that the only measured quantity is the amount of labelled ligand [A]
that is bound, that is the concentration [AR]. However, when plotting the solutions for
all concentrations, using three different parameter sets, we see how these all result in
the same measured output curve, even though the concentrations of [R] and [BR] evolve
very differently. In a case such as this, it is then not possible to determine the model
parameters from the measured output. We note that the parameter values for this plot
along will the full analysis can be found in Chapter 5.
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1.7 Thesis overview
In this thesis, we develop mathematical models, first for ligand binding and later include
receptor activation, where receptors have the ability to form dimers. We follow a frame-
work of analysis for each model, where we first look at equilibrium solutions, followed by
then exploring time-dependent behaviours. The main goal for this thesis is to contribute
to existing receptor theory by giving qualitative and quantitative information for ligand-
receptor interactions, and provide models that can be of practical use to pharmacologists.
The remainder of the thesis is laid out as follows.
In Chapter 2 we present three models for ligand binding to pre-dimerised GPCRs.
In the first model we assume all dimers are homodimers and consider binding with a
single ligand, focussing on the effect and quantification of cooperativity across the dimer.
At equilibrium we give analytical solutions and find conditions on the model parameters
that give biphasic dose-response curves (curves with multiple points of inflections). As
the system is small and linear, we compute time-dependent analytical solutions and use
these to understand possible time course dynamics. We then build upon this model,
where we first introduce a second ligand, then also consider binding to a pre-dimerised
heterodimer. In these, we again give analytical expressions for equilibrium solutions, but
instead use numerical methods to examine time course behaviours under various param-
eter regimes.
In Chapter 3 we build on the single ligand, homodimer equilibrium model, by includ-
ing receptor activation. As each receptor within the dimer has the ability to bind a ligand
molecule and activate individually we treat each receptor as an individual entity, as op-
posed to a single dimer unit. This results in a much larger system, with more complex
behaviours to explore and understand. At equilibrium, varying the different cooperativity
factors leads to the emergence of some unusual signal curves, such as extra inflections
and overshoots in the curve.
In Chapter 4 we look at the binding of VEGF to VEGFRs. This receptor system
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is within the growth factor family of receptors and is known to dimerise in response to
ligand binding. Including the dimerisation process leads to a nonlinear system, whereas
our previous models have been linear. Numerical results for time course dynamics show
peaks and curves evolving on multiple scales and we use asymptotic analysis to under-
stand these. The model is validated by fitting to published data.
In Chapter 5 we study the identifiability of model parameters when fitting to data,
using existing structural identifiability analysis techniques. We apply these to a range of
classical ligand binding models as well as some of our existing dimer models. For each
model, we apply relevant techniques to determine identifiability from a single set of time
course data, in order to give a comparison of the methods. For non-identifiable models
we give identifiable parameter combinations and explore ways to make all parameters,
and therefore the whole system, identifiable. This includes using equilibrium data, data
from washout experiments and multiple time courses to identify the parameters.
In Chapter 6, we summarise the work done throughout the thesis, discuss ongoing
work, and suggest possible directions for future work.
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Chapter 2
Binding Models for GPCR
homodimers
We note that much of the work in this chapter is published by White and Bridge in [135].
Furthermore, some paragraphs are quoted verbatim from this paper.
Mathematical modelling of binding to dimerised GPCRs has largely focused on equi-
librium binding models, such as those presented by Franco et al [40, 41, 39] and Durroux
[33]. Typically, these equilibrium models yield analytical solutions for total bound labelled
ligand, derived algebraically using mass action and receptor conservation considerations.
Corresponding log dose-response (logDR) curves for bound ligand may be multiphasic,
exhibiting multiple inflections [37, 19, 108]. For models of dimerised receptor binding, this
departure from monophasic logDR curves (typical of monomeric receptor binding) may
be quantified by a dimer cooperativity index [44, 20, 38], which relates to the apparent
binding cooperativity in the Hill function sense. Within a Hill function analysis, however,
there is the possibility that information is missed due to the inability of Hill coefficients
to distinguish interaction mechanisms [106]. These works appear to be the state-of-the
art in practical GPCR models, while more mathematically abstract approaches are taken
elsewhere: an algebra of dimerisation is presented in [139], and generalised multi-site
binding models are analysed in [61].
Dynamic models of binding and signalling for dimerised receptors are less common
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than equilibrium models. Spatial models of the dimerisation process and subsequent sig-
nalling are developed in [85], while dynamics of receptor and transducer protein dimeri-
sation are studied using an ordinary differential equation (ODE) model in [127], wherein
it is suggested that homodimerisation may serve to regulate signalling over multiple time
scales. Ligand-induced dimerisation of VEGF receptors is modelled using ODEs in [80].
In order to lay the foundations for dynamic modelling of signalling via dimerised GPCRs,
we refer to a more recent study of GPCR ligand binding dynamics (May et al. [83]).
Therein, linear ODE models of single-ligand and competition dynamics at pre-dimerised
homodimeric receptors are presented, with a brief model analysis and numerical data
fitting, without presenting analytical solutions to the ODE systems. In the current work,
we describe a simplified formulation of the May et al. models, and derive their ana-
lytical solutions. For the single-ligand model, the solution structure (bi-exponential in
time, reflecting two distinct eigenvalues) is reminiscent of Motulsky-Mahan competition
dynamics at a monomer [95].
In this Chapter, we develop mathematical models for the dynamics of ligand binding
at pre-dimerised receptors. In Section 2.1, we formulate and solve (analytically) a linear
ODE model for single-ligand (A) binding kinetics at constitutively dimerised receptors.
We first relate our model to existing models, and find an analytical equilibrium solution
for total bound ligand. From this solution, we derive a condition under which multiple
inflections in the logDR curve appear, in terms of the mechanistic binding cooperativity
coefficient (α). Further, we show that the time-dependent problem has an analytical
solution which may be easily constructed and computed without the need for numerical
ODE solvers, and use this solution to simulate the binding dynamics. In Section 2.2, we
extend our model to account for the presence of a second competing ligand (B). Again,
we relate to previous models, and begin by finding the equilibrium solution. This enables
us to derive a condition for multiple inflections in the logDR curve for total bound ligand
A, which this time depends on multiple mechanistic binding cooperativity coefficients and
the concentration of B. The ODE model for competition dynamics is linear as before,
but its analytical solution is more laborious to compute. We again simulate the binding
dynamics to explore the effects of the dynamic cooperativity factors. In Section 2.3 we
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again consider a single ligand binding a pre-dimerised receptor, however, assume this
dimer is a heterodimer, in that it consists of two similar but non-identical receptors. We
follow the framework of analysis as in the previous sections to analyse results both at
equilibrium and for time-course dynamics.
2.1 A single drug binding model
In this initial model, we consider a single ligand, A, binding to a pre-dimerised receptor
complex. In this model, we assume all dimers are homodimers, so consist of two identical
receptors bound together. We denote these dimers as R for simplicity in the model but
keep the assumption that ligand molecules can bind to either side of the dimer. Associ-
ation and dissociation rates are ka+ and ka− respectively and we assume there is no bias
to which protomer the ligand molecule binds to first. As the second ligand binding may
be affected by one side of the dimer being already bound we introduce α = α+/α− which
represents the equilibrium binding cooperativity, that is the factor change in affinity for
the dimer when it is already ligand-bound. The value α = 1 represents neutral cooper-
ativity, and α > 1 and α < 1 represent positive and negative cooperativity respectively.
Figure 2.1.1 shows the system of biochemical reactions. Since R represents a dimer, AR










Figure 2.1.1: Schematic: A ligand A binds to one side of a dimer, R, creating AR. A
second ligand subsequently binds this complex, creating ARA.
Applying the law of mass action, the binding kinetics are governed by the following system
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of ordinary differential equations (ODEs):
d[R]
dt
= ka−[AR]− ka+[A][R], (2.1a)
d[AR]
dt
= ka+[A][R]− ka−[AR]− α+ka+[A][AR] + α−ka−[ARA], (2.1b)
d[ARA]
dt
= α+ka+[A][AR]− α−ka−[ARA], (2.1c)
The number of receptors is a conserved quantity. Similarly, as we are replicating in vitro
(lab experiment) conditions, the cell (or cell membrane) is also a constant. As such,
the concentration of receptors is also conserved, hence, this allows us to give the total
concentration of dimerised receptors as
Rtot = [R] + [AR] + [ARA], (2.2)
which we use to reduce the system to two ODEs. We also assume that the concentration
of ligand is much larger than the concentration of receptors (this is usually the case
experimentally), hence the depletion of ligand is negligible and the ligand concentration
can be assumed to be constant. Thus, taking [A] as a constant, we state the system in
the form d
dt
X(t) = MX(t) + f where X = ([AR], [ARA])T ,
M =
−(ka− + ka+[A] + α+ka+[A]) α−ka− − ka+[A]
α+ka+[A] −α−ka−













We later look at a time course analysis and find analytical solutions to the the system,
but in the spirit of classical receptor theory, we first investigate the equilibrium behaviour
of the system, in particular the effect of α. The law of mass action allows us to state the
equilibrium relationships as
[AR] = KA[A][R], (2.5a)
[ARA] = αKA[A][AR], (2.5b)
where KA = ka+/ka− is the equilibrium association constant and α = α+/α− is the
equilibrium binding cooperativity. The total concentration of dimers is
Rtot = [R] + [AR] + [ARA]




which we can combine with equations (2.5) to express the equilibrium concentrations in
terms of parameters only, giving us
[R] =
1











1 +KA[A] + αK2A[A]
2
Rtot. (2.7c)
We can clearly see that as [A]→∞ the concentrations of [R] and [AR] fall to 0, whereas
[ARA] tends to Rtot. The total amount of ligand bound at equilibrium is:
Abound = [AR] + 2[ARA], (2.8)
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due to a single ligand molecule being bound in [AR] and two ligand molecules being






1 +KA[A] + αK2A[A]
2
Rtot. (2.9)
This result is equivalent to the result Giraldo [44] states when discussing the mechanistic
model for a single ligand binding to a dimerised receptor. We see the equivalence to his
model if we take KA = 1/KD1 and α = KD1/KD2. Letting [A] tend to infinity in this
result gives us the maximal ligand bound as 2Rtot, thus we can state that half of the
maximal Abound is Rtot. Setting Abound = Rtot and solving for [A] gives us the amount of







Figure 2.1.2 shows how the equilibrium cooperativity factor α affects the log dose-response
(logDR) binding relationship. In the majority of cases the concentration curves behave as
expected, with increasing cooperativity leading to dimers becoming dual-bound for lower
concentrations of [A] along with smaller peaks in [AR]. However, if we look to the plot
of total ligand bound we see a curve that is not usual for monomer binding. Clearly as
α increases we see a leftward shift in the curve. However, we can also see that for small
values of α we get three inflections in the curve instead of just one.
Since the existence of extra inflections depends on α we seek a condition on α for
when these appear. Following the calculation in Appendix B, with a = 1, b = α, c = 1
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Figure 2.1.2: LogDR curves (plotted using equation (2.9)) for α ranging from extreme
negative to extreme positive cooperativity. We see that extra inflections appear in Abound
when we have extreme low cooperativity.




(8α− 1)2 − 4α
2
, (2.12)
under the conditions of
0 < α < 1/16. (2.13)
When α is within this range the inflection at α = A50 changes from a rising inflection
point to a falling one and we get two extra inflection points, one for [A] < A50 and one
for [A] > A50. We see in Figure 2.1.2 that this results in a biphasic curve. We note
here that a biphasic logDR curve with three inflections as shown would not be seen for
monomeric receptors, and this is suggestive of the possibility of pre-dimerised receptors
and very negative cooperativity. If the extra inflections are evident in a data set, and the
receptors are homodimers, then we can conclude that α < 1/16.
2.1.2 Binding dynamics - analytical solutions
Analytical solutions aid pharmacologists by allowing them to easily run simulations.




MX(t) + f where
M =
−(ka− + ka+[A] + α+ka+[A]) α−ka− − ka+[A]
α+ka+[A] −α−ka−











As this is a linear system we are able to solve it to find exact solutions as functions of time,
using the method outlined in Section 1.6.1. We note that det(M) > 0 and Tr(M) < 0,


























Tr(M)2 − 4 det(M)
2
. (2.18)





( λ2(α−ka− + λ1 + 2α+ka+[A])eλ1t − λ1(α−ka− + λ2
+ 2α+ka+[A])e





Looking more closely at the components of these solutions we see that we have two
exponential components meaning we would expect to see biphasic curves. As λ1 and λ2
are real, distinct and always negative, providing all parameters in the model are positive
we can say with certainty that as t −→ ∞ the exponential components will reduce to




















Expanding det(M) and simplifying in MATLAB [2] confirms the equivalence of these to
equations (2.7).
Having these analytical solutions (equations (2.16) and (2.17)) to the ODE system
allows time courses to be plotted without the need for numerical ODE solvers. This
is particularly useful for pharmacologists without numerics expertise, allowing them to
construct exact solutions for any parameter values in software packages such as Excel [88]
and Graph Pad [1].
2.1.3 Single ligand time course results
Here we present numerical results which demonstrate the effects of cooperative dynam-
ics across dimerised receptors, particularly contrasting with the dynamics observed for
monomeric receptors. Figure 2.1.3 shows the binding of ligand [A] to the dimerised re-
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ceptor [R] with the ligand being added as a constant 10−8M . Initially, ligand molecules
bind singularly to dimers, creating an increase in [AR]. As time increases, a positive
cooperativity factor means that the chance of a second ligand molecule binding to the
singularly bound dimer is increased; thus, [ARA] increases. This increase in [ARA] also
has the effect of reducing [AR] which then falls towards zero. Hence, we see a peak in [AR].





























Figure 2.1.3: The binding of ligand A to a pre-dimerised receptor results in slight peaks
in [AR], while positive cooperativity leads to all dimers becoming dual bound. The plot
shows a numerical solution to the system in equations (2.1). We use a ligand concentration
of [A] = 10−8M while the cooperativity factors were set at α+ = 2 and α− = 0.01 giving
positive cooperativity.
In fact, this peak becomes a point of interest as we look at Figure 2.1.4. In this, we
consider a range of values of [A] and study the effect this has on the binding dynamics.
It is clear that not only does Abound increase to a higher equilibrium concentration as
[A] increases, but also, equilibration is reached in a shorter timescale. While [A] is
low, [AR] approaches equilibrium monotonically, whereas a peak in [AR] occurs for high
concentrations of A.
We notice in Figure 2.1.4 that as [A] increases there is a leftward shift in the peak as
the time at which it occurs decreases. Using equation (2.16) we can find when this peak
occurs exactly. To find a solution we differentiate this equation with respect to t then set
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Figure 2.1.4: Plot shows a numerical solution to equations (2.1) for a varying ligand
concentration. With high levels of [A] in the system we no longer see peaks in [AR].
Cooperativity values are fixed at α+ = 2 and α− = 0.01.



















α−ka− + λ1 < 0.
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Substituting in the full expression (equation (2.18)) for λ1, gives
α− < KA[A]. (2.25)
To evaluate the peak concentration [AR], we substitute the peak time, equation (2.23),














as the corresponding concentration of [AR].
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Figure 2.1.5: Plot shows a numerical solution to equations (2.1) for a varying forward
cooperativity factor. As we move from positive to negative cooperativity we see a more
pronounced peak in [AR] with Abound tending to lower concentrations. Ligand concen-
tration for the plot is [A] = 10−8M .The value α− = 1 was fixed so that cooperativity
depends solely on α+.
In Figure 2.1.5 we look at how a range of cooperativity factors affect the binding of ligand
[A]. Clearly, the binding rate for a second ligand to the dimer increases and decreases
for positive and negative cooperativity, respectively. We see a peak in [AR] whose timing
and concentration are dependent on α+. As α+ increases, the peak in [AR] decreases and
occurs earlier. Both [ARA] and Abound increase as α+ increases.
49
2.2 A two drug binding model
We now introduce a second ligand, B, to the system. The rationale for this is that
quantification of effects of unlabeled ligands can be achieved by competition experiments
with labeled and unlabeled ligands, as seen in previous studies involving monomeric and
dimeric receptors [95, 83]. The kinetics of this system are key in highlighting and quan-
tifying allosteric interactions across dimerised receptors, as indicated by May et al [83],
who discuss the influence of an unlabeled ligand on the dissociation (washout) kinetics
of a labeled ligand, when dimers are present.
We assume the association rates remain as they were in the previous model, along
with the cooperativity factor α to describe the cross talk across a dimer dual bound by
[A]. We express the association and dissociation of ligand B by the rates kb+ and kb−
respectively and now require two extra cooperativity factors. We denote β = β+/β− as
the influence a protomer bound by ligand B has on a second B binding, and vice-versa,
and γ = γ+/γ− as the cooperativity factor describing the interaction between A and B























Figure 2.2.1: Schematic: Two ligands, A and B compete for binding sites on dimer R.
2.2.1 Differential equations
We use the law of mass action to derive from these reactions a system of differential
equations that govern the binding kinetics of the system:
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As the total concentration of receptors is conserved we can state that
Rtot = [R] + [AR] + [BR] + [ARA] + [ARB] + [BRB]. (2.27)




= −(ka+[A] + ka− + α+ka+[A]− γ+kb+[B])[AR]− ka+[A][BR]




= −kb+[B][AR]− (kb+[B] + kb− + γ+kb+[A] + β+kb+[B])[BR]




= α+ka+[A][AR]− α−ka−[ARA], (2.28c)
d[ARB]
dt
= γ+kb+[B][AR] + γ+ka+[A][BR]− γ−kb−[ARB]− γ−ka−[ARB], (2.28d)
d[BRB]
dt


















We note that this system is a simplification of the one developed by May et al [83]. We
recall the model presented in [83] in Figure 2.2.2. When translating the schematic to a















Figure 2.2.2: Schematic of the two-ligand dimer model presented by May et al. in [83].
AR-R is the same as R-RA, for example, and denoting this [AR]. We take this one step
further by assuming symmetry in the model initially, thus reducing the both the number




, ka− = k̃a− kb+ =
k̃b+
2
, kb− = k̃b−, (2.30)
α+ = 2α̃+, α− =
α̃−
2
, β+ = 2β̃+, β− =
β̃−
2















where a tilde denotes a parameter or variable in the May et al [83] model.
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2.2.2 Equilibrium analysis
Once the system reaches equilibrium we have the set of relations








[ARB] = γKA[A][BR] = γKAKB[A][B][R], (2.33c)
Since we can write the total concentration of dimerised receptors as
Rtot = [R] + [AR] + [BR] + [ARA] + [ARB] + [BRB]
= [R](1 +KA[A] +KB[B] + αK
2
A[A]






























D = 1 +KA[A] +KB[B] + αK
2
A[A]




Here we consider, as in May et al [83], competition experiments where ligand A is
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labelled and ligand B is unlabelled. We can clearly see that, providing [B] is fixed
[R], [AR], [BR], [ARB], [BRB]→ 0, and [ARA]→ Rtot as [A]→∞. (2.37)
The total concentration of bound ligand A (assumed an experimentally measurable quan-
tity) is
Abound = [AR] + 2[ARA] + [ARB]
= [R](KA[A] + 2αK
2
A[A]
2 + γKAKB[A][B]). (2.38)






1 +KA[A] +KB[B] + αK2A[A]
2 + γKAKB[A][B] + βK2B[B]
2
Rtot. (2.39)










which we note is independent of the A-B cooperativity factor γ (we return to this point
when varying γ). In the following sections we show the effects of each of the cooperativity
factors α, β, γ in turn. We vary each of the equilibrium cooperativity factors individually
while keeping the others set to 1 to give neutral cooperativity to be able to study the
effects the individual cooperativity factors has on the system. In each case we plot logDR
curves for Abound for a range of values for [B]. To begin we consider a range of values of
α, hence fix β and γ.
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Figure 2.2.3: Plotting logDR curves, using equation (2.39), for varying α shows extra
inflections when we have low A-A cooperativity regardless of [B]. Other cooperativity
factors are fixed at β = γ = 1.
Again we see extra inflections for low values of α, similarly to the single ligand system,
as shown in Figure 2.2.3. While [A]  [B] dimers are primarily bound by molecules of
B. As [A] increases we see increases in concentrations of AR. However, low cooperativity
means that these become bound by molecules of [B], forming ARB complexes, but few
become bound by a second molecule of A, and as such, [ARA] remains low. It is not until
[A] [B] that the low cooperativity is countered, where we then see increases in [ARA],
corresponding to a fall in dimers bound by a single molecule of [A], thus creating peaks
in these. It is this that changes the nature of the original inflection point for Abound, as
well as creating two extra inflections. This is clear if we look to the individual species
plots in Figure 2.2.4.
The effects of β cooperativity
Figure 2.2.5 shows the effect of varying the B-B cooperativity factor, β. We see inflections
still appear when we have both low β and high [B]. In Figure 2.2.6 we look at the
individual species curves, with [B] fixed at a high concentration, showing inflections for
all Abound curves where β < 1. With β < 1, these become then bound by a molecule of
A, giving an increase in [ARB]. However, as [A] → ∞ this is countered and all dimers
become dual bound by A, so [ARA] → Rtot while all other complexes fall to zero. This
increased peak in [ARB] results in an extra inflection in the Abound curve.
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Figure 2.2.4: Individual species plots (equations (2.35)) for a varying α help to understand
the effects of cooperativity on the dose response curves. Competition ligand concentration




























































































Figure 2.2.5: Plotting logDR curves, using equation (2.39), for varying β shows extra
inflections appear when we have both low B-B cooperativity and low [B]. Other cooper-
ativity factors are fixed at α = γ = 1.
The effects of γ cooperativity
In Figure 2.2.7 we look at the effects of A-B cooperativity factor γ and see slightly differ-
ent results. To get extra inflections, γ is required to be high as opposed to low. We again
require there to be a high concentration of B in the system for inflections to appear. We
again fix B at a high concentration to study the individual species curves, in Figure 2.2.8.
With a large γ (and sufficiently large [B]), we see large increases in [ARB], creating a
peak once [A] ≈ [B]. A much higher concentration of A is required for concentrations of
ARB to fall. This large peak creates the extra inflections in the Abound curve. We also
note that, γ does not shift the curve, as α and β do. Varying γ changes the slope of the
curve, but the point of inflection and thus the A50 value, remain the same for all curves.
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Figure 2.2.6: Individual species plots for a varying β help to understand the effects of
cooperativity on the dose response curves. Competition ligand concentration is fixed at
B = 10−5M , while α = γ = 1.
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Figure 2.2.7: Plotting logDR curves, using equation (2.39), for varying γ shows extra
inflections when we have high A-B cooperativity as well as low [B]. Other cooperativity
factors are fixed at β = γ = 1.
This can be seen in the Abound curve in Figure 2.2.8.
Investigating the inflections
Similarly to the single ligand system we also get extra inflections in the Abound curve
when we have two ligands in the system. Investigating these extra inflections in Abound
(Appendix B with a = 1 + γKA[B], b = α, c = 1 + KB[B] + βK
2
B[B]
2 and X = KA[A]),
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Figure 2.2.8: Individual species plots for a varying γ help to understand the effects of
cooperativity on the dose response curves. Competition ligand concentration is fixed at
B = 10−8M , while β = γ = 1.









We further find that extra inflections appear under the condition
16α(1 +KB[B] + βK
2
B[B]
2) < (γKB[B] + 1)
2, (2.42)




(a2 − 16bc)(a2 − 4bc)
2abKA
. (2.43)
2.2.3 Time course results
Analytical solutions for the system (2.28) are theoretically possible, given that the system
is linear. However, the task of computing eigenvalues exactly becomes laborious and im-
practical; we instead construct the solutions by numerical evaluation of the eigenvalues.
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A numerical ODE solver could also be used.


























Figure 2.2.9: In the time course plot, we have a numerical solution to the system in
equations (2.28), where we see peaks in both [AR] and [BR]. Cooperativity values are
α+ = β+ = γ+ = 2, α− = β− = γ− = 0.01, while ligand concentrations used are
[A] = 10−8M , [B] = 2× 10−8M .
We now consider two-ligand competition in time course simulations. The concentra-
tion of [A] remains the same as in the single ligand binding section, and a second ligand
[B] is introduced, with [B] > [A]. Association and dissociation rates kb+ and kb− are set
such that kb+ < ka+ and kb− > ka−. Figure 2.2.9, with all forward and reverse cooper-
ativity factors fixed at 2 and 0.01 respectively, shows [AR] and [ARA] dynamics similar
to that of the single ligand problem.
While the curves of [BR] and [BRB] are similar to those of [AR] and [ARA], as
[B] > [A], this results in an increased peak in [BR] and an increased equilibrium concen-
tration of BRB. As [ARB] has a contribution from both ligands A and B, it increases
in the same way but tends to an equilibrium between [ARA] and [BRB].
In Figure 2.2.10 we see the effect α+ has on the time course dynamics of the system.
Varying α+, while keeping all other cooperativity factors fixed equal to one isolates the
effects of forward A− A binding cooperativity. Clearly, peaks appear in [AR] and [BR]
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Figure 2.2.10: Plotting the numerical solution to equations (2.28) with a varying α+
while all other cooperativity factors equal 1. Increasing α+ results in increases in [ARA].
Ligand concentrations are [A] = 10−8M , [B] = 2× 10−8M .
for all values of α+. However, increasing α+ results in a smaller peak in [AR], as these
quickly become bound by two molecules of A, thus we see [ARA] increasing more quickly
and to a higher concentration. This in turn means that we see decreases in [BR], [ARB]
and [BRB] due to less available receptors.
In Figure 2.2.11 we vary β+ while all other cooperativity factors are equal to one. In
this, we see the results mirrored in [A] and [B] from when we varied α+. Increasing β+
shows a decreased peak in [BR] and consequently, an increase in [BRB]. Concentrations
of [AR], [ARA] and [ARB] are reduced as there are less available free receptors for the
binding of [A].
In Figure 2.2.12 we demonstrate the effect of varying γ+. As molecules of A and B
become bound to free receptors we again see [AR] and [BR] increase. Once a dimer
becomes bound by a ligand molecule, a small γ+ means that it is less likely to become
bound by an alternate molecule, so dimers become bound by two of the same ligand,
hence [ARA] and [BRB] increase while [ARB] remains low. As γ+ increases, the con-
verse happens and instead we see increases in [ARB].
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Figure 2.2.11: Plotting the numerical solution to equations (2.28) with a varying β+
while all other cooperativity factors equal 1. Increasing β+ results in increases in [BRB].
Ligand concentrations are [A] = 10−8M , [B] = 2× 10−8M .
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Figure 2.2.12: Plotting the numerical solution to equations (2.28) with a varying γ+
while all other cooperativity factors equal 1. Increasing γ+ results in increases in [ARB].
Ligand concentrations are [A] = 10−8M , [B] = 2× 10−8M .
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2.3 A heterodimer binding model
It is widely acknowledged that GPCRs can also exist as heterodimers, that is a dimer
consisting of two non-identical receptors [91, 92, 93, 115]. In the previous dimer model,
we used the symmetry inherent in the homodimer model to reduce the model, resulting
in a clean formulation amenable to algebraic manipulation. In this section we extend
this to a more general model which will encompass heterodimers. This model is similar
in form to the May et al schematic [83], with an implicit asymmetry which will allow for
an “extra level of complexity” [6].
The proposed model consists of a single ligand, A, binding to a pre-bound heterodimer,
R1-R2 and we assume that the ligand is able to bind to either of the receptors. The first
reaction consists of a molecule of ligand A binding to either of these receptors creating
the complexes AR1-R2 or R1-R2A. Association and dissociation rates of ligand binding
to the R1 receptor are ka1+ and ka1− respectively, while binding rates of the R2 receptor
are ka2+ and ka2−. We also introduce a cooperativity factor α = α+/α− which describes
the crosstalk between the receptors. This affects the binding rates of the second ligand
molecule to the dimer, upon when the complex AR1-R2A is created. We have positive
cooperativity when α > 1, so the equilibrium binding affinity of the second ligand binding
is increased and negative cooperativity for α < 1. We have a total of four possible















Figure 2.3.1: Schematic: the binding of a single ligand to a pre-formed heterodimer.
of ordinary differential equations (ODEs) that govern the binding kinetics of the system
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by applying the law of mass action. Fixing [A] as a constant we express these as
d[R1-R2]
dt
= −(ka1+ + ka2+)[A][R1-R2] + ka1−[AR1-R2] + ka2−[R1-R2A], (2.44a)
d[AR1-R2]
dt
= ka1+[A][R1-R2]− (ka1− + α+ka2+[A])[R1-R2A] + α−ka2−[AR1-R2A], (2.44b)
d[R1-R2A]
dt
= ka2+[A][R1-R2]− (ka2− + α+ka1+[A])[AR1-R2] + α−ka1−[AR1-R2A], (2.44c)
d[AR1-R2A]
dt
= α+ka2+[A][AR1-R2] + α+ka1+[A][R1-R2A]− (α−ka1− + α−ka2−)[AR1-R2A].
(2.44d)
The total concentration of receptors is
Rtot = [R1-R2] + [AR1-R2] + [R1-R2A] + [AR1-R2A], (2.45)
which is a conserved quantity, hence we can use this to reduce the system of ODEs by
one, which we can write in the form d
dt















−(ka1−[A] + ka1− + α+ka2+[A]) −ka1+[A] α−ka2− − ka1+[A]
−ka2+[A] −(ka2+[A] + ka2− + α+ka1+[A]) α−ka1− − ka2+[A]
















Investigating the behaviour of the system at equilibrium allows us to see the effect of α.
At equilibrium we have the relationships
[AR1-R2] = KA1[A][R1-R2], (2.49a)
[R1-R2A] = KA2[A][R1-R2], (2.49b)
[AR1-R2A] = αKA2[A][AR1-R2] = αKA1KA2[A]
2[R1-R2], (2.49c)
where KA1 = ka1+/ka1− and KA2 = ka2+/ka2− are the equilibrium association constants.
The total concentration of dimers can be given as
Rtot = [R1-R2] + [AR1-R2] + [R1-R2A] + [AR1-R2A] (2.50)
= [R1-R2](1 +KA1[A] +KA2[A] + αKA1KA2[A]
2), (2.51)
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(1 +KA1[A] +KA2[A] + αKA1KA2[A]2)
Rtot. (2.52d)
From these it is clear that as [A]→∞ the concentrations [R1-R2], [AR1-R2], [R1-R2A]→
0 and [AR1-R2A] → Rtot. As the primary interest is the total amount of ligand bound,
due to it generally being a measurable quantity in experiments. At equilibrium this is
Abound = [AR1-R2] + [R1-R2A] + 2[AR1-R2A] (2.53)
=
KA1[A] +KA2[A] + 2αKA1KA2[A]
2
(1 +KA1[A] +KA2[A] + αKA1KA2[A]2)
Rtot. (2.54)






In Figure 2.3.2 we look at the curves of Abound along with the individual species curves
to study the effect the equilibrium cooperativity factor α has on the binding relationships.
We fix association constants with KA1 > KA2. It is clear in this figure that the curves are
similar in shape to the logDR curves in the homodimer model. As α increases the curves
shift towards the left, with a higher concentration of ligand required to reach equilibrium.
We also notice we again have inflections in the Abound curve for low cooperativity values,
in much the same way as we did in the homodimer model. We also point out that,
although the curves of [AR1-R2] and [R1-R2A] are identical in shape, having KA2 < KA1
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results in a much lower concentration of [R1-R2A].
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Figure 2.3.2: Plotting logDR curves, using equation (2.54), for varying α show extra
inflections appear for heterodimers, similar to those in the homodimer binding curves.
To determine the point of these extra inflections and derive a condition under which
these appear we again follow the analysis outlined in Appendix B (with a = KA1 +







We further find that extra inflections appear at the points
[A]± =
−(8αKA1KA2 − (KA1 +KA2)2)
±
√




if the following holds
(KA1 +KA2)
2 > 16αKA1KA2. (2.58)
Under these conditions we see that, as in the homodimer model, the inflection at the A50
value changes from a rising to a falling inflection and we get two extra inflections, one at
either side of the A50 value.
2.3.2 Single ligand time course results
Here we move on to consider the effects cooperativity has on time course binding dy-
namics of the system, and observe how having a system consisting of heterodimers differs
from that of a homodimer system. In theory, analytical solutions can be found, however
these are impractical to compute, so we use numerical methods to create simulations of
the results.
In Figure 2.3.3 we fix ka1+  ka2+ and ka1−  ka2−, and cooperativity is fixed to












































Figure 2.3.3: Plotting the numerical solution to equations (2.44) shows peaks appearing
in the time course curves for [AR1-R2] and [R1-R2A]. Cooperativity values used for the
plot are α+ = 2 and α− = 0.01, while ligand concentration is [A] = 10
−8M .
give positive cooperativity, though we look at other possibilities later. For the purposes
of discussion we describe R1 receptors as being on the left side of the dimer with R2
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receptors on the right. The curves have clear similarities to the homodimer results (as
in Figure 2.1.3), in that we have peaks in the singularly bound receptors followed by an
increase in dual bound dimers. Though, as ka1+  ka2+ we initially see a much larger
peak in [AR1-R2] while [R1-R2A] remains lower.
Figure 2.3.4: Plotting the numerical solution to equations (2.44) for a range of both
cooperativity factors (α+ and α−) result in peaks appearing in some of the [AR1-R2] and
[R1-R2A] curves. Ligand concentration used is [A] = 10
−8M .
In Figure 2.3.4 we see a number effects arising from varying the cooperativity factors
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α+ and α−. In the Abound curves we see that increasing α+ results in an increase in the
total concentration of ligand bound by equilibrium, while decreasing α− gives the same
effect. Peaks form in the curves of both [AR1-R2] andf [R1-R2A], predominantly when
α− is small, although α+ also plays a role in the effect. The rate of increase in [AR1-R2]
is ka1+, hence this initially increases the same for all cooperativity values. With an in-
creased α+ these quickly become dual bound, hence [AR1-R2] falls, and we see an increase
in [AR1-R2A]. Increasing α+ results in the peak and then fall happening more quickly
and therefore a smaller peak also. This has the added effect that the system then also
reaches equilibrium more quickly. The same argument also holds for [R1-R2A], although
as ka1+ > ka2+ and ka1− > ka2− the overall concentration levels are lower. However, if
α− is increased, when the dimers become dual bound one of the bound ligand molecules
quickly become unbound, hence we do not see the fall in [AR1-R2] and [R1-R2A], and
instead [ARA] remains low.
2.4 Conclusions
In this Chapter, we have presented dynamic models of ligand binding to pre-dimerised
GPCR homodimers, for both a single ligand and two-ligand competition, and single lig-
and heterodimers. The models are linear ODE systems, allowing analytical solutions for
time-dependent and equilibrium responses. The model formulation, solution and results
serve as a contribution to the field of pharmacological modelling, and are expected to be
of practical use, given the ease with which we can compute solutions. In particular, the
bi-exponential single-ligand binding kinetics show a similar model solution structure to
the widely-used Motulsky-Mahan model for competition binding at monomers [95]. We
therefore propose that these models can be adopted, interpreted and implemented with
relative ease by pharmacologists, and as such we have provided a recipe for computational
solution.
There are interesting features in the equilibrium logDR curves for the experimental
readout (signal) Abound. We have noted the possibility for multiple inflections in logDR
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curves, for all models. Multiphasic features in logDR curves are not reproducible by
standard Hill functions [32] which only support single-inflection curves. For single-ligand
binding, multiphasic logDR curves theoretically rule out monomeric receptor binding
as the only ligand binding mechanism; such experimental data therefore would suggest
another binding setup, possibly due to dimeric receptors. The existence of multiple inflec-
tions depends on the level of cooperativity across a dimerised receptor, and importantly
we are able to give conditions on cooperativity factors for a three-inflection curve. The
practical use of these conditions is clearly in assessing the sign and magnitude of co-
operativity towards quantitative classification of drug-receptor interactions. Given that
Hill functions are not suitable for fully characterising multiphasic logDR curves [32], our
analysis here goes beyond dimer cooperativity indices which stem in part from coopera-
tivity in the Hill function sense [44]; the present work concerns mechanistic cooperativity
which is explicit in the original model schematic, as opposed to empirical measures from
a more limited model. In [32], it is noted that multiphasic logDR curves have particular
importance in a number of contexts including cancer pharmacology, and effort should be
made to move beyond Hill function fitting wherever possible.
70
Chapter 3
Modelling GPCR binding and
activation
Dimeric receptors can theoretically elicit a diverse range of pharmacological effects [91].
With the implications of these on downstream signalling yet to be fully explored, many
questions remain, such as, how ligand-receptor crosstalk can be distinguished from down-
stream crosstalk when interpreting experimental results [92, 93, 22]. The logical next
steps in the modelling of dimeric receptors and exploring these possible downstream ef-
fects involves extending our GPCR models to include receptor activation [44], G protein
binding [93, 6], and ultimately G protein activation and cycling [137, 13].
In this chapter, to begin understanding the downstream effects we extend the GPCR
binding models we presented in Chapter 2 to include receptor activation. There are
currently few mathematical models of GPCR binding and activation where receptors
have formed dimers. Franco et al. [40] present a model for the binding and activation
of homodimers, where they consider each receptor within the dimer to have its own
orthosteric binding site, however, activation occurs for the unit as whole. In [141], Zhou
and Giraldo extend the canonical operational model to include homodimers. In their
paper they simulate and analyse the functional effect curves seen at equilibrium. Rovira et
al [109] present a model that describes the binding and activation of homodimers. In their
model, they define a dimer with only one protomer active as ’asymmetric’, while a dimer
with both protomers active as ’symmetric’. They propose that dimers in an asymmetric
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state activate a different pathway to those in a symmetric state, hence, compare the
signalling outcomes for the two individual pathways. In contrast to the models in the
literature, we now present a more complete model, free of any restrictive assumptions.
3.1 The model
The schematic of the model we present is shown in Figure 3.1.1. In this model, we
consider a single ligand, A, binding to a pre-dimerised receptor complex. We assume all
dimers are homodimers, so the receptors within the complex are identical. Each protomer





























Figure 3.1.1: The binding of a ligand A, and activation of pre-dimerised receptors show a
spherical schematic describing interactions with ten dimer complexes. Binding is deter-
mined by KA, while activation Kact. Cooperativity factors α, λ, ν and ξ describe crosstalk
and the more complex interactions.
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3.1.1 Notation
The notation we have used to describe the state of each species is as follows:
− Each protomer is denoted by R, hence an unbound, inactive dimer is RR.
− A subscripted A attached to an R indicates that the receptor is bound by a ligand
molecule. As such RAR implies that one of the protomers in the dimer is bound,
while RARA represents a dimer that is dual bound. We assume there is no preference
for which protomer the ligand molecule binds to first.
− Ligand association and dissociation kinetic rate constants, for inactive receptors are
ka+ and ka− respectively, and KA = ka+/ka− is the equilibrium binding constant.
− An active receptor is represented by an asterisk, hence, R∗R indicates that one
receptor within the dimer is active. Similarly, R∗R∗ is a dimer with both protomers
active. We follow the work of Rovira et al and denote these ’asymmetric’ and
’symmetric’.
− We have kact+ and kact− as the activation and deactivation rates, and Kact =
kact+/kact− is the equilibrium activation constant. These account for the basal
activation of receptors in the absence of ligand, otherwise known as constitutive
activity.
As the dimer consists of two identical receptors we assume symmetry throughout, hence
RAR, for example, describes a dimer with a single molecule bound, regardless of which
side it is bound to. Furthermore, for simplicity of notation, we order the receptors within
the dimer such that a receptor that is bound will be listed first, followed by an active
receptor, then finally a free receptor. This means that, a dimer that has one protomer
bound by ligand, and the other active, will be written RAR
∗. We highlight however, the
reaction
A + R∗R RAR
∗
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to make note of the ordering. This reaction simply binds a ligand molecule to the inactive
protomer, giving one active unbound protomer and one inactive bound protomer within
the dimer. Whilst before binding ordering is such that the active receptor is on the left,
once binding occurs, ordering dictates that the bound receptor is written first, hence
the active receptor appears on the right. This ordering is simply a necessity in order to
exploit the symmetry of the dimer.
3.1.2 Cooperativity factors
We also require some extra cooperativity factors to fully describe all binding and activa-
tion processes:
− The parameter α remains the same as in Figure 2.1.1, in Chapter 2, where its
effects were explored extensively. It represents equilibrium binding cooperativity,
that is the change in ligand affinity for the dimer when it is already ligand-bound.
The value α = 1 represents neutral cooperativity, and α > 1 and α < 1 represent
positive and negative cooperativity respectively. With positive cooperativity, less
ligand is required for the dimer to become bound by a second molecule, due to the
dimer already being bound, and more ligand is needed for negative cooperativity.
− Similarly we have the equilibrium activation cooperativity factor λ which allows for
the change in propensity for receptor activation of one receptor within the dimer
when the other side is already active. With λ > 1 there is an increased propensity
for activation of the second protomer, while the converse is true if λ < 1.
− The parameter ν represents the intrinsic efficacy of the ligand and accounts for the
change in propensity for receptor activation when ligand is bound as well as change
in affinity of the ligand for active protomers over inactive protomers, where detailed
balance states that these must be equal. This parameter specifically represents these
changes when ligand binding and activation occur on the same receptor within the
dimer. Hence, with ν > 1, if a protomer is ligand bound, there is an increased
propensity that the same protomer will become active. Similarly, for ν > 1, if a
protomer is active it will have a higher affinity for the ligand. The parameter ν
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has no effect on the binding and activation rates of the opposite receptor within
the dimer. In the two-state model by Leff [76], the parameter K∗A is defined as
an alternate binding rate grouping the cooperativity factor and binding constant
together.
− The parameter ξ accounts for the change in propensity for receptor activation when
ligand is bound as well as change in affinity of the ligand, where ligand binding
and activation occur on opposite receptors. For example, with ξ > 1, when one
protomer becomes bound, the propensity for activation of the other protomer is
increased, and similarly activation of one of the protomers increases the affinity for
ligand binding to the opposite protomer.
3.2 Equilibrium analysis
We explore the behaviour of the system, particularly focusing on the effects of the pa-



































which we combine with equations (3.1) to give the equilibrium concentration of each





















































σ = 1 +Kact + λK
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It is well documented that, receptors in an active state elicit a biochemical response
[76]. Although this response will also depend on the downstream signalling pathway,
here we define a cursory signal as simply the response coming from an active receptor.
However, it is unknown whether a dimer with both protomers active simply gives twice
the signal as a single active protomer, or whether other factors may affect this. So in
deriving a signal, we introduce an extra parameter ω to account for this. If ω = 2, we
assume that the signal arising from a symmetric dimer is exactly twice the signal of an
asymmetric dimer, while ω = 1 assumes that, although both protomers within the dimer
are active, the signal being transmitted is unchanged by the activation of the second
receptor. We therefore state the proposed signal as
S = [R∗R] + [R∗AR] + [RAR






This gives the equilibrium signal as
Seq =








1 +Kact + λK
2










which we will use to analyse the effect each cooperativity factor has on the dose-response
curves.
3.3 Dose-response curves: single parameter effects
We now explore how the parameters α, λ, ν and ξ affect the dose-response relationship. In
the following sections, we vary each of these individually while keeping the others fixed,
to isolate the effects of a single parameter. The parameters KA, Kact and Rtot are fixed in
each case with values taken from Woodroffe [138], though we note that these are taken for
illustrative computations only, as the values given by Woodroffe are for monomers. All
parameter values can be found in Table A.4 in Appendix A. The weighting parameter in
the signal is set to ω = 2, so that the signal given from a symmetric dimer is twice that of
an asymmetric dimer, although we also later discuss the possible effects of this parameter
being other values. All dose-response plots are normalised with respect to Rtot, and as
such, when referring to the signal, or Seq, we are assuming this to be the normalised
signal. All plots in this chapter were created using equation (3.6) for the overall signal
and equations (3.3) for the individual species plots.
3.3.1 Varying binding cooperativity parameter α
The first parameter we analyse the effects of is the binding cooperativity factor, α. To
do this we fix all other cooperativity factors as λ = ν = ξ = 1, to focus on the effects of α
alone. Although we note, that these values indicate that the ligand is an antagonist and
also constitutive activity is low, and so the signal will also be low. However, fixing the
values in this way allows us to isolate the effects of α in order to gain a fuller understand-
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ing of the potential consequences of having positive or negative binding cooperativity. We
later vary all parameters simultaneously to explore a range of possible signal outcomes.
Before analysing the signal curves, and as α is a binding parameter, we first comment
on the amount ligand bound. This allows us to directly compare the results with the
previous binding results, in Section 2.1, where we recall the concentration of ligand bound,








1 +KA[A] + αK2A[A]
2
. (3.7)
The superscript b indicates that the expression is from the binding model. To find the
equivalent expression for this model we use the expressions that were given in equations
(3.1), while setting λ = ν = ξ = 1. Noting that
Aabound
Rtot
= [RAR] + [R
∗
AR] + [RAR
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1 +Kact +K2act + (1 + 2Kact +K
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1 + 2Kact +K
2
act ≈ 1 +Kact +K2act, (3.10)
as Kact  1 (although this also holds for Kact  1), which then gives
Aabound ≈ Abbound. (3.11)
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Hence, we can conclude that the concentration of ligand bound in the two models is,
for all intents and purposes, approximately equal. This is also confirmed in Figure 3.3.1
where we plot dose-response curves showing ligand bound, using the expressions from
both the previous binding model and this activation model.
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Figure 3.3.1: The logDR Abound curve for this activation model (equation (3.8)) is plotted
alongside the logDR Abound curve for the binding model (Section 2.1, equation (3.9)).
With equal binding parameters we see that the curves appear to be the equal.
In Figure 3.3.2 we explore the signalling implications of a varied α while fixing
λ = ν = ξ = 1. On the x axis we have ligand concentration, on a log scale. On
the top row, we have the overall signal plotted beside the Abound plot. Underneath these
we plot dose-response curves for each individual species in order to assist in understand-
ing the signal plot.
Unlike the sigmoidal shape we see for monomer dose-response curves (as we discussed
in Chapter 1), we instead have a bell-shaped signal curve. The signal increases as the
ligand concentration increases, and then falls back to the basal level. Research has shown
that this can be indicative of non-standard monomer-ligand binding [100]. To understand
why this effect occurs we look at the individual species curves.
While the ligand concentration is very low, the signal remains close to the basal level,
with most dimers being in the form of either RR, R∗R or R∗R∗. As the ligand in the
system increases we first see an increase in singularly bound dimers, that is, [RAR],
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Figure 3.3.2: Plotting a logDR curve (equation (3.12)) for a range of values for binding




∗]. This is followed by a fall in these same concentrations once
all dimers become dual bound by the ligand, thus causing a peak in singularly bound
species concentrations. This phenomenon was explored extensively in Chapter 2, where
we saw that low cooperativity exaggerated the effect, thereby causing a larger peak in
singularly bound dimers. Cooperativity values that caused this larger peak also gave an
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extra inflection in the total bound ligand curve. In fact, with this Abound plot (top right)
alongside the signal (top left), we see how the extra inflection correlates to the largest
peaks in the signal curve.
The bell shape in the signal curve comes from the concentrations [R∗AR] and [RAR
∗].
Notice that, when binding cooperativity is taken to be extremely low, the peak value of
the signal is exactly double that of the basal level. This low cooperativity, combined with
sufficient ligand, means most dimers become trapped in a form with only one receptor in
each dimer bound. There are then two ways a singularly bound dimer can be also active
(and therefore eliciting a signal), hence we have increases in both [R∗AR] and [RAR
∗],
which leads to the signal doubling in this phase.
This can also be seen mathematically. Taking the signal expression, as in equation
(3.6), with ν = ξ = λ = 1 and ω = 2 gives
Seq =




1 +Kact +K2act + (1 +Kact)










(1 +Kact +K2act + (1 +Kact)












This is clearly identical to the [A]50 value and point of inflection in the Abound curve given
in Chapter 2 when considering single ligand binding, hence the inflection in the Abound
curve directly relates to the peak in the signal curve. Substituting this back into equation
81
(3.12) gives the signal at this point as
Seq
∣∣∣∣[A]= 1KA√α = 2Kact(1 +Kact +
√
α(1 + 2Kact)




As the signal appears to reach a maximum value when the binding cooperativity factor














Furthermore, taking the limit of the signal, as given in equation (3.12), as [A]→ 0, and









confirming that at high ligand concentrations the signal falls to the same level as when
ligand concentrations are low. One particular point of interest occurs when binding
cooperativity is extremely low, enough so that the maximum peak is reached. With the
parameters as we fixed them in Figure 3.3.2, the signal does not begin decreasing until
the ligand concentration reaches 10−4M . Typically, concentrations used in experiments
are much lower than this. This could potentially result in curves that appear to be
monomeric, sigmoidal shaped curves. Not only would this lead to flawed assumptions
being inferred, but would also result in the fitting to a model that is not representative
of the biological system, and inaccurate binding estimates made.
3.3.2 Varying activation cooperativity parameter λ
We now fix α = ν = ξ = 1 and instead vary λ, to investigate the effects of the acti-
vation cooperativity factor. Again, these values mean signal is overall very low, but it
is necessary to understand the effects of λ without influence from other cooperativity
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values. In Figure 3.3.3 we again plot the overall signal curve, along with all individual
species curves. In order to be able to see the details in the curves that are on a lower
order concentration, we split the signal plot across two subplots. Clearly the shape of the
signal curve is similar to that of the signal curve when we varied α (Figure 3.3.2), that is,
a bell-shaped curve. However, we notice that varying λ appears to shift the whole curve,
with an increased λ resulting in an increase in concentration at all points.
Again, the individual species curves give explanation for this. It is clear that varying
λ has little effect on many of the curves. As the only reactions involving the parameter
λ are those that involve the activation of a second protomer, it follows that the concen-




A]. If we focus on these three concentrations, the reason for the changes in the signal








and a decrease in [R∗R∗] as free dimers become bound by a single ligand molecule. As
[A] continues to increase, all dimers eventually become dual bound due to an abundance
of ligand, hence we see an interchange of [R∗AR
∗] and [R∗AR
∗
A], thus creating the peak in
[R∗AR
∗].
As we increase λ, however, we see that this effect becomes more exaggerated, as re-
gardless of the amount of ligand in the system, increasing λ means more asymmetric
dimers becoming symmetric. If λ is high, more dimers are in the form [R∗R∗] in the
absence of ligand, hence the basal signal is increased with λ. Similarly, once the ligand
concentration increases, a high λ leads to an increased peak in [R∗AR
∗], as well as a higher
concentration of [R∗AR
∗
A] once there is sufficient ligand for all receptors to become bound.
To determine how much the signal increases at the peak, we consider the equilibrium
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Figure 3.3.3: Plotting a logDR curve (equation (3.18)) for a range of values for activation
cooperativity factor λ. Increasing λ increases the signal for all concentration of [A].
signal, with α = ν = ξ = 1 and ω = 2, which gives
Seq =
Kact(1 + 2λKact + 2(1 + λKact)KA[A] + (1 + 2λKact)KA
2[A]2)
1 +Kact + λK2act + (1 + 2Kact + λK
2
















1 +Kact + λK2act
, (3.19)
confirms that the signal is equal at both zero and infinity. Furthermore, if we let λ→∞
in equation (3.18) we have
lim
λ→∞
Seq = 2, (3.20)
which verifies that, as equilibrium cooperativity increases, the signal tends to a constant,
maximal signal.
We also use equation (3.18) to investigate the peak in the signal curve. Differentiating





(1 +Kact + λK2act + (1 + 2Kact + λK
2













This confirms that the peak occurs at the same point regardless of the value of λ. Sub-
stituting equation (3.22) into equation (3.18) gives the signal at the stationary point as
Seq
∣∣∣∣[A]= 1KA = 2Kact(2 + 3λKact)3 + 4Kact + 3λK2act . (3.23)
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The difference between the peak and the basal signal can then be calculated as
Sp =
Kact(1− λK2act)




As this expression contains the parameter λ, we find that the height of the peak, in
relation to the basal signal, does change as the parameter λ changes. Furthermore, if we
let λ→∞ we have
lim
λ→∞
Sp = 0, (3.25)
which confirms that, for a high enough λ, the peak decreases until the curve flattens out,
giving a constant maximal signal.
3.3.3 Varying efficacy parameter ν
We now fix α = λ = ξ = 1 and instead vary the efficacy parameter, ν. We see in Figure
3.3.4 that varying ν results in dose-response curve that are shaped similar to monomeric
curves (with the exception of the ν = 1 curve), as opposed to the bell-shaped curves we
saw when varying α and λ. As ν is an efficacy parameter, increasing ν by one order of
magnitude causes a large increase in signal, until the maximum signal is reached. This,
however, means that the signal with ν < 1 are on a much smaller scale than with ν > 1,
and so when plotting the signal we have again separated these in order to see the full
details of each curve.
Whilst there is little ligand available, varying ν has no effect on any of the concen-
trations, and therefore the signal. It then follows that the basal level of activity is the
same for all values of ν. Once the ligand concentration increases, we then see the effect
ν has on the curves. Increasing ν leads to a typical agonist response. The signal curve
is sigmoidal in shape, with an increasing ligand concentration leading to an increase in
signal. Increasing ν leads to an increased peak in [R∗AR], which results in increases in
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Figure 3.3.4: Plotting a logDR curve (equation (3.26)) for a range of values for efficacy
parameter ν. This parameter determines whether the ligand acts as an agonist (when
ν > 1), or inverse agonist (ν < 1), while ν = 1 shows a curve with a small peak.
R∗AR




A]. Whilst increasing ν does mean we also see a decrease
in [RAR
∗], we note that this concentration is on a much smaller scale than the increasing
concentrations, and as such, the increases far outweigh the decreases.
Conversely, if ν decreases, such that ν  1, then the ligand acts as an inverse agonist
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and decreases the signal below the basal level. With a small ν, ability for a protomer to
be both bound and active is almost blocked, which leads to an increase in [RAR
∗], and a
decrease in [R∗AR]. As the ligand concentration increases the system becomes flooded by
the ligand, leading to more dimers becoming bound on both sides. In turn the low value
of ν stops either protomer from becoming active, hence we see a drop in active receptors
and, therefore, the signal.
To determine how much of an increase (or decrease) in signal is gained from increasing
(or decreasing) ν, we set α = ξ = λ = 1 and ω = 2 in equation (3.6), giving
Seq =
Kact(1 + 2Kact + (1 + ν + νKact)KA[A] + ν(1 + 2νKact)KA
2[A]2)
1 +Kact +K2act + (1 + (ν + 1)Kact + νK
2














as the basal signal under these conditions, which we notice depends only on Kact and,






1 + νKact + ν2K2act
, (3.28)
as the increased or decreased signal level (once saturation is reached). We use this
to find the order of magnitude of the signal under a varying ν, noting that this will
depend on both ν and Kact. First we point out that, if νKact  1 then it follows that
(νKact)
2 > νKact. We can then state that, if
νKact  1, ⇒ Seq ≈ 1. (3.29)
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Conversely, if





1 + νKact + ν2K2act
= 2, (3.31)





1 + νKact + ν2K2act
= 0, (3.32)
concluding that as ν → 0 the signal is inhibited entirely, with constitutive activity being
suppressed, giving the ligand as a full inverse agonist.
























Figure 3.3.5: We plot the signal curve (equation (3.26)) for values of ν close to one,
showing the smoothing out of the peak.
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We also explore the peak seen in the ν = 1 curve. For a monomeric model, having
both ν = 1 and ξ = 1 would equate to a neutral agonist, and the signal would be con-
stant. For this dimer model, however, we see a peak appear in the curve. We discussed
the reason for the peak appearing when α = ν = ξ = λ = 1 in Section 3.3.1. In Figure
3.3.5 we plot the signal for values of ν close to one. In this we see that, as ν increases
past one, the peak increases, however, the saturation signal increases by a larger amount,
until the curve smooths out. Similarly for ν decreasing, the peak decreases as ν decreases,
until there is no longer a peak.
3.3.4 Varying efficacy parameter ξ
In this section, we note that varying ξ gives exactly the same signal as when we varied
ν. To show this we take ν = x1 and ξ = x2, giving the signal as
Seq =



















+ x1KAKact[A] + x2KAKact[A] +KA[A] + λKact
2 +Kact + 1
.
(3.33)
Similarly, taking ν = x2 and ξ = x1, gives the signal as
Seq =



















+ x1KAKact[A] + x2KAKact[A] +KA[A] + λKact
2 +Kact + 1
,
(3.34)
hence, the signals are equal. This comes from the symmetry in the sphere (Schematic
in Figure 3.1.1), and in particular the concentrations of the species R∗AR and RAR
∗. If
ν > ξ then [R∗AR] increases to a higher concentration than [RAR
∗], while if ν < ξ then
[RAR
∗] increases to the higher concentration. However, the sum [R∗AR] + [RAR
∗] is the
same for both cases. This effect is illustrated in Figure 3.3.6 where we fix all other pa-
rameters and take two different values for ν and ξ. Although the curves for [R∗AR] and
[RAR
∗] change as the parameters change, their sum is the same. This results for all other
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Figure 3.3.6: Plotting two sets of logDR curve (equation (3.33)), with ν = 100, ξ = 0.1
and also ν = 0.1, ξ = 100. The symmetry in the model sphere means that, although the
curves of [R∗AR] and [RAR
∗] change with varying ν and ξ, their sum, as well as all other
concentrations, is equal.
species are equal for both cases. We note that, having this symmetry in the parameters
ν and ξ will result in identifiability issues if the model is used for data fitting, as it is
unable to uniquely identify them individually from the model equations. Identifiability
is something we return to in Chapter 5 (though not for this model).
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3.3.5 Varying signal weighting parameter ω
The final parameter we consider the effect of is ω. This parameter dictates how much of
a signal is elicited from a symmetric dimer in relation to an asymmetric one. Changing
this parameter does not affect any of the individual species concentrations, it simply
describes how much of a contribution to the overall signal each species has. With ω = 1
the contribution from symmetric dimers is equal to that of asymmetric dimers. Increasing
ω means that the signal from symmetric dimers is scaled so that they give a larger
contribution to the signal. As such the signal is increased. Similarly, if ω < 1, the
contribution from symmetric dimers is less than that of asymmetric ones, and the overall
signal is decreased. This can be seen in Figure 3.3.7.
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Figure 3.3.7: Plotting a logDR curve (equation (3.6)) for a range of values for weighting
parameter ω, with all cooperativity factors fixed at one. Increasing ω increases the
contribution symmetric dimers have to the signal, which then increases the signal.
3.4 Dose response curves: varying multiple parame-
ters
Although it was important to vary each of the parameters individually, in order to fully
understand the effect they have on the system, it is more likely that these parameters
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will all be values other than one. In particular, we are usually interested in the effects of
an agonist, that is when efficacy parameters are greater than one. We now examine the
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Figure 3.4.1: We fix ξ = 1 and vary λ on each row, ν in each column and α within each
subplot (using equation (3.6)). We see effects such as inflections and overshoots in some
of the curves.
In Figure 3.4.1 we plot only signal curves. We fix ξ = 1, then on each row we vary the
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parameter λ, each column has a different value of ν, while α is varied within each plot.
We note that, although it is unlikely that ξ = 1, for now we keep it fixed this way in
order to understand the results using findings from the previous sections. In these plots,
we observe a number of behaviours that did not appear in the signal curves when varying
only a single parameter. The neutral curve (with all cooperativity factors equal to one)
appears to be an almost constant signal for most ligand concentrations, though with a
small peak for a small range of concentrations. We found that changing the binding
cooperativity factor α increases or decreases the size of this peak, while the activation
cooperativity factor λ shifts the whole curve. Varying the efficacy parameter ν increases
or decreases the signal from the basal level, without affecting the basal level, giving ago-
nist or inverse agonist behaviour. When all parameters are varied simultaneously, we see
how these effects combine and result in the emergence of new behaviours, such as extra
inflections (for example in subplots (d) and (k)) or overshoots (subplots (n) or (q)) in
some of the dose-response curves.
If we focus on one particular curve as an example, we will discuss how each parameter
contributes to these new effects. We take the green curve in plot (q), that is, with
α = 10−4, ν = 10, λ = 0.1, and plot this in Figure 3.4.2. Along with this signal curve, we
also plot the neutral curve for a point of reference, and the resulting signal for each of
these parameter values being applied individually, for example, α = 10−4, ν = 1, λ = 1.
In this plot, we can clearly see that ν increases the signal from the basal level, and has
the biggest contribution in the curve overall.
Whilst it appears that λ has no effect on the curve, we remind the reader of the results
in Figure 3.3.3 where we saw that, as λ decreases from λ = 1 to λ = 10−1, the signal does
decrease but on a much smaller scale, hence it appears to have no effect when plotting on
a larger scale, as in Figure 3.4.2. This contribution creates a slight decrease of the satu-
ration signal. Finally, the binding cooperativity factor α is what creates the overshoot in
the signal curve. Notice in the curve where α = 10−4 and all other cooperativity values
are one, the peak increases by approximately 0.001, from the basal level. This appears
to be the same as the increase of the overshoot above the saturation signal level, thus
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Figure 3.4.2: We plot dose response curves (equation (3.6)) for α = 10−4, ν = 10 and
λ = 0.1, as well as for these each being set individually.
indicating that the large peak arising from having such low binding cooperativity causes
the overshoot.
Upon closer inspection, we notice that all curves that have these unusual behaviours
when binding cooperativity α is low. This is a clear link to our findings in Chapter 2
where we found low cooperativity to result in extra inflections in dose-response curves
for all binding models. However, we also note that we do not see extra inflections or
overshoots in all low binding cooperativity signal curves in Figure 3.4.1, and so we find
that all cooperativity factors have an effect on whether these occur or not. While it is
theoretically possible to derive conditions under which these appear, the calculations are
impractical for use and require the solution of high degree polynomials.
Finally, in Figure 3.4.3, instead of fixing ξ = 1 we consider the more realistic case,
where ξ = ν. That is the efficacy of each protomer is the same. In this, we notice that,
while we still see inflections in some of the curves, these appear in fewer plots. Also,
there are no overshoots at all that can be seen. It seems that, increasing (or decreasing)
ξ together with ν counters some of these effects. We do not explore why this happens at
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Figure 3.4.3: We fix ξ = ν and vary λ on each row, ν in each column and α within each
subplot. We see some extra inflections but now no overshoots in the curve.
3.5 Conclusions
In this chapter, we have extended the dimer binding model (Chapter 2) to include re-
ceptor activation. The increase in complexity of the model from our previous GPCR
models is clear, and we also see many new behaviours emerging in the dose response
curves. The focus remains on the cooperativity factors that affect secondary binding
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and activation. We first considered the effect of each of these parameters individually,
observing the effect each had on the dose response curves. With all cooperativity factors
being neutral, that is equal to one, the signal curve remains almost constant for most
ligand concentrations, but with a small peak for a range of ligand concentrations. This
peak is a point of interest as it appears with efficacy parameters equal to one, that is, the
ligand acting as a neutral agonist. For monomeric receptors, the signal for a neutral ag-
onist is constant, hence a peak such as this can be used to identify the presence of dimers.
We use this neutral curve as the baseline when comparing the effects of varying the
other parameters. The cooperativity factor α causes the peak to increase with an de-
creasing α. This bell shaped curve is often indicative of dimerised receptors [100]. We
also saw how the peak in the signal curve is directly related to the extra inflections seen
in the ligand-bound curve. The primary effect of varying λ is a shift in the whole curve.
Increasing λ increases the signal for all ligand concentrations and causes subtle changes
in the peak size. The symmetry in the model means that we obtain the same results
when varying ν or ξ, hence we choose to only explore the effects of ν. Doing so results in
a change of the shape of the curve. Increasing ν from neutral leads to the ligand acting as
an agonist, while decreasing ν from one sees inverse agonist curve shapes. Furthermore,
the amount of increase or decrease in the signal at saturation is directly proportional to
the increase or decrease in ν. That is, increasing ν, results in an increase in signal, at
saturation.
We also consider how these effects combine, by looking at the results when varying
multiple parameters together. In these, we see new behaviours emerge, such as extra
inflections and overshoots in the signal curves. We show how each of the parameters
contribute to these curves. The model formulation, solution and results serve as a con-
tribution to the field of pharmacological modelling. The expressions given are practical
in use and are easily used to simulate results. The findings presented in this chapter can
explain experimental data that has a bell-shaped curve or overshoots in the curve, which
can, in turn, be used to inform further experiments.
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While we have explored some of the possible effects that can be seen at equilibrium, we
note that this work is ongoing. Next steps would be to understand why more inflections
and overshoots can be seen in the dose response curves when ξ = 1 as opposed to when
ξ = ν. Following this,we would investigate the time course dynamics of the system, where
we expect to see many more interesting behaviours appear.
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Chapter 4
The vascular endothelial growth
factor system
In Chapter 4 (Section 1.4) we introduced the vascular endothelial growth factor (VEGF)
system. VEGF is a key mediator of angiogenesis; a process whereby new blood vessels
are formed from the pre-existing vasculature [80, 3]. As angiogenesis is a key factor
in many conditions, including cancer and inflammation [80, 111, 102], research into the
mechanism of VEGF binding and signalling is essential towards progress in development
of new therapies. Although advancements have been made towards understanding the
interactions of receptor tyrosine kinase (RTK) ligands and receptors, further research is
needed to fully understand their role as therapeutic targets [102, 101, 111].
Although much of existing research is done at equilibrium [80], a recent study by Kil-
patrick et al [70] has used new technologies to provide a real time quantitative evaluation
of VEGF-VEGFR binding. Developments in fluorescent ligand technologies have allowed
the complexities of ligand-receptor interactions in living cells to be observed[70, 102]. In
this study, synthesized dual poled VEGF ligand molecules, that is, a ligand that can bind
two receptors simultaneously, were monitored binding in real time to VEGFR-2 recep-
tors. Results were fitted to a simple association exponential model, however, in many
cases the results failed to fit with the standard model for simple mass-action equilibrium.
Hence there is need for a model that incorporates the complexities of the VEGF binding
dynamics, also taking into account the dimerisation that is induced from ligand binding.
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The ligand induced dimerisation process is investigated extensively in [3], where mul-
tiple stochastic models are analysed to further understand the role the VEGF receptor
system plays in tumour growth, although most models given there include biological pro-
cesses beyond binding. An interesting point that is also mentioned in [3] is that at high
ligand concentrations there is an inhibition of cellular response. This is a phenomenon
that is also seen experimentally in [15], although they describe it as a ’window of desen-
sitisation’ to VEGF, with a continued increase in signal after a short decrease. Spatial
models of the dimerisation process and subsequent signalling are developed in [85], while
dynamics of receptor and transducer protein dimerisation are studied using an ordinary
differential equation (ODE) model in [127], wherein it is suggested that dimerisation
may serve to regulate signalling over multiple time scales. An ODE model of receptor
binding and aggregation is presented in [132], although only equilibrium is analysed.
Equilibrium models in [136] and [71] also explore the possibility of heterodimers. Mac
Gabhann and Popel [80] combine a ligand induced dimerisation model with a ’dynamic
pre-dimerisation’ model, whereby the dimers are formed before ligand binding, in order to
explore the mechanisms of the dimerisation of VEGFR and the possibility of the VEGF
receptors having the ability to dimerise in the absence of ligand as well as being induced
by ligand. Gabhann and Popel also consider the possibility of VEGF receptors having
the ability to form heterodimers, although to what extent this is possible biologically is
currently unknown, however their findings suggest that the level of heterodimer formation
could be significant as the signalling initiated by these is different and unique.
When formulating our previous GPCR models, we introduced the idea of a coopera-
tivity factor; an extra parameter that alters the binding rate of a second ligand molecule
to a pre-formed dimer, due to a first already being bound. Using this cooperativity factor
we were able to analyse equilibrium binding results, and contribute to current receptor
theory by also considering binding dynamics. Furthermore, analytical expressions for
both equilibrium concentration curves and binding kinetics, in terms of this cooperativ-
ity value, gave insights into the effects dimerisation has on binding. In this chapter, we
continue this work by applying the same framework as we did to the GPCR models in
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Chapter 2 to the VEGF-VEGFR system. We again formulate a model in terms of a co-
operativity factors, although due to the difference in the dimerisation mechanism of this
system, cooperativity in this paper is defined as a factor that alters the binding rate of a
second receptor (as opposed to second ligand molecule), once a first receptor is bound to
the ligand. The inspirations for this paper lie in the work by Mac Gabhann and Popel
[80], where they present a model for the binding and dimerisation of VEGF-VEGFRs.
However, while the model Mac Gabhann and Popel present also includes activation
and diffusion, we choose to focus on binding only. Binding dynamics are a current topic
of experimental study and a simpler model allows for the study of time course dynamics
as well as equilibrium results. Furthermore, this allows us to follow the analysis methods
we used in our previous work. However, this ligand induced model that we develop
results in a nonlinear system of ODEs (in contrast to the GPCR model in Chapter 2),
for which we are unable to give exact analytical solutions. However, the structure of
our model is inline with more complex receptor dynamics models ([138], [137], [14]),
hence we follow their lead in analysing the system dynamics. We use numerical methods,
for a range of control parameters, to explore possible time course behaviours, whilst
perturbation analysis gives analytical solutions for reduced problems under interesting
parameter regimes. Finally, the model is validated by fitting to recently published data,
quantifying the ligand-receptor interactions.
4.1 Model formulation
In formulating the model we assume that all receptors exist constitutively as monomers,
represented by R, while ligand A is a two-poled ligand, which has the ability to bind
to two receptors simultaneously. Ligand binding and dimerisation is a two step process
which can be visualised as in Figure 4.1.1 or given as a reaction scheme in Figure 4.1.2. In
the first reversible reaction the ligand, which we fix at a constant concentration, binds to a
free monomeric receptor, with association and dissociation rates of k+ and k− respectively,
thus creating the complex AR. Once a ligand molecule is bound to a receptor the ligand





ψ−k−R R AR R RAR
Figure 4.1.1: Ligand binding and dimerisation is a two step process whereby a two poled
ligand (in red) first binds a monomeric receptor (blue) before then binding a second and
instantaneously dimerising the monomers.
We define the parameter ψ = ψ+/ψ− as the cooperativity factor, describing the ligand’s
increased (or decreased) affinity for the second receptor binding due to the first ligand
pole being bound. If, for example, ψ+ > 1 we have positive forward cooperativity, where










Figure 4.1.2: Schematic representing the reactions resulting from the binding of a two
poled ligand to two monomeric receptors.
In Chapter 2 we also explored the effect cooperativity has on binding, this time in GPCRs.
However, there are differences in how cooperativity is described in the earlier chapters
and this model. In the previous models we assumed all receptors were predimerised, and
so cooperativity was the change in affinity of a second ligand binding, where as in this
model it describes the change in affinity of a second receptor binding.
The law of mass action gives rise to a system of ordinary differential equations (ODEs)
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that govern the binding kinetics of the reactions, namely:
d[R]
dt
=− k+[A][R] + k−[AR]− ψ+k+[R][AR] + ψ−k−[RAR], (4.1a)
d[AR]
dt
= k+[A][R]− k−[AR]− ψ+k+[R][AR] + ψ−k−[RAR], (4.1b)
d[RAR]
dt
= ψ+k+[R][AR]− ψ−k−[RAR]. (4.1c)
with initial conditions
[R](0) = Rtot, [AR](0) = 0, [RAR](0) = 0 (4.2)
where square brackets denote concentration, and all parameters and measured quantities
are restricted to be positive. The signal of interest is proportional to the number of
receptors bound [70], so we can therefore state this as
S = a([AR] + 2[RAR]), (4.3)
where a is a scaling constant. The signal consists of the concentration of AR and double
the concentration of RAR. This is because each molecule of RAR is made up of two
receptors, hence the signal given off is twice that of the concentration, as is described in
[70]. The total concentration of receptors is conserved, with
Rtot = [R] + [AR] + 2[RAR], (4.4)
where Rtot is the total concentration of receptors. We use this to reduce the system (4.1)
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The initial value problem has the initial conditions
[R](0) = Rtot, [AR](0) = 0, (4.5c)
since we assume that no bound complex is present to begin. We note here that we assume
there exists no constitutive dimerisation, hence dimers are solely ligand-induced. It is
worth observing here that the model we have developed is structurally similar to that
of ’Model 1’ in [3], though moving forward we focus on analysing the binding dynamics,
whereas the authors of [3] continue to expand the model to include other biological
features of the signalling pathway.
4.2 Equilibrium analysis
In the spirit of classical receptor theory, and in keeping with our previous work, we
first investigate the equilibrium behaviour of the system, in particular the effect of the
equilibrium cooperativity factor ψ = ψ+/ψ−. The equilibrium relationships are
[AR] = KA[A][R], (4.6a)





where KA = k+/k− is the equilibrium association constant (that is KA = 1/KD). Com-





















From this we can state the overall signal at equilibrium to be
Seq =




(1 +KA[A])2 + 8ψK2A[A]Rtot)
4ψK2A[A]
. (4.8)
If we let [A] → ∞ we have [R], [RAR] → 0, while [AR], Seq → aRtot. This signal
is a scaled concentration of the total bound ligand, hence is comparable to the total
ligand bound expression in our Chapter 2, which we see, although there is similarity in
the models, these expressions are very different. Whilst analysing the GPCR model we
presented in this earlier chapter, we found a condition under which dimer cooperativity
caused there be to extra inflections in the log dose-response (logDR) curve. We check
whether it is also possible to get these extra inflections with this ligand induced model.
Taking the expression for the (unscaled) signal
Seq =

































This is zero when
3K2A[A]
2 +K3A[A]























2 = ((1 +KA[A])
2 + 8ψK2A[A]Rtot)
3. (4.12)
Expanding and simplifying gives
−8ψK3A[A]3Rtot(2ψKARtot + 1)(K4A[A]4 + 2K3A(4ψKARtot + 1)[A]3
+ 8ψK3ARtot(2ψKARtot + 1)[A]
2 − 2KA(4ψKARtot + 1)[A]− 1) = 0.
(4.13)
The left hand side (LHS) is zero when [A] = 0, and also when
K4A[A]
4 + 2K3A(4ψKARtot + 1)[A]
3 + 8ψK3ARtot(2ψKARtot + 1)[A]
2
− 2KA(4ψKARtot + 1)[A]− 1 = 0. (4.14)
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For this fourth degree polynomial, we do not find the roots exactly, however we can de-




i be a polynomial of degree n with real coefficients that has
exactly p positive real roots, counted with multiplicities. Let v = var(a0, ..., an) be the
number of sign variations in its coefficient sequence. Then v ≥ p and v ≡ p( mod 2). If
all roots of A(X) are real, then v = p.
As all parameters are positive, we have v = 1, that is one sign change, and so only one
positive real root, and therefore only a single inflection point. This concludes that there
is no condition under which we get extra inflections. Hence, a logDR curve, for binding,
with extra inflections should not be seen for ligand induced dimerisation so may indicate
pre-dimerised receptors but not ligand induced ones.
In Figure 4.2.1 we look at the effect the equilibrium cooperativity factor ψ has on the
log dose-response (logDR) relationship. Parameter values for the plot can be found in
Appendix A. As the maximal ligand bound is Rt, we can calculate the EC50 value (the
concentration giving half-maximal effect) for the signal, using equation (4.8), as
EC50 =
a
KA(2a− 1)(a+ (2a− 1)ψKARtot)
. (4.15)





Again this expression is very different from the EC50 expression in our previous models,
in Chapter 2, with the most noticeable difference being that this now also depends on
Rtot. We see in Figure 4.2.1 that as ψ increases there is an approximate leftward shift in
the overall signal, indicating the smaller EC50. Looking at the individual species curves
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explains why this occurs.
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Figure 4.2.1: LogDR curves for varying cooperativity factor, ψ. The plots show the
overall signal as well as concentrations of R (equation (4.7a)), AR (equation (4.7b)) and
RAR (equation (4.7c)).
When high cooperativity is combined with low concentrations of A, most ligand
molecules bind two receptors and thus form dimers, due to the concentration of receptors
being much higher than that of the ligand, hence we see [RAR] increase with [A] whilst
[AR] remains close to zero. Recalling that the signal is made up of one [AR] and two
[RAR] we see the signal is approximately twice the concentration of RAR. This continues
until the ligand concentration reaches the point that there are no longer enough monomers
to bind both poles of the ligand. From this point we see a plateau in [RAR] and instead
[AR] increases. Once the system is saturated with ligand [RAR] falls back towards zero,
as the concentration of ligand is so much higher than the receptor concentration, hence
there are no available receptors to bind the second pole of the ligand. Interestingly we
see that the overall signal reaches saturation at a much lower concentration of A than
[AR]. This occurs once the system reaches the point where almost all receptors are bound
and so as [A] increases from this point there is an interchange of each dimerised bound
receptor to two single bound receptors, however, as all receptors are still bound there is
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no apparent change in the overall signal.
With low cooperativity, the decreased propensity for dimerisation results in lower
concentrations of [A] being required for the same increase in bound monomers than when
cooperativity is high. Although a small percentage of ligand bound monomers still bind
a second receptor, causing dimerisation, low cooperativity prevents this from increasing
substantially. Hence the signal increases largely with monomeric bound receptors. In-
terestingly we see that the peak in [RAR] appears at the same level of [A] regardless of
the cooperativity value. To find the point at which this occurs we begin with expression













(1 +KA[A])2 + 8ψK2A[A]Rtot
. (4.17)





ie, the dissocitation constant, KD. This is only dependent on the binding rates, hence
this peak will appear to some extent regardless of the cooperativity levels. To find the








































as all other terms tend to zero, we find Rtot/2.
4.3 Binding dynamics: numerical simulations
Here we present some numerical results to show how cooperativity affects the binding
dynamics of the individual species and the resulting overall signal. We fix k+ and k−,
within the range of reported binding affinities ([80] and references within), to allow us to
focus on the effects that cooperativity factors ψ+ and ψ− have on the binding dynamics.
In Figure 4.3.1 we see how these parameters are a major factor in the behaviour of the
individual species dynamics and the overall signal.
First looking to the overall signal, we notice that increasing ψ+ leads to an increased
signal at equilibrium. Increasing ψ+ gives an increased rate of binding of a second
monomer, hence, once a ligand binds a receptor it very quickly binds a second, and
so the elevated signal levels come from an high concentration of [RAR]. Similarly, de-
creasing ψ− gives an increase in the equilibrium signal, as in this case, once a dimer is
formed it very quickly returns to bound monomer form, leading to an increased [AR]. As
ψ− decreases, the time taken to reach equilibrium is also increased, and in fact, looking
further at the signal curves when ψ− is low is the first indication that there may be further
intricacies in the dynamics to be explored, and for this we look at the individual species
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Figure 4.3.1: A numerical investigation into the effects of cooperativity factors ψ+ and
ψ−. The columns show the overall signal as well as individual species (equations 4.1)
while in each row we fix the ψ+ value. Each plot then shows a varied ψ−. Plots are
created with ligand concentration [A] = 10−10M .
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curves.
On closer inspection we see three features of interest. Firstly, when ψ− is small, and
therefore a slowed dimer dissociation rate, we see peaks forming in the [AR] curve. Al-
though monomers are initially bound to the ligand, once these form dimers, having a slow
dimer dissociation rate reduces the chance of them returning to monomers, so for a time
each dimer is essentially stuck in this form, and so the concentration of bound monomers
falls. This also explains the extended time for the system to reach equilibrium with small
ψ− as this interchange between bound monomers and dimers increases the time in which
it takes the concentrations to come into balance. Conversely, if ψ− is large, peaks appear
instead in the dimer concentration, [RAR]. Ligands bind monomers and in turn form
dimers. However, with an increased dimer dissociation rate these quickly return back to
monomers, and so we see a peak in the curve.
The final feature we notice is again in the [AR] curve, but this time when ψ+ is large.
In this case the [AR] curves in particular appear to have an initial rapid increase in
concentration, indicating that we have multiple time scales. The forward cooperativity
factor being large drastically increases the rate at which bound monomers form dimers,
and so [RAR] increases much faster than when ψ+ was smaller. This in turn means
that there are fewer available monomers to become bound, and so [AR] remains low.
Overall, however, the dimerisation happens on a much shorter time scale, hence we see
this short transient period in the [AR] concentration curve. We also note that these
effects are combined, for example, when we have a large ψ+ with a small ψ−, we see the
concentration of [AR] increases rapidly to a peak before decreasing towards equilibrium.
The analytical tools we used in Chapter 2, for the linear GPCR system, do not apply
here, so we instead use asymptotic analysis to explore system (4.1).
4.4 Dimensionless differential equations
To be able to analyse system (4.1) asymptotically we first require it to be nondimen-
sionalised. To rewrite the variables to nondimensional form we first give the units of all
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Table 4.1: The units of the variables and parameters in the system (4.1).
We begin by nondimensionalising [R]. As [R] has units M , for balance, we require a
scalar that also has units M to rescale with. The natural choice for this is Rtot, and so
we let dimensionless free receptor r be given by




To scale [AR] and [RAR] we first recall the equilibrium concentrations




We use these to give us scalings for [AR] and [RAR] as these are the natural scalings to
ensure that [AR] and [ARA] are O(1) at equilibrium. Hence, we have












where r, p and q are the new nondimensional free receptor, single bound receptor and
dimerised receptor, respectively. As t has dimension s, we nondimensionalise by a param-
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eter with the same dimension. As equilibrium is reached approximately when t = k−1− ,




⇒ t̃ = k−t. (4.26)


































α = KA[A], β =
ψ+Rtot
[A]
, γ = ψ−, (4.28)
are the dimensionless parameters for the system. The initial conditions, in equation
(4.5c), now become
r(0) = 1, p(0) = 0. (4.29)
It is also worth noting that the conservation law, given in equation (4.4), now becomes




which can be used to calculate the concentration of q where necessary. Biologically, α is
the ligand concentration scaled by equilibrium dissociation rate, so α  1 if either the
ligand concentration is very high or has a very high affinity. The grouped parameter β
depends on the cooperativity factor ψ+ as well as the ligand-receptor ratio, so can be
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considered a scaled dimerisation rate. So β  1 if either ψ+ is large, which leads to an
increase in the rate at which dimers are formed, or there is a much higher concentration
of receptors than there is ligand. As γ is simply the parameter ψ−, if γ  1 then we have
fast dimer dissociation. We can also state the equilibrium solutions for this dimensionless
system as
req = peq =
γ
(
−(1 + α) +
√





, qeq = (req)2. (4.31)
4.5 Asymptotic analysis
In Section 4.3 we noticed that a choice of small ψ− leads to a peak in the [AR] curve,
whilst a large ψ− leads to a peak instead in [RAR]. Also, choosing ψ+ to be large
gives a rapid increase in [AR]. This leads to three cases to investigate using asymptotic
analysis to further understand these features. As the system is now governed by the
three nondimensional parameters α, β and γ, we use these to gain insights into how it
will evolve over time. To do this we use the nondimensional system in equations (4.27),
though for simplicity we drop the tildes. Binding rates of VEGF are well documented [80]
(and references within), and so throughout this section we assume α = O(1), allowing us
to focus on the possible effects of cooperativity.
4.5.1 Small γ asymptotics (slow dimer dissociation)
In Figure 4.3.1 we saw that having a slow dimer dissociation rate gave peaks in [AR]. As
a slow dimer dissociation is equivalent of having a small γ in the dimensionless system,






































(1− r − αp) (4.32c)
This is a regular perturbed problem. Assuming asymptotic approximations
r ≈ r0 + εr1 + ..., p ≈ p0 + εp1 + ..., (4.33)
where each ri, pi is O(1), and substituting these into equations (4.32) gives the leading
order problem at O(1) as
dr0
dt
= − αr0 + αp0 − α2βr0p0, (4.34a)
dp0
dt
= r0 − p0 − αβr0p0, (4.34b)
r(0) = 1, p(0) = 0, (4.34c)
Although this is still a nonlinear system that we are not able to solve analytically, we
can still make some observations. The terms that remain in the ODEs are the linear
terms, representing the reversible binding of the ligand, as well as the nonlinear term
that dictates the formation of the dimer, that is, the forward dimerisation. With γ = ε,
the terms representing the dissociation of the dimers are approximately zero, hence do
not appear in these equations. As such we would expect that as dimers are formed they
become stuck in this form, hence we would expect to see the concentration of dimers
increasing monotonically. In Figure 4.5.1 we plot the solutions of the full, nondimensional
system, as given in equations (4.27), along with the approximated system in equations
(4.34). In this we see there is little difference in the two solutions, confirming that
negating the terms in the approximated solution has little effect on the overall dynamics.
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Figure 4.5.1: Both the solution to the full system in equations (4.32) is plotted along side
the solution of the reduced, approximated system (equations (4.34)) in red. Conservation
of receptors is used to show the approximation for q. Parameters used to create plots are
α = β = 1 and γ = ε = 0.001.
4.5.2 Large β asymptotics (fast dimerisation)
Another feature appearing in Figure 4.3.1 is that, when ψ+ is large (particularly in the
top row in the figure), we see an initial increase in the concentration of [AR] in a short
time period, before the concentration increases towards equilibrium. This indicates that
the concentration is evolving on at least two different timescales. This happens when we
have a fast dimerisation and ψ+ large, and since ψ+ is incorporated in β, we set β = 1/ε,



































r(0) = 1, p(0) = 0. (4.35c)




(1− r − αp) (4.35d)
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As ε is multiplying the highest derivatives, this is a singular perturbed problem, which
supports our observation of multiple timescales in the concentration curves. In Figure
4.5.2 we view the numerical solution to this system on a log-log scale where it also is
apparent that the dynamics are evolving on more than one time scale. This plot is used
to suggest the time scales needed to asymptotically analyse the system. We find that we
require three solutions to accurately approximate all of the intricacies of the curves.


















































Figure 4.5.2: Numerical solutions of the full system (equation (4.35)), on a log-log scale.
Plot created with α = 6.8, β = 1/ε, γ = 1.4 with ε = 10−4.
Inner solution
Looking at Figure 4.5.2, we see two plateaus in the p curve, with the first one appearing
when t = O(ε), hence we assume this to be first time scale of interest. We call this region
the inner region. We also note that within this region, p is of O(ε), while r remains O(1).
Hence we rescale
p = εp̃, t = ετ. (4.36)
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For matching convenience later, we also use the change of variable r = r̃. This now gives

































r̃(0) = 1, p̃(0) = 0. (4.37c)
Substituting asymptotic approximations
r̃ ≈ r̃0 + εr̃1 + ..., p̃ ≈ p̃0 + εp̃1 + ..., (4.38)















r̃0(0) = 1, p̃0(0) = 0. (4.39c)
This has the solution




which is valid while t ε. Interestingly, the solution p(t) depends only on α. Biologically,
this implies that, in this initial layer, the concentration of p, and therefore [AR], is




Figure 4.5.2 suggests that the long time solution of both r and p are O(ε
1
2 ). We can also
confirm this using the equilibrium concentration as stated in equation (4.31). Setting
β = 1/ε in this, and using a Taylor series expansion to approximate the square root term
gives
req = peq =
εγ
(
−(1 + α) +
√



































2 + higher order terms (4.43)
hence confirming that the long time solution of both r and p are O(ε
1
2 ). As such we
rescale these by substituting
r = ε
1
2 r̂, p = ε
1
2 p̂. (4.44)















































We assume asymptotic expansions
r̂ = r̂0 + ε
1
2 r̂1 + ..., p̂ = p̂0 + ε
1
2 p̂1 + ..., (4.46)
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To find the expressions for r̂0 and p̂0 we also need to consider the O(ε
1





























p̂0 − α(r̂0p̂1 + r̂1p̂0). (4.48b)
To eliminate the nonlinear terms coming from the higher order terms in the expansion





= 2α(p̂0 − r̂0). (4.49)




















This equation can be solved by using separation of variables, with the solution r̂0(t) given
implicitly by
2α log(r̂0)− (α + 1) log(|2α2r̂20 − γ|) = 2α(2t+ c1), (4.52)














hence we can remove the absolute value, giving the solution as
2α log(r̂0)− (α + 1) log(2α2r̂20 − γ) = 2α(2t+ c1). (4.54)












= 2α(2t+ c1). (4.55)
Matching
The usual method (as outlined in [96]) at this point would be to match the inner and
outer solutions to determine the constant c1. This would be done by taking the limits of
the inner solutions as τ → ∞ and equating these with the limits of the outer solutions
















which is a clear contradiction to the product of the outer solutions as found in equation
(4.47), hence there is no way that both solutions r and p can match.
Intermediate solution
To overcome the matching problem we consider the solutions in an intermediate layer,
between the inner and outer layer. Looking at Figure 4.5.2 we can see that, as t tends to
O(1), then r and p begin at order 1 and ε respectively before tending to the equilibrium,
so for an intermediate solution we rescale
r = r̄, p = εp̄. (4.58)
We note here that these scalings are the same scalings we used for the inner solutions
(although we use a separate notation for clarity when matching), in this intermediate

























































Solving this system gives
r̄0(t) = c2e
−2αt, p̄0(t) =
(2α− γ)c2 + γe2αt
2α2c2
. (4.61)
Matching the intermediate to inner region






Taking these limits gives
c2 = 1. (4.63)
















(2α− γ) + γe2αt
2α2
. (4.65)
As the parameter γ appears in this solution we can see that as we move into this region
the second reaction, whereby the ligand binds a second monomer, now also plays a role
in the dynamics of the system.
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Matching the intermediate to outer region






















We also need to confirm that the solutions for p match in this region. To do this we use
equation (4.47), but first noting that
r̄0(t)p̄0(t) =
(2α− γ)e−2αt + γ
2α2
, (4.68)












As we have already determined that the solutions for r match, we can therefore con-
clude that p must also match. Figure 4.5.3 shows a good match between the intermediate
solution and both the inner and outer solutions for all variables, and together the approx-
imations agree with the numerics in each region. These solutions give us insights into
the reaction sequences that contribute to the interesting dynamics we see under these
conditions. Initially, while time is O(ε), we have solutions depending only on α, indicat-
ing that only the first reaction, binding a ligand molecule to a monomer, contributes to
an increase in p, whilst there almost no change in r. Once we move to the intermediate
region, that is as t = O(εθ) where θ > 1, we see how the second reaction, whereby the
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ligand binds a second monomer, begins to have an effect. The solutions indicate that the
concentration of r begins to decay exponentially, although this solution is still dependent
only on α, so we can assume that this concentration is still governed by the first reaction.
However, looking to the solution for p, we see that the concentration increases exponen-
tially, but also the solution contains the parameter γ, hence both reactions play a part
in the dynamics in this region. Moving to the outer region, we see how all solutions now
depend on both parameters, so we can conclude that by this point, both reactions now
affect all concentrations.






















































Figure 4.5.3: Plotting the numerical solution of equation (4.35) with inner (equation
(4.40))), intermediate (equation (4.65)) and outer (equations (4.52) and (4.55)) solutions.
The intermediate solution matches both the inner and outer solution, creating a full
approximation to the numerical solution. Conservation of receptors is used to show the
approximation for q. Plot created with α = 6.8, γ = 1.4 and β = ε = 10−4.
4.5.3 Large γ asymptotics
The last case we consider is when we have fast dimer dissociation, that is when γ is large.
In Figure 4.3.1 we saw that taking ψ−, and hence γ = ψ−, large caused a peak in the
bound dimer, [RAR], curve. As such we set γ = 1/ε, with ε  1, in equations (4.27),
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r(0) =1, p(0) = 0. (4.70c)




(1− r − αp) (4.70d)
As ε is multiplying the highest order terms we find we again have a singular perturbation
problem indicating that the solutions evolves on multiple time scales. In Figure 4.5.4 we
plot the solutions on a log-log scale, to help determine the required scalings.
















































Figure 4.5.4: Numerical solutions of the full system in equation (4.70) on a log-log scale.
Plot created with α=6.8, β=1, γ = ε = 10−4.
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Inner Solution
To determine the inner region we rescale time with t = εaτ . We also rescale r = εbr̃ and



































To determine a, b and c we use a principle called detailed (or dominant) balance. In Figure
4.5.4 we see that, up to t = O(1) both t and p evolve on the same order, indicating that
a = c. Furthermore, the relationship between p and t is linear, hence we balance the LHS
of (4.71b) with the p term of the equation
1− a+ c = c, ⇒ a = c = 1. (4.72)
As this results in ε still multiplying the LHS, to have a nontrivial solution, we must have
ε0 on the LHS of (4.71a), and so
1− a+ b = 0, ⇒ b = 0. (4.73)


































r(0) =1, p(0) = 0 (4.74c)
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Assuming asymptotic approximations
r̃ ≈ r̃0 + εr̃1 + ..., p̃ ≈ p̃0 + εp̃1 + ..., (4.75)















which gives the solution
r̃0(τ) = 1. (4.77)
Considering the O(ε) terms gives
dr̃1
dτ
















r̃1(0) =0, p̃0(0) = 0. (4.78c)
Substituting in r̃0 = 1 and solving, yields
r̃1(τ) = −ατ, p̃0(τ) = τ. (4.79)
As the features we are particularly interested in occur in [RAR], and therefore q, curve,
we also give these solutions. To do this we require the conservation law (equation (4.70d))
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which, noting that in the inner region q̃ = O(ε), states that
1 = (r̃0 + εr̃1 + ...) + αε(p̃0 + εp̃1 + ...) + 2α
2βε2(q̃0 + εq̃1 + ...). (4.80)
Equating powers of ε, we have
1 = r̃0, (4.81)
0 = r̃1 + αp̃0, (4.82)
0 = r̃2 + αp̃1 + 2α
2βq̃0. (4.83)
We see that, to find the leading order solution for q we require further solutions for r and
p. To find these we consider O(ε2) terms in system (4.74a), which, after substituting in
r̃0, r̃1 and p̃0, gives
dr̃2
dτ














r̃2(0) =0, p̃1(0) = 0. (4.84c)








(α + 1)τ 2 − αβ(τ + e−τ − 1). (4.86)
Substituting this into equation (4.78c) gives the leading order solution for q as
q̃0(τ) = τ + e
−τ − 1. (4.87)
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Together, these give the inner solution to the system as
r̃0(τ) = 1. p̃0(τ) = τ, q̃0(τ) = τ + e
−τ − 1. (4.88)
The solution for p, in this region, has unbounded, linear growth, while the solution for q
is also increasing monotonically. However, these solutions are independent of any model
parameters indicating that, under the conditions of large γ, the curves will evolve in this
way regardless of the parameters α and β.
Outer Solution
For an outer solution, while time is O(1), r and p are also O(1). This is confirmed
mathematically by looking to the equilibrium concentration in equation 4.31, with γ =
1/ε. Using Taylor series approximation for the square root term, we have
req = peq =
(
−(1 + α) +
√


















hence confirming the long time solutions of r and p as O(1). Assuming asymptotic
expansions
r ≈ r0 + εr1 + ..., p ≈ p0 + εp1 + ..., (4.92)
and substituting these into the ODEs in (4.70) gives a leading order solution





Looking to the O(ε) terms in (4.70) gives
dr0
dt
= − αr0 −
1
2
r1 + αp0 −
1
2






r1 − p0 −
1
2
p1 − αβr0p0. (4.94b)
We compute ((4.94a)−α(4.94b)) to eliminate the nonlinear terms, giving
dr0
dt
= 1− (α + 1)r0, (4.95)













As the conservation law says
1 = (r0 + εr1 + ...) + α(p0 + εp1 + ...) + 2α
2βε(q̂0 + εq̂1 + ...), (4.97)
we use this to equate powers of ε on the LHS and RHS, giving
1 = r0 + αp0 (4.98)
which, substituting in equations (4.96), confirms this equation is true. Considering the ε
terms then gives
0 = r1 + αp1 + 2α





which, combining with equation (4.94a), gives the time dependent solution for q̂0 as
q̂0 =










Taking the limits of r0(t) in (4.96) and r̃0(τ) in (4.77), gives
c1 = α. (4.102)
As the limit of p̃0(τ) in (4.79) as τ → ∞ is ∞ we instead introduce an intermediate
variable to show that p also matches. Recall the inner solution, (rewritten in terms of
the original variables) as
pin(t) = t, (4.103)















Expanding the exponential terms in a Taylor series gives
pout =
1− [1− (α + 1))εδξ + 1
2
(α + 1)2ε2δξ2 − ...]
α + 1
=εδξ − higher order terms, (4.107)













Again, the parameter β does not appear in any of these solutions, suggesting that the
first reaction, binding ligand to monomer, dominates the dynamics in this region. Clearly,
having such a large γ, and therefore increased rate of dimer dissociation means that any
formed dimers quickly return to monomeric state, hence the second reaction, dictating
dimer formation has very little effect on any of the concentrations.
The solution for q(t) in (4.108) also governs the peak that appears in the curve.
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−e−2(α+1)t(2α + e(α+1)t − αe(α+1)t)
α + 1
. (4.109)









which has solutions for α > 1. To determine the nature of the stationary point, we use









which is negative, as α > 0, thus concluding the stationary point is a maximum. Hence,
we conclude that a peak will appear if α > 1.
In Figure 4.5.5 we see a good match between the inner and outer solution in all curves.
We also see good agreement between the approximate solution to the numerics in both
regions, confirming our findings. In the inner region we see very little change in r while
p and q begin to increase. Once we move to the outer region, we see exponential decay
in the concentration of free receptors, r, while the concentration of bound monomers, p,
increases to equilibrium. The concentration of q takes longer to reach equilibrium and
is not monotonic, where we see the multiple exponential terms in the solution having an
impact on the dynamics.
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Figure 4.5.5: Plotting the numerical solution of equation (4.70) with asymptotic solutions
(4.88) and (4.108) show good agreement in both regions. Parameters used to create plot
are α=6.8, β=1, ε=1e-4.
































































Figure 4.6.1: Data published in [101] is used to estimate the model parameters. Experi-
ments were performed using five concentrations of three different VEGF isoforms (VEGF
165a-TMR, VEGF 165b-TMR and VEGF 121a-TMR) and are scaled with respect to Rtot.
An excellent fit to the data is seen from fitting to all data sets simultaneously. Parameter
values returned can be seen in Table 4.2.
4.6 Model validation
In this section we take the first steps towards validating our model by fitting to pub-
lished, experimental data, with raw data kindly provided by Dr Chloe Peach [30]. In the
paper by Peach et al [101], three VEGF isoforms (VEGF 165a-TMR, VEGF 165b-TMR
and VEGF 121a-TMR), in five concentrations, are observed binding to VEGFR2. While
experiments are performed on both HEK293T cells and membranes, we focus only on
membrane results, thus reducing the possibility of data being affected by other processes
such as receptor internalisation which may cause a reduction in signal on longer time
scales. Including receptor internalisation is something we consider for future work.
The experiments were performed ten times and the average of these was used for fit-
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ting. Fitting is performed in Copasi [55] using a particle swarm optimisation method with
a swarm size of 100 and 3000 iterations. We note that Copasi is a software application
for simulating and analysing biochemical networks and their dynamics. Copasi has many
optimisation methods available and fitting was performed using each of these, however,
the particle swarm method was chosen as it gave the smallest total error. All data sets
are fitted to simultaneously, with a and Rtot fixed across all sets, and k+, k−, ψ+ and ψ−
specific to each isoform.
a k+ k− ψ+ ψ− Rtot
VEGF 165a-TMR 8.90× 10−2 7.57× 106 2.76× 10−2 1.87× 103 1.49× 103 2.52× 10−9
VEGF 165b-TMR 8.90× 10−2 1.63× 106 7.72× 10−2 5.88× 103 1.10× 102 2.52× 10−9
VEGF 121a-TMR 8.90× 10−2 2.95× 106 2.64× 10−2 1.38× 105 3.88× 104 2.52× 10−9
Table 4.2: Estimated parameters returned from fitting to the data, as seen in Figure
4.6.1.
In Table 4.2 we have the parameter estimates returned from fitting, while in Figure
4.6.1 we plot the fitted curve together with the data. Clearly the estimates give an
excellent fit to all data sets. Goodness of fit figures can be seen in Table 4.3, where we
use the Chi-square test to determine the correlation between each data set and the fit
values.
[A] = 10−9 3× 10−9 5× 10−9 10−8 2× 10−8
VEGF 165a-TMR 0.0696 0.0213 0.0133 0.0168 0.0342
VEGF 165b-TMR 0.0591 0.0276 0.0183 0.0175 0.0125
VEGF 165a-TMR 0.0324 0.0320 0.0116 0.0183 0.0225
Table 4.3: Goodness of fit values, determined by the Chi-square test.
Looking at the estimated parameter values, we also note that all on and off rates fall
into the reported ranges [80] (and references within). In all cases, we have ψ+ > ψ−
and, therefore, positive cooperativity overall. In Table 4.4 we compare these estimates
with those returned in the paper by Chloe Peach et al [101], where the data was fitted
to a simple monomeric binding model. We see some significant differences in some of
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k+ estimate k+ in [101] k− estimate k− in [101]
VEGF 165a-TMR 7.57× 106 1.27× 107 2.76× 10−2 3× 10−2
VEGF 165b-TMR 1.63× 106 3.69× 106 7.72× 10−2 2.9× 10−2
VEGF 165a-TMR 2.95× 106 5.13× 106 2.64× 10−2 1.9× 10−2
Table 4.4: Comparing the on and off rates returned from fitting to our model with the
values reported in [101].
the values. We see that our association rates are lower than theirs, but in both sets of
estimates the on rate for VEGF 165a-TMR are substantially higher than the other iso-
forms. This is not, however, the case for the dissociation rates. In our estimates, the
value for VEGF 165b-TMR is significantly higher than the other estimates, but this is not
the case for those reported in [101] where all dissociation rates are similar values. This
increased value could be explained by looking at the cooperativity values, as we notice
that the dimer dissociation rate for the VEGF 165a-TMR isoform is lower than the others.
VEGF 165a-TMR VEGF 165b-TMR VEGF 121a-TMR
α = KA[A] 2.74E+08×[A] 2.11E+07×[A] 1.12E+08×[A]
β = ψ+Rtot/[A] 4.71E-06/[A] 1.48E-05/[A] 3.49E-04/[A]
γ = ψ− 1.49E+03 1.10E+02 3.88E+04
Table 4.5: Nondimensional parameter combinations with estimated parameters.
To further understand the implications of these estimations we plot the individual
species curves for all results in Figure 4.6.2. The first thing we notice is the appearance
of peaks in some of the [RAR] curves. In particular, these appear for the higher lig-
and concentrations of the VEGF 165a-TMR and VEGF 121a-TMR curves. In Table 4.5
we look at the nondimensional parameter combinations for the estimated parameters.
Clearly, for all curves we have both large β (to varying degrees) and large γ. However,
our asymptotic analysis was based around α being O(1). Only the curves with a higher
ligand concentration, for isoforms VEGF 165a-TMR and VEGF 121a-TMR meet this re-
quirement, hence this is why we only see the peaks arising from a large γ in these curves.
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Figure 4.6.2: Individual species curves using the estimated parameters show peaks some
of the [RAR] curves.
While the work in this section is the beginnings of model validation, we note that there
is still some way to go to fully achieve this. We recommend that next steps towards this
goal are further experiments, ideally with differing ligand concentrations, to determine
whether the estimates can accurately predict experimental outcomes.
4.7 Conclusions
In this chapter we have presented a model for the binding of VEGF to VEGFRs which
leads to the induced dimerisation of these receptors, and is a stripped down version of
those models presented in [80] and [3]. Considering a model of such simplicity allows
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for in depth analysis of potential responses given various choices of model parameters.
Analytical expressions for equilibrium responses provide a user friendly way for pharma-
cologists to compute solutions, as well as explain how increasing cooperativity leads to
a shift in the experiment readout signal. Although in contrast to GPCR dimer binding
[135], dose response curves are monophasic, hence there is no parameter values that give
extra inflections in the curve. If these are present in the data we can assume that the
system may contain pre-dimerised receptors but not ligand induced dimers. Equilibrium
results are supported by Gabhann and Popel [80] who also find that increasing the ligand
concentration increases the concentration of ligand bound monomers, something that is
indicative of ligand induced dimerisation. We extend the previous research in this area by
also considering time course dynamics for the model. The model is a non-linear system
of ODEs that is unable to be solved analytically, hence numerical methods are used to
explore the time dependent behaviour of the curves under different parameter regimes.
Upon investigation of the time course behaviour of the system, a number of emerging
effects in the individual species curves can be seen contributing to the overall signal.
Depending on the parameters chosen we have the possibility of peaks emerging in the
concentration curves of AR and RAR, either individually or in both simultaneously.
Also, the numerics show how there are multiple time scales contributing to the dynamics.
Asymptotic analysis is used to explain these behaviours and help understand the reaction
sequences that create these effects. In summary
− With a small γ, that is a small reverse cooperativity value, giving a reduced rate
of dimer dissociation, we obtain a regular perturbation problem where we see, as
expected intuitively, that the reversing of the second reaction, binding ligand to a
second monomer, can be negated altogether.
− With a large β, that is when either the forward cooperativity value is large or there
is a high receptor to ligand ratio, we see multiple time scales emerge. Initially the
dynamics are dominated by the first reaction, binding ligand to monomer, however,
as time moves past O(1) the second reaction begins to have an effect.
− When γ is instead large, so the dimer dissociation rate is increased, we again have a
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singular perturbation problem with multiple time scales contributing to the dynam-
ics. Initially, the concentrations of AR and RAR increase monotonically, regardless
of model parameters. As time moves to O(1) we see these increases slow, and a
possible drop in the concentration of RAR, however, as β does not appear in any of
the solutions we conclude that the second reaction has no effect on the dynamics.
Finally, we take steps towards validating the model by fitting to published, experimental
data, where we see the model gives an excellent fit to the data across all curves. This
gives some confidence that the model accurately describes the binding and dimerisation
processes for the VEGF-VEGFR system. While we have given estimates for the param-
eter values, we note that, there may be identifiability issues, and as such, other values
that give the same fit. This is something we discuss in the next chapter, where we take
a theoretical look at which of these parameter values can be relied upon to be accurate.
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Chapter 5
Structural identifiability of ligand
binding models
5.1 Introduction
In Chapter 1 we introduced the idea of structural identifiability analysis (SIA). Through-
out this thesis, we have presented many models representing drug binding scenarios.
These have generally resulted in a system of ODEs that govern the system dynamics.
While we have mostly looked at possible time course results in a purely theoretical way,
the intention is that one of the ways in which these models are used is, by pharmacolo-
gists, to fit to experimental data and quantify ligand-receptor interactions. Hence, it is
important to understand whether parameter estimates returned from fitting are accurate.
We saw an example of this in Chapter 4 (section 4.6) where we fit the ligand induced
dimerisation model to real, experimental data. In this, we gave a set of parameter values
for the model that gave a ‘best fit’, however, it is unclear whether there are other values
that can possibly give the same fit. The model is mechanistic and the parameters repre-
sent biological processes, and so inaccurate parameter estimations may lead to incorrect
conclusions being drawn about these.
In this chapter, we first review some of the theoretical foundations of existing SIA
techniques, and discuss current work in the field. We cover a variety of methods for
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applications to both linear and nonlinear problems, such as those that make use of the
Laplace transformation [9] (though this only applies to linear problems), Taylor series
expansions [105] and similarity transforms [23, 124]. While the goal is to determine the
identifiability of our previous dimer models, we first take tutorial type approach in order to
close the gaps in the current literature. To do this, we show the steps taken to determine
identifiability of some classical ligand binding models before then also including some of
our previous dimer models. For each model we apply a number of the available techniques
to determine which parameters can be identified using a single set of time course data.
This allows us to give a comparison of the methods and ascertain the ideal method for each
scenario. For models that are unidentifiable, we also give, where possible, the identifiable
parameter combinations. Following this, for unidentifiable models, we explore alternate
ways in which the models can be made to be identifiable. This includes using equilibrium
data or washout experiments together with the time course data, or using multiple time
course data sets.
5.2 Theoretical foundations
We first discuss some of the theoretical underpinnings of SIA and the methods we will
use in the later examples, following the notation as used in [28]. We define
∑
(p) as the








where x = (x1, ..., xnx)
T ∈ Rnx is the state vector (the space Rnx also contains the initial
state), u = (u1, ..., unu)
T ∈ Rnu is the vector of inputs, and y = (y1, ..., yny)T ∈ Rny is
the output vector of experimentally observed quantities. The functions f : Rnx → Rnx
and g : Rnx → Rnx × Rnu are analytical function that describe the evolution of the
state variable in time, while h : Rnx → Rny determines the model outputs. The vector
p ∈ Ω ⊂ Rnp are the unknown parameters of the system.
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Definition 5.2.1 1. A parameter pi, i = 1...np, is structurally globally (or uniquely)




(p̃)⇒ pi = p̃i.
2. A parameter pi, i = 1...np, is structurally locally identifiable (s.l.i) if for almost any
p̃ ∈ Ω, there exists a neighborhood V(p) of p such that




(p̃)⇒ pi = p̃i.
3. A parameter pi, i = 1...np, is structurally unidentifiable if for almost any p̃ ∈ Ω,
there exists no neighborhood V(p) of p such that




(p̃)⇒ pi = p̃i.
The model is then said to be s.l.i if all parameters are s.l.i and s.g.i if all parameters are
s.g.i [28]. Further theory and the proofs for these definitions can be found in [49].
Although there are now many available methods to determine identifiability, we choose
to focus on the transfer function method (based on the Laplace transform), the Taylor
series method and the similarity transformation method, for our analysis. While the
transfer function method is only applicable to linear systems, its simplicity of application
makes it a natural choice for these models. The Taylor series method is one of the
most flexible and can be applied to most ODE systems, although does have limitations
[24]. The similarity transformation method, although also applicable to linear systems,
is one of the most well established for nonlinear systems. Furthermore, these methods
are suitable to systems of low dimensionality and have been proven to work well for
compartment models that have a similar structure to binding models. We will now
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outline the underlying theory for each of these methods before applying them to the
models.
5.2.1 Transfer function method
The transfer function method was first proposed by Bellman and Åström [9] and is one
that is simple in nature, although is restricted to linear time-invariant systems. Assume








which is a specific case of the system given in equation (5.1). We then have F ∈ Rnx×Rnx ,
G ∈ Rnx ×Rnu and H ∈ Rny ×Rnx . We also note that we do not consider inputs directly
to observable function as these are not applicable to the models we use in this chapter.
The Laplace transformation provides us with a transfer function, Q(s,p), describing
the input-output relation. Taking the transforms of the system defined in equation (5.2)
and applying linearity and time-derivative rules gives
sX(s,p)− x0 = FX(s,p) +GU(s,p), (5.3a)
Y(s,p) = HX(s,p), (5.3b)
where X(s,p), Y(s,p) and U(s,p) are the Laplace transforms of x, y and u respectively.
Using the properties of the Laplace transform, we can then state
X(s,p) = (sI − F )−1x0 + (sI − F )−1GU(s,p), (5.4a)
Y(s,p) = H(sI − F )−1x0 +H(sI − F )−1GU(s,p). (5.4b)
145
Assuming the system has initial conditions x0 = 0, that is the input-output relation is
given entirely by the impulse, then we can define
Q(s,p) = H(sI − F )−1G, (5.5)
as the transfer function (when Q(s,p) is a single entry) or matrix of transfer functions
of the system. The expanded form of Q(s,p) is the ny × nu matrix, given as
Q(s,p) =











nx−2 + ...+ b(i,j),nx
snx + a1snx−1 + ...+ anx
. (5.7)
Each transfer function (and as such the function in each matrix entry) is a unique func-
tion relating each input to an output. Thus, the coefficients ak and b(i,j),k are unique to
the transfer function. This uniqueness means we can use these coefficients to determine
which parameters are uniquely identifiable. Creating a vector of these coefficients and
denoting this vector as ζ(p), identifiability is then established by setting ζ(p) = ζ(p̃)
and applying definition 5.2.1. We outline how this is applied to a system in Figure 5.2.1.
5.2.2 Taylor series method
The Taylor series method was first developed by Pohjanpalo [105], and can be applied to
either linear or nonlinear systems, although the algebra involved in applying the method
to nonlinear problems can be difficult [24]. We assume a system as defined in equation
(5.1) and assume that the functions f and g are continuously differentiable, and as such
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Applying the transfer function method
1. Ensure the model is in the formulation as given in (5.2), that is, with F , G and
H non-zero.
2. Calculate the transfer function for the system, using equation (5.7). This will
return a matrix.
3. Create the vector ζ(p) with the coefficients of s in both the numerator and
denominator of each entry of the matrix.
4. Assume a second vector, ζ(p̃) and set ζ(p) = ζ(p̃).
5. Simplify the relationships in ζ(p) = ζ(p̃) to reduce the expressions.
6. The resulting expressions of ζ(p) are the identifiable combinations. Expressions
that are reduced to a single parameter are then identifiable parameters.
Figure 5.2.1: An algorithm for using the transfer function method to determine identifi-
ability.
the state vectors and observables have infinitely many derivatives with respect to time.
We also assume that h has infinitely many derivatives with respect to the state variables.
The Taylor series approach then exploits the fact that, the observations (as given in
y(t,p)) are unique analytic functions of time and so all their derivatives with respect to
time should also be unique, and should therefore, hold all possible information about the
unknown parameters [28]. Thus, the observables can be represented by a Taylor series
about the initial state, that can be used to establish identifiability. The Taylor series of
y in a neighbourhood of the initial state is then given by









y(t0,p), k = 0, 1, ..., kmax. (5.9)
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as the Taylor series derivatives. These then create a system of non-linear algebraic equa-
tions in the parameters, which we use to check whether the system has a unique solution.
That is, the model is evaluated at ak(p) and ak(p̃), and the model is structurally identi-
fiable if ak(p) = ak(p̃)⇒ p = p̃ ([28]).
For linear problems the maximum number of coefficients, that is kmax, needed to
determine identifiability is
kmax = 2nx − 1, (5.10)
where nx is the number of state variables [28]. The number of coefficients required is
unbounded for nonlinear problems, and as such is one of the disadvantages of the Tay-
lor series method for these type of problems. Furthermore, for nonlinear problems, the
coefficients can be algebraically complex and hence, identifiability cannot always be de-
termined using this method. In Figure 5.2.2 we outline the steps needed to use this
method to determine identifiability of the system.
5.2.3 Similarity transformation method
The similarity transformation method (or exhaustive modelling approach) was first pro-
posed by Walter and Lecourtier [131], though originally was only applicable to linear
problems. This was later extended to include nonlinear problems [123]. Before we dis-
cuss the method itself and its implementation, we first detail some requirements on the
system for the method to be applicable.
Controllability and observability
In order to use the similarity transformation method, the system must be a minimal
representation, that is it must be both controllable and observable, concepts introduced
by Kalman in 1960 [62]. A system is said to be controllable if the system states, in x,
are changed by changing the input, and observable if the initial state x0 can be uniquely
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Applying the Taylor series method
1. Calculate the first Taylor series coefficient by substituting the initial condition
into the observable function, that is, calculate y(t0). This is the first element
of ζ(p).
2. Differentiate y to give the next Taylor coefficient.
3. Substitute the expressions in f, into this coefficient, to reduce the differential
terms to algebraic expressions.
4. Substitute the initial conditions of the system in place of the state variables.
This should result in an expression containing only model parameters.
5. Add the resulting expression to the vector ζ(p).
6. Repeat steps 2-5, repeatedly differentiating y to calculate higher order deriva-
tives and repeatedly substituting in f in place of state variables.
7. Assume a second vector, ζ(p̃) and set ζ(p) = ζ(p̃).
8. Simplify the relationships in ζ(p) = ζ(p̃) to reduce the expressions.
9. The resulting expressions of ζ(p) are the identifiable combinations. Expressions
that are reduced to a single parameter are then identifiable parameters.
Figure 5.2.2: An algorithm for using the Taylor series method to determine identifiability.
determined from a set of input-output measurements. For a linear system, in the form
of equation (5.2), we define the controllability matrix as
C = [G...FG...F 2G... · · · ...F nx−1G], (5.11)











The system is then said to be controllable if rank(C) = nx, and observable if rank(O) = nx
[123]. The derivation of these matrices, and the theorems detailing these rank tests, along
with the theory they are built upon can be found in [113].
For a nonlinear system, as in equation (5.1), the controllability matrix makes use of
the Lie bracket, which can be stated as






with higher order derivatives calculated as
(adkf ,g) = [f, (ad
k−1
f ,g)]. (5.14)
The full definition of the Lie bracket can be found in Section C.1, while further explanation
of the physical meaning of the Lie bracket and how this relates to controllability can be
found in [134]. The controllability matrix is then given by
C = [g, (ad1f ,g), · · · , (adn−1f ,g)], (5.15)
Following this, calculating the observability matrix involves using the Lie derivative,











The full definition of the Lie derivative can be found in Section C.2. The observability












Again, the system is controllable and observable if rank(C) = nx and rank(O) = nx
respectively.
The method
The objective of this method is, given the model (5.1), with p ∈ Ω, find all parameter




x̃′(t, p̃) = f(x̃(t, p̃), p̃) + g(x̃(t, p̃), p̃)u(t),
y(t, p̃) = h(x̃(t, p̃), p̃),
x̃(0, p̃) = x̃0(p̃).
 (5.19)
that have the same input-output map. This involves assuming the existence of an alter-
nate system,
∑
(p̃), and applying a set of conditions on this alternate system to ensure
that it is equivalent to the original system,
∑





(p̃)⇒ p = p̃. (5.20)
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Linear systems
The linear equivalence of two linear systems is given by the algebraic equivalence theorem
[46, 112] for ODE systems. We consider a system in the form of equations 5.2, and assume
an alternate system with F̃ = F (p̃), G̃ = G(p̃) and H̃ = H(p̃). These are then equivalent
if there exists a matrix T ∈ Rnx × Rnx such that
detT 6= 0, (5.21a)
T x̃0 = x0, (5.21b)
T F̃ = FT, (5.21c)
TG̃ = G, (5.21d)
H̃ = HT, (5.21e)
The full equivalence theorem can be seen in Section C.3. The process is then to apply
the constraints on F , G and H to determine the parameters p. The system is globally
identifiable if it follows from applying these conditions that p = p̃ and locally identifiable
if there is a finite number of possibilities for each pi.
Nonlinear systems
The equivalence theorem has also been extended to include nonlinear systems [24, 28,
123]). With a system in the form of equations (5.1), the conditions to ensure equivalence
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= nx, ∀x̃ ∈ V, (5.22a)









h(λ(x̃),p) = h(x̃, p̃), (5.22e)
for some linear transformation λ(x̃). Then the system is globally identifiable if applying
these conditions implies p̃ = p.
The steps needed to apply this method can be seen in Figure 5.2.3.
Applying the similarity transformation method
1. Calculate the rank of the controllability and observability matrices. These must
both be equal to the number of state variables to proceed.
2. If the system is linear, assume a square transformation matrix (denoted T ) of
equal size to the number of state variables. For nonlinear systems, assume the
existence of a linear transformation, denoted λ(x), equal in size to the state
vector.
3. Assume all conditions hold. For linear systems these conditions are given in
(5.21) while the conditions for nonlinear systems can be found in (5.22). The
conditions can be applied in any order, depending on the individual system
they are being applied to.
4. While applying the conditions, it may be found that pi = p̃i for any param-
eter. This parameter is then considered identifiable. Identifiable parameter
combinations may also be found.
5. The system is fully identifiable if it is found that T is the identity matrix (for
linear systems), or λ(x) = x (for nonlinear systems).




The origins of SIA lie in the works of Kalman [62] for linear systems, and Hermann and
Krener [53] for nonlinear models. Following these, many methods have emerged to assess
the identifiability of a model. The methods previously discussed in this chapter (transfer
function, Taylor series and similarity transformation methods) are still some the most
commonly used methods and have formed a basis for much of the SIA work over the past
decades. Often compartment models are used as an example of application [24, 123, 45].
In [25], Chappell and Gunn explore the possibility of reparameterising unidentifiable non-
linear systems in order to force locally identifiability. This work is continued by Evans
and Chappell in [35].
In [140], the authors develop a method that builds upon the similarity transformation
method to determine the identifiability of nonlinear models. This method also has the
potential to also be applicable to partial differential equations (PDEs). Cheung and Yates
[26] consider whether models are identifiable if data from multiple experiments is used.
The paper looks at linear compartment models and uses the similarity transformation
method to determine identifiability. In [129], Villaverde, Barreiro and Papachristodoulou
develop a novel method where they assume local identifiability is a generalised form of
observability, if the parameters are viewed as constant state variables. With this work,
the authors also present a software implementation of their algorithm, named STRIKE-
GOLDD, which is given as a Matlab [2] toolbox. In this the user is able to input their own
model and the software determines parameter identifiability and, in some cases, returns
identifiable parameter combinations. Anguelova et al [4] take a different approach and
consider the effect conservation laws have on identifiability.
Further methods have been also developed, and are reviewed in [28] and [27]. One
such method is the differential algebra approach which can be applied to linear or nonlin-
ear models, providing the functions are polynomial or rational in form [81]. The method
involves replacing the input-output relationship of the model by a polynomial and testing
for injectivity [28]. The software tool, DAISY [10], implements the differential algebra
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method using the computer algebra system, REDUCE version 3.8. Lecourtier and Rak-
sanyi [75] also use REDUCE to look at algorithms for reducing lengthy expressions. The
generating function approach [131] follows the Taylor series method but makes use of
the Lie derivative, although a major limitation of this method is that the number of
coefficients needed to be calculated is unknown [27]. Lecourtier, Lamnabhi-Lagarrigue
and Walter extend this method together with Volterra [74] to develop a new method
that overcomes the limitations of the generating series approach. This new method that
they propose creates a transformation that is a generalisation of the Laplace transform,
though the method is still applicable to nonlinear systems. Identifiability tableaus [7]
are frequently used with the generating series approach. Calculating the Jacobian of the
power series coefficients, with respect to the parameters, the tableau shows the non-zero
elements. The rank of this matrix is then used to determine identifiability.
Despite the importance of SIA when fitting ODE models to experimental data, it is
frequently overlooked for binding models such as those presented throughout this thesis,
although Janzén et al [59] take some steps towards showing the benefits of SIA for phar-
macodynamics models. Also, Middendorf and Aldrich, in [89] and [90] develop a method
to determine the identifiability of equilibrium binding parameters for models that de-
scribe ligand binding to proteins that have multiple binding sites. Their method aims to
overcome the limitations of existing methods such as those that use likelihood intervals
or brute-force methods.
5.3 Structural identifiability analysis of ligand bind-
ing models with a single time course
In this section we show how the techniques can be applied to some ligand binding models.
We perform SIA for a range of models, beginning with some classical binding models
before then analysing our new models for dimer binding. For each of these, we consider
a single set of time course data and apply three methods (transfer function, Taylor series
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and similarity transformation methods). Not only does this provide a tutorial of how
each of the methods work in practice but also allows to compare the different techniques
and explore which is best in each situation.
5.3.1 Monomeric receptor binding with a single drug
The simple model of a ligand binding with a monomeric receptor has been the basis of
much of the theoretical foundations of receptor theory of the past few decades and is still
widely used in drug development research [66, 69]. For this reason (and because of its
simplicity), we begin our analysis with this model. Assuming the ligand, A, is a constant
concentration that binds to the monomeric receptor [R] with association and dissociation






The law of mass action gives us the system of ODEs
[R]′ = −ka+[A][R] + ka−[AR], (5.23a)
[AR]′ = ka+[A][R]− ka−[AR], (5.23b)
which, together with the initial conditions
[R](0) = Rtot, [AR](0) = 0, (5.23c)
where Rtot is the total receptor concentration, form the initial value problem describing
the kinetics of the system. The concentration of [AR] is measured experimentally, hence
the observed output is
y = [AR]. (5.23d)
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Assuming the only known parameter is the drug concentration [A], then we have p =
(ka+, ka−, Rtot). Although this is a very simple system and can be solved analytically, we
will still perform each of the SIA methods for the model. This will allow us to illustrate
the methods for the simple case before increasing the complexity.
The transfer function method
We first outline the transfer function method. In its current form, the input to the system
is in the initial conditions. This means that we have G = 0 in equation (5.2), and so the
transfer function will also be zero. To overcome this we need to reformulate the system
equations. Either we use conservation laws to reduce the system, or we use the Dirac
δ function so that the input appears as a forcing term. As throughout this thesis we
have used conservation laws to reduce the system dimensions we will continue to use this
method in this chapter also. In this model, the conservation law can be stated as
Rtot = [R] + [AR], (5.24)
to reduce the system by removing [R]. This gives the single differential equation
d[AR]
dt
= −(ka+[A] + ka−)[AR] + ka+[A]Rtot, (5.25a)
with initial condition
[AR](0) = 0, (5.25b)
and output
y = [AR]. (5.25c)
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Calculating the transfer function of a single ODE is trivial as each component is one-
dimensional. We have
F = −(ka+[A] + ka−), G = ka+[A]Rtot, H = 1, (5.26)
which gives a transfer function of
Q(s,p) =
ka+[A]Rtot
s+ ka+[A] + ka−
. (5.27)





Clearly we have three unknowns and only two expressions so it is not possible to identify
all parameters, in fact none of the parameters are identifiable individually, and so we
conclude that only the grouped parameters
ka+Rtot and ka+[A] + ka−, (5.29)
are identifiable.
Non-identifiability can be seen in Figure 5.3.1, where we see how three different param-
eter sets can result in the same measured output curve but have different concentration
magnitudes of the free receptor concentrations (not observed), showing the obviously
different binding parameters. However, in Table 5.1 where we calculate these grouped
parameters for these three parameter sets, we see that these are equal for all sets, and
therefore identifiable.
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Figure 5.3.1: Three sets of parameters are used to plot the system given in equations
(5.23). All three parameter sets give the same measured output curve, Abound. However,
non-identifiability can be seen in the individual species curves. Each set of plots is created
using the values in Table 5.1 together with [A] = 10−8M .
Set 1 Set 2 Set 3
ka+ 3.4× 105M−1s−1 1.7× 104M−1s−1 1.23× 107M−1s−1
ka− 1.2× 10−1s−1 1.23× 10−1s−1 10−5s−1
Rtot 6.12× 10−10M 1.22× 10−8M 1.68× 10−11M
ka+Rtot 2.07× 10−4M 2.07× 10−4M 2.07× 10−4M
ka+[A] + ka− 1.23× 10−1s−1 1.23× 10−1s−1 1.23× 10−1s−1
Table 5.1: The parameters for three different parameter sets are used to plot Figure
5.3.1. The parameter combinations are equal in each case, so we can confirm these as
identifiable.
Taylor series method
For this method we use the system in the form as given in (5.23), although results would
be the identical if using the reduced system. We recall equation (5.10), which states that
the maximum number of Taylor series coefficients (we refer to these simply as coefficients
throughout) is 2nx − 1, where nx is the number of state variables. As in this case we
have nx = 2 we will need to calculate a maximum of 3 coefficients. The first coefficient
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is simply
y0 = y(x0) = [AR](0) = 0. (5.30)
We note that a subscript zero indicates that we are evaluating at t = 0. As this contains
no parameters it gives no information about parameter identifiability. As we have only
two remaining coefficients to calculate but three unknown parameters, we determine
that the system will not be globally identifiable. However, we will still continue to
determine which, if any, parameters are identifiable and also any identifiable parameter
combinations. The first derivative of the output function is simply
y(1) = [AR](1) = ka+[A][R]− ka−[AR]. (5.31)
Substitution of the initial conditions gives the first coefficient as
y
(1)
0 = ka+[A]Rtot. (5.32)
This can be simplified to
c1 = ka+Rtot, (5.33)
where we denote ci as the coefficient in its minimal form. A coefficient is considered to
be in a minimal form once it is not possible to simplify it using already known quanti-
ties or expressions. Further derivatives are calculated with recursive substitution of the
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equations in system (5.23). This gives the second derivative as
y(2) = [AR](2) = ka+[A][R]
(1) − ka−[AR](1)
= −ka+[A](ka+[A][R]− ka−[AR])− ka−(ka+[A][R]− ka−[AR])
= −ka+[A](ka+[A] + ka−)[R] + ka−(ka+[A] + ka−)[AR], (5.34)
leading to, after substitution of the initial conditions, the second coefficient as
y
(2)




0 = −c1[A](ka+[A] + ka−), (5.36)
we are able to simplify and reduce this, leaving
c2 = ka+[A] + ka−, (5.37)
as the second identifiable parameter combination. Hence, we have two identifiable pa-
rameter combinations which agree with the parameter combinations found when using
the transfer function method. As the complexity of the calculation for each is similar, the
only real difference is in the requirements of the methods. For completeness we will show
that calculating further derivatives gives no unique expressions. The third derivative is
calculated in the same way, which, after some simplification gives
y(3) = ka+[A](ka+[A] + ka−)
2[R] + ka−(ka+[A] + ka−)
2[AR], (5.38)
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which gives the next coefficient as
y
(3)








this gives no further information, hence, we have only the same two identifiable parameter
combinations as we found in the transfer function method.
Similarity transformation method
We first note that, with the system in its original form, we have G = (0, 0)T in equation
(5.2), hence we are unable to determine identifiability. Similar to the transfer function
method, this is due to the inputs being in the initial conditions as opposed to the model
equations, hence a reformulation is required. We again use the reduced system, using
conservation of receptors, to overcome this problem, giving
F = −(ka+[A] + ka−), G = ka+[A]Rtot, H = 1. (5.41)
As n = 1, the system must be both controllable and observable, hence we now move
forward with checking identifiability. To do this we assume a transformation matrix T
and apply conditions (5.21). As nx = 1, then T is a single entry matrix, and so we first
note that detT 6= 0, providing T 6= 0, and so condition (5.21a) holds if this remains true.
From condition (5.21e) we have
H̃ = HT, ⇒ 1 = 1 · T, ⇒ T = 1, (5.42)
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hence conditions (5.21a) and (5.21b) both hold. Applying condition (5.21d), we have
TG̃ = G, ⇒ k̃a+[A]R̃tot = ka+[A]Rtot, ⇒ k̃a+R̃tot = ka+Rtot. (5.43)
Finally, we have, from condition (5.21c)
T F̃ = FT, ⇒ −(k̃a+[A]+k̃a−) = −(ka+[A]+ka−), ⇒ k̃a+[A]+k̃a− = ka+[A]+ka−.
(5.44)
Hence, we have the same identifiable parameter combinations as in the previous methods.
This confirms that all methods give the same results. Comparing the methods is futile
in this case, however, as the model is of such low dimension.
5.3.2 Monomeric receptor two drug competition binding
The next model we consider is a competitive binding scenario as in Motulsky-Mahan [95],
where two ligands, A and B, are each able to bind to a monomeric receptor. The ligands
are assumed to be constant in concentration and are similar in formation, hence both








The system of ODEs governing the dynamics of the system is given as
[R]′ = −(ka+[A] + kb+[B])[R] + ka−[AR] + kb−[BR], (5.45a)
[AR]′ = ka+[A][R]− ka−[AR], (5.45b)
[BR]′ = kb+[B][R]− kb−[BR], (5.45c)
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together with the initial conditions
[R](0) = Rtot, [AR](0) = 0, [BR](0) = 0, (5.45d)
where Rtot is the total receptor concentration, form the initial value problem describing
the kinetics of the system. Only the concentration of [AR] is measured experimentally,
hence the output is
y = [AR]. (5.45e)
We assume the only known parameters are the drug concentrations [A] and [B], hence
we have p = (ka+, ka−, kb+, kb−, Rtot). We again apply the transfer function method, the
Taylor series method and the similarity transformation method to determine identifiabil-
ity.
Transfer function method
We first apply the transfer function method to determine identifiability of the parameters.
Reducing the system (5.45) using the conservation law, Rtot = [R] + [AR] + [BR] gives
[AR]′ = −(ka+[A] + ka−)[AR]− ka+[A][BR] + ka+[A]Rtot, (5.46a)
[BR]′ = −kb+[B][AR]− (kb+[B] + kb−)[BR] + kb+[B]Rtot. (5.46b)
Hence, we have the matrices, as in equation (5.2), as
F =
−(ka+[A] + ka−) −ka+[A]
−kb+[B] −(kb+[B] + kb−)
 , G =
ka+[A]Rtot
kb+[B]Rtot
 , H = [1, 0]. (5.47)
164
To check the identifiability of the system, we calculate the transfer function as
Q(s,p) =
ka+[A]Rtots+ ka+kb−[A]Rtot
s2 + (ka+[A] + kb+[B] + ka− + kb−)s+ ka+kb−[A] + ka−kb+[B] + ka−kb−
, (5.48)





ka+[A] + kb+[B] + ka− + kb−
ka+kb−[A] + ka−kb+[B] + ka−kb−
 . (5.49)
Setting ζ(p) = ζ(p̃) allows us to determine identifiability. Using the first two entries we
find kb− to be identifiable, however, this is the only parameter to be so. This leaves the




ka+[A] + kb+[B] + ka−
ka+kb−[A] + ka−kb+[B] + ka−kb−
 . (5.50)
In Figure 5.3.2 the non-identifiability of the model is clear, as three parameter sets (as
given in Table 5.2) result in vastly different species curves, yet the measured output curve
of [AR] is the same for all sets. In particular, we notice that the [BR] curves have peaks
in some of the curves, depending on the parameters used.
Taylor series method
To apply the Taylor series method we again use the full system, as stated in equation
(5.45). As we now have three state variables, we have nx = 3 and so require a maximum
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Figure 5.3.2: Three sets of parameters are used to plot the system given in equations
(5.45). All three parameter sets give the same measured output curve, Abound. However,
non-identifiability can be seen in the individual species curves. Each set of plots is created
using the values in Table 5.2 together with [A] = 10−8M .













ka+[A] + kb+[B] + ka− 0.12s
−1 0.12s−1 0.12s−1
ka+kb−[A] + ka−kb+[B] + ka−kb− 0.044s
−2 0.044s−2 0.044s−2
Table 5.2: The parameters for three different parameter sets are used to plot Figure 5.3.2.
The parameter kb−, as well as the parameter combinations are equal in each case, so we
can confirm these as identifiable.
of five coefficients to determine identifiability. Again, the first coefficient is
y0 = 0, (5.51)
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hence gives no information regarding identifiability. As we have five unknown parameters,
we can conclude that the system is not globally identifiable. The first derivative is
y(1) = ka+[A][R]− ka−[AR], (5.52)
giving the first Taylor coefficient as
y
(1)
0 = ka+[A]Rtot, (5.53)
and as such, the first identifiable parameter combination as
c1 = ka+Rtot. (5.54)
Using recursive substitution of equations (5.45), we have the second derivative as
y(2) = −ka+[A]((ka+[A] + kb+[B])[R]− ka−[AR]− kb−[BR])− ka−(ka+[A][R]− ka−[AR])
= −ka+[A](ka+[A] + kb+[B] + ka−)[R] + ka−(ka− + ka+[A])[AR] + ka+kb−[A][BR],
(5.55)
which gives the coefficient
y
(2)





0 = ka+[A]Rtot(ka+[A] + kb+[B] + ka−), (5.57)
= c1[A](ka+[A] + kb+[B] + ka−) (5.58)
and therefore, we have a second identifiable combination as
c2 = ka+[A] + kb+[B] + ka−. (5.59)
Further coefficients are calculated in the same way, using recursive substitution of the
system variables to calculate higher order derivatives followed by substitution of the initial






2 + 2ka+kb+[A][B] + 2ka+ka−[A]
+ k2b+[B]





2 + kb+(ka− − kb−)) (5.60)
which gives the third identifiable combination as






































































2 + c3(2c2 + kb−)) (5.63)
which gives the identifiable parameter
c4 = kb−. (5.64)
We note that calculations are all performed using Matlab’s symbolic toolbox [2]. To





ka+[A] + kb+[B] + ka−.
 (5.65)
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Although it appears that these parameter combinations are not identical to the ones
found from the transfer function method (equation (5.50)), we note that
kb+(ka− − kb−) + kb−(ka+[A] + kb+[B] + ka−) = ka+kb−[A] + ka−kb+[B] + ka−kb−, (5.66)
hence, they are equivalent for identifiability purposes.
Similarity transformation method
To apply the similarity transformation method we require the system to be controllable
and observable, however, in its original form the system has a zero input vector, so we
are unable to determine controllability. Therefore, we instead reformulate and use the
reduced form. Recall, in this form we have
F =
−(ka+[A] + ka−) −ka+[A]
−kb+[B] −(kb+[B] + kb−)
 , G =
ka+[A]Rtot
kb+[B]Rtot
 , H = [1 0] .
(5.67)
In this case, we have nx = 2, and so the controllability matrix is given as
C =
ka+[A]Rtot −ka+[A]Rtot(ka+[A] + ka− + kb+[B])
kb+[B]Rtot −kb+[B]Rtot(ka+[A] + kb+[B] + kb−)
 , (5.68)
which has rank(C) = 2, and so the system is controllable. The observability matrix is
O =
 1 0
−(ka+[A] + ka−) −ka+[A]
 , (5.69)
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which also has rank(O) = 2, therefore, both controllability and observability conditions





and first noting, that (5.21b) holds for any T as we have x0 = x̃0 = (0, 0)
T , and therefore
T x̃0 = (0, 0)









 ⇒ t11 = 1, t12 = 0, (5.71)














From the top row, we have
k̃a+[A]R̃tot = ka+[A]Rtot ⇒ k̃a+R̃tot = ka+Rtot, (5.74)
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which is our first identifiable parameter combination. The second row gives


















−(k̃a+[A] + k̃a−) −k̃a+[A]
−k̃b+[B] −(k̃b+[B] + k̃b−)

=
−(ka+[A] + ka−) −ka+[A]
















M11 = k̃a+[A] + k̃a−, (5.79a)
M12 = k̃a+[A], (5.79b)















N21 = kb+[B] + t21kb+[B] + t21kb−, (5.80c)
N22 =
(kb+[B] + kb−)(kb+[B]Rtot − t21k̃a+[A]R̃tot)
k̃b+[B]R̃tot
. (5.80d)








We note that, with this the transformation matrix becomes
T =











As det(T ) 6= 0, we find that condition (5.21a) holds. After substituting in the expression
for t21, we equate M11 = N11, giving
k̃a+[A] + k̃a− =
ka+kb+[B]Rtot + k̃a+ka−R̃tot + ka+k̃a+[A]R̃tot − k̃a+k̃b+[B]R̃tot
k̃a+R̃tot
. (5.84)
However, as we have already determined that k̃a+R̃tot = ka+Rtot, we have
k̃a+[A] + k̃a− =
k̃a+ka−R̃tot + ka+k̃a+[A]R̃tot + k̃a+kb+[B]R̃tot − k̃a+k̃b+[B]R̃tot
k̃a+R̃tot
⇒ k̃a+[A] + k̃a− = ka− + ka+[A] + kb+[B]− k̃b+[B]
⇒ k̃a+[A] + k̃a− + k̃b+[B] = ka+[A] + ka− + kb+[B]. (5.85)







With k̃a+R̃tot = ka+Rtot, this can simplified to give
k̃b− = kb−. (5.87)
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Finally, equating M21 = N21, after some simplification, gives
k̃b+(k̃a− − k̃b−) = kb+(ka− − kb−). (5.88)





ka+[A] + kb+[B] + ka−,
 (5.89)
as in the previous case. Comparing the methods, it is clear that, although all methods
give the same identifiable parameter and parameter combinations, the transfer function
method is by far the simplest in terms of ease of use. The Taylor series method, in partic-
ular, results in expressions that are algebraically complex and require much simplification
in order to obtain reduced expressions.
5.3.3 Pre-formed homodimer binding with a single drug
The next model, and final linear model, we consider is the GPCR homodimer model we









The ODE system describing the model dynamics is given as
d[R]
dt
= −ka+[A][R] + ka−[AR], (5.90a)
d[AR]
dt
= ka+[A][R]− (ka− + α+ka+[A])[AR] + α−ka−[ARA], (5.90b)
d[ARA]
dt
= α+ka+[A][AR]− α−ka−[ARA], (5.90c)
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with initial conditions
[R](0) = Rtot, [AR](0) = 0, [ARA](0) = 0, (5.90d)
The measured quantity is bound ligand, hence the output can be stated as
y = [AR] + 2[ARA]. (5.90e)
We assume the only known parameter is the drug concentration, [A], and so we have the
vector of unknown parameters as p = (α+, α−, ka+, ka−, Rtot). Whilst at first glance this
system looks similar to the previous system, for monomer competition binding, in terms
of complexity, we note that the output function is now a combination of two states, as
opposed to just one, adding a slight but significant difference to the proceeding compu-
tations.
Transfer function method
Again, we first consider the transfer function method to determine identifiability. We
first use conservation of receptors, which is stated in this case as
Rtot = [R] + [AR] + [ARA], (5.91)
to reduce the system, giving
d[AR]
dt




= α+ka+[A][AR]− α−ka−[ARA]. (5.92b)
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This gives the components, as stated in equation (5.2), as
F =






 , H = [1 2] . (5.93)
We give the transfer function of the system as
L(s,p) =
ka+[A]Rtot(s+ 2α+ka+[A] + α−ka−)
s2 + (ka+[A] + ka− + α+ka+[A] + α−ka−)s+ (α+k2a+[A]
2 + α−ka+ka−[A] + α−k2a−)
,
(5.94)













Hence we have no identifiable parameters but do have four identifiable parameter combi-
nations. Again this can be seen in Figure 5.3.3 where we show how three sets of different
parameter values result in vastly different individual species curves, yet all give the same
Abound, measured output curve. While the curves of [R] and [ARA] are similar in shape,
they have different magnitudes of concentration. However, the largest differences are seen
in the [AR] curves, where the different parameter sets result in curves that have distinctly
different evolution patterns, with some curves have a peak and fall while others don’t.
This highlights how naive parameter estimation performed without this knowledge of
identifiability could lead to incorrect conclusions being drawn about the underlying qual-
itative dynamics. The parameter values used for the plots can be seen in Table 5.3.
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Figure 5.3.3: Three sets of parameters are used to plot the system given in equations
(5.90). All three parameter sets give the same measured output curve, Abound. However,
non-identifiability can be seen in the individual species curves. Each set of plots is created
using the values in Table 5.3 together with [A] = 10−8M .
Taylor series method
We proceed with the Taylor series method to determine identifiability, with repeated
substitution of the ODEs and initial conditions. While the process is the same as when
we applied this method to the competition binding model, the output function being a
combination of two state variables adds an extra complexity to the calculations. As in
all previous sections, the first coefficient is trivial, that is
y0 = 0. (5.96)
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Set 1 Set 2 Set 3
ka+ 10
7M−1s−1 5× 106M−1s−1 103M−1s−1
ka− 0.1s
−1 0.14s−1 0.18s−1
α+ 0.8 1.35 5.74× 103
α− 0.01 0.19 0.26
Rtot 10
−10M 2× 10−10M 10−6M
ka+Rtot 10
−3s−1 10−3s−1 10−3s−1
2α+ka+[A] + α−ka− 0.161s
−1 0.161s−1 0.161s−1








Table 5.3: The parameters for three different parameter sets are used to plot Figure
5.3.3. The parameter combinations are equal in each case, so we can confirm these as
identifiable.
The first derivative of the output function is given as
y(1) = ka+[A][R]− (ka− + α+ka+[A])[AR] + α−ka−[ARA] + 2(α+ka+[A][AR]− α−ka−[ARA])
= ka+[A][R]− (ka− − α+ka+[A])[AR]− α−ka−[ARA], (5.97)
giving the first unique coefficient as
y
(1)
0 = c1 = ka+[A]Rtot. (5.98)
The remaining three coefficents are calculated in much the same way, repeatedly differ-









































a−[A]− α+ka+k2a−[A]− 3ka+k2a−[A]− k3a−). (5.101)
These can again be reduced by division and subtraction of previous coefficients, giving








2 + α−ka+ka−[A] + α−k
2
a−
ka+[A] + ka− − α+ka+[A]
 , (5.102)
hence, the results are the same as when using the transfer function method (that is, equal
to equation (5.95)).
Similarity transformation method
Recall the reduced form of the system as
F =






 , H = [1 2] . (5.103)
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Before we determine identifiability for the system, we first check whether the controllabil-
ity and observability conditions are satisfied. The controllability matrix for this system
is given as
C =






and the observability matrix is
O =
 1 2
α+ka+[A]− ka+[A]− ka− −(α−ka− + ka+[A])
 , (5.105)
As rank(C) = rank(O) = 2 we can conclude that the system is both controllable and






we first note that again having all initial conditions being zero means that condition










From this we determine
t11 = 1− 2t21 (5.108)
t12 = 2− 2t22, (5.109)
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which gives the transformation matrix as
T =
1− 2t21 2− 2t22
t21 t22
 . (5.110)
We next apply condition (5.21d), giving








From the bottom row, we find
t21 = 0. (5.112)
With this, the top row then gives the identifiable parameter combination
k̃a+R̃tot = ka+Rtot. (5.113)














M11 = α̃+k̃a+[A]− k̃a+[A]− k̃a− − 2t22α̃+k̃a+[A], (5.116a)
M12 = 2t22α̃−k̃a− − k̃a+[A]− α̃−k̃a−, (5.116b)
M21 = t22α̃+k̃a+[A], (5.116c)
M22 = −t22α̃−k̃a−, (5.116d)
and
N11 = −(ka+[A] + ka− + α+ka+[A]), (5.117a)
N12 = t22(ka+[A] + 2ka− + 2α+ka+[A] + α−ka−)− 2(ka+[A] + ka− + α+ka+[A]),
(5.117b)
N21 = α+ka+[A], (5.117c)
N22 = 2α+ka+[A]− 2t22α+ka+[A]− t22α−ka−. (5.117d)





We note that, while it is possible to begin with a different matrix entry, and therefore
have a different expression for t22, this should still give the same identifiability results.















hence, condition (5.21a) holds. We substitute the expression for t22 into the remaining
matrix entries. Solving M11 = N11, we have, after some simplification
k̃a+[A] + k̃a− − α̃+k̃a+[A] = ka+[A] + ka− − α+ka+[A]. (5.121)
Equating M22 = N22 and M12 = N12, we obtain









2 + α−ka+ka−[A] + α−k
2
a−, (5.123)









2 + α−ka+ka−[A] + α−k
2
a−
ka+[A] + ka− − α+ka+[A]
 , (5.124)
confirming that all methods give the same results. Again, if we compare the three meth-
ods applied to this system, we find that the transfer function method to be decidedly
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simpler to use, whereas the Taylor series method results in expressions that require much
simplification.
5.3.4 Ligand induced dimerisation with a single drug
The final model we consider is the VEGF, ligand induced dimerisation model that we








The ODE system that governs the system dynamics can then be stated as
d[R]
dt
=− k+[A][R] + k−[AR]− ψ+k+[R][AR] + ψ−k−[RAR], (5.125a)
d[AR]
dt
= k+[A][R]− k−[AR]− ψ+k+[R][AR] + ψ−k−[RAR], (5.125b)
d[RAR]
dt
= ψ+k+[R][AR]− ψ−k−[RAR]. (5.125c)
with initial conditions
[R](0) = Rtot, [AR](0) = 0, [RAR](0) = 0 (5.125d)
The signal of interest, and measured output for the system, is proportional to the number
of receptors bound, that is
y = a([AR] + 2[RAR]), (5.125e)
for a scalar a. Again the only known parameter is the drug concentration, [A], and so we
have p = (a, k+, k−, ψ+, ψ−, Rtot). We note that this system is nonlinear, which affects the
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available methods to determine identifiability. The transfer function method is applicable
only to linear systems, and so we are unable to use this method.
Taylor series method
We first apply the Taylor series method to the VEGF system. While we have n = 3, the
system is nonlinear and so it is unknown how many coefficients will need to be calculated
for identifiability to be established. As in all previous sections, the first coefficient is
trivial, that is
y0 = 0. (5.126)
and so gives no information. The first derivative of the output function is given as
y(1) = a([AR] + 2[RAR]) (5.127)
= a(k+[A][R]− k−[AR] + ψ+k+[R][AR]− ψ−k−[RAR]),
(5.128)
giving the first unique Taylor coefficient as
y
(1)
0 = c1 = ak+[A]Rtot. (5.129)
The second coefficient we calculate as
y
(2)
0 = ak+[A]Rtot(k+[A] + k− − ψ+k+Rtot)
⇒ c2 = k+[A] + k− − ψ+k+Rtot. (5.130)
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2 + 2k+k−[A] + k
2
− − 4ψ+k2+[A]Rtot








































− ψ+k+k2−Rtot − k3+[A]3 − 3k2+k−[A]2 − 3k+k2−[A]− k3−), (5.132)
y
(5)






















































−[A]Rtot − 2ψ+k+k3−Rtot − k4+[A]4 − 4k3+k−[A]3
− 6k2+k2−[A]2 − 4k+k3−[A]− k4−). (5.133)
Although theoretically it may be possible to reduce these expressions, as we did with the
linear models, it is not obvious as to how to do this. Using these coefficients directly
to create the vector of identifiable parameter combinations is also impractical, as setting
ζ(p) = ζ(p̃) would involve solving a fourth order polynomial. If further coefficients were
also needed to determine identifiability these would be of higher degree still. These issues
were also noted by Chappell, Godfrey and Vajda [24] where they compared the Taylor
series method and similarity transformation method for nonlinear compartment models.
Hence, we conclude that the Taylor series method is impractical to use for nonlinear
problems.
Similarity transformation method
Although we have used this method to establish identifiability for the previous models,
these were all linear models. There are a number of key differences in the steps taken to
apply the method to a nonlinear system. We first reduce the system (equation (5.125)),
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using the conservation law
Rtot = [R] + [AR] + [RAR], (5.134)




2 + 2ψ+k+[AR][RAR]− (k+[A] + k−
+ ψ+k+Rtot)[AR] + (ψ−k− − 2k+[A])[RAR]






h(x,p) = a([AR] + 2[RAR]). (5.137)
In order to use this method, we require the system to be observable and controllable.
Recall, the definitions of controllability and observability as given in Section 5.2.3. The
observability condition makes use of the Lie derivative, so we calculate







= −a(ψ+k+([AR] + 2[RAR]−Rtot)[AR]
+ (k+[A] + k−)[AR] + (ψ−k− + 2k+[A])[RAR]), (5.139)





−Rtot) + (k+[A] + k−))
−a(2ψ+k+[AR][AR]
+ (ψ−k− + 2k+[A]))
 , (5.140)














giving the controllability matrix as
C =





which also has rank(C) = 2. Hence, we can confirm that the system is both observable
and controllable. We now assume a transformation λ(x) = (λ1(x), λ2(x)) and assume
that this transformation preserves the system output, y(x), as well as the algebraic struc-
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ture of the system. This is done by showing that all conditions in equations (5.22) hold.
The first condition we check is (5.22e), that is, h(λ(x̃),p) = h(x̃, p̃). This gives
a(λ1 + 2λ2) = ã([AR] + 2[RAR]), ⇒ λ1 =
ã
a
([AR] + 2[RAR])− 2λ2. (5.143)

























































































Substituting this into the first row gives our first identifiable parameter combination as
ak+Rtot = ãk̃+R̃tot. (5.150)


























a(ak+(2 + ψ− + 2ψ+k+Rtot)− 2ãψ+k+([AR] + 2[RAR]))λ2
− ã([AR] + 2[RAR])(a(k+[A] + k− + ψ+k+Rtot)− ã([AR] + 2[RAR]))
−a(aψ−k− + ψ+k+(aRtot − ã([AR] + 2[RAR])))λ2


















− (k̃+[A] + k̃− + ψ̃+k̃+R̃tot)[AR] + (ψ̃−k̃− − 2k̃+[A])[RAR]
−ψ̃+k̃+[AR]2 − 2ψ̃+k̃+[AR][RAR] + ψ̃+k̃+R̃tot[AR]− ψ̃−k̃−[RAR]
 .
(5.152)
Solving these for λ2 and ∂λ2/∂[RAR] gives
λ2 =
ã(c1[AR]
2 + c2[AR][RAR] + c3[AR] + c4[RAR]
2 + c5[RAR])
a(ak−(2− ψ−) + 2ψ+k+(ã([AR] + 2[RAR])− aRtot))
, (5.153)
where
c1 = ãψ+k+ − aψ̃+k̃+,
c2 = 4ãψ+k+ − 2aψ̃+k̃+,
c3 = a(k+[A] + k− − ψ+k+Rtot − (k̃+[A] + k̃− − ψ̃+k̃+R̃tot))
c4 = 4ãψ+k+,






3 + 4[AR]2[RAR] + 4[AR][RAR]2)
+ d2[AR]
2 + d3[AR][RAR] + d4[AR] + d5[RAR]
2 + d6[RAR]
a(ψ̃+k̃+([AR] + 2[RAR])[AR]− R̃tot) + ψ̃−k̃−[RAR])





d2 = 2ãψ+k+(k̃− − k+[A] + k̃+[A]− ψ̃+k̃+R̃tot)− aψ̃+k̃+(ψ−k− + 2ψ+k+Rtot),
d3 = 2ãψ+k+(2k̃− − 4k+[A] + 4k̃+[A]− 2ψ̃+k̃+R̃tot)− 2aψ̃+k̃+(ψ−k− + 2ψ+k+Rtot),
d4 = a(ψ−k−(k− + k+[A]− k̃− − k̃+[A] + ψ̃+k̃+R̃tot)
+ 2ψ+k+Rtot(k+[A]− k̃+[A]− k̃− + ψ̃+k̃+R̃tot)),
d5 = 8ãψ+k+(2k̃+[A]− 2k+[A] + ψ̃−k̃−),
d6 = a(ψ−k−(2k− + 2k+[A]− ψ̃−k̃− − 2k̃+[A]) + 2ψ+k+Rtot(2k+[A]− 2k̃+[A]− ψ̃−k̃−)).





2 + 4[AR][RAR] + 4[RAR]2) +m2[AR] +m3[RAR] +m4)




m1 = 2ãψ+k+(ãψ+k+ − aψ̃+k̃+),
m2 = −2a(ãψ+k+ − aψ̃+k̃+)(ψ−k− − 2k− + 2ψ+k+Rtot),
m3 = 2a(ãψ+k+(4k− − 2k̃− − 2ψ−k− + ψ̃−k̃− − 4ψ+k+Rtot
+ 2ψ̃+k̃+R̃tot) + aψ̃+k̃+(ψ−k− − 2k− + 2ψ+k+Rtot)),
m4 = −a2(ψ−k− − 2k− + 2ψ+k+Rtot)(k+[A] + k− − ψ+k+Rtot − (k̃+[A] + k̃− − ψ̃+k̃+R̃tot)).
However, we found earlier, in equation (5.149), that ∂λ2/∂[AR] = 0, hence each of
these coefficients (m1-m4) must equal zero. We find
m1 = 0, ⇒ ãψ+k+ = aψ̃+k̃+, (5.156)
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as a second identifiable parameter combination. Also
m3 = 0, ⇒ 2k− − ψ−k− − 2ψ+k+Rtot = 2k̃− − ψ̃−k̃− − 2ψ̃+k̃+R̃tot. (5.157)
Differentiating λ2 with respect to [RAR], and simplifying using the combinations identi-







2 + 4[AR] + 4[RAR]2)
a(ak−(2− ψ−) + 2ψ+k+(ã([AR] + 2[RAR])− aRtot))2
. (5.158)
This must be equal to equation (5.154). Equating coefficients, while using previously
identified parameter combinations to simplify where possible, we find
aRtot = ãR̃tot, k+ = k̃+, k− = k̃−, ψ+Rtot = ψ̃+R̃tot, ψ− = ψ̃−. (5.159)











λ1(0) = 0, and λ2(0) = 0, (5.162)
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This has rank = 2, hence we have confirmed that the final condition (5.22a) also holds,
concluding that the algebraic structure is preserved under this linear transformation.
With this we can successfully identify parameters
k+, k−, ψ−, (5.165)





Although the system in not fully identifiable, we note that this is due only to the
output being scaled. If this is not the case, or if the value of this scaler is known, the
system becomes fully identifiable. This is clear if we look at Figure 5.3.4 together with
parameter values in Table 5.4. In these we see that, although we have nonidentifiability,
the differences in the curves are simply a change in magnitude of concentrations. That
is, they are all scaled to a different magnitude.
The results are also confirmed using the STRIKE-GOLDD toolbox [129], in Matlab
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Figure 5.3.4: Three sets of parameters are used to plot the system given in equations
(5.125). All three parameter sets give the same measured output curve, Abound. However,
non-identifiability can be seen in the individual species curves. Each set of plots is created
using the values in Table 5.4 together with [A] = 10−8M .
[2] toolbox, the results of which can be seen in Figure 5.3.5.
5.3.5 A comparison of methods
For linear systems, we can conclude that all methods give the same results for the models
studied. In all considered models, we find that it is not possible to identify all parameters
from a single set of time course data. In fact, very few parameters can be successfully
recovered, hence further information is required to ensure identifiability. In all cases, we
find the transfer function method requires the least computation, with the identifiable
combinations returned directly, that is, without the need for simplification. The Taylor
series the returned parameter combinations are substantially more complex than those
found in the transfer function method, requiring much more simplification. The Taylor
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Set 1 Set 2 Set 3
a 0.07 0.7 0.007
k+ 8.4× 106M−1s−1 8.4× 106M−1s−1 8.4× 106M−1s−1
k− 0.037s
−1 0.037s−1 0.037s−1
ψ+ 187 1.87 18.7
ψ− 26 26 26
Rtot 10
−10M 10−11M 10−9M
k+Rtot 7× 10−12s−1 7× 10−12s−1 7× 10−12s−1
ψ+Rtot 1.87× 10−8M 1.87× 10−8M 1.87× 10−8M
Table 5.4: The parameters for three different parameter sets are used to plot Figure
5.3.4. The parameter combinations are equal in each case, so we can confirm these as
identifiable.
series method does have the advantage, however, that the system can remain in its full
form without any reformulation needed, and unknowns in the initial conditions can also
be determined. The main disadvantage of the similarity transformation method is in the
inability to algorithmically compute the solutions. That is, the results of each step need
to be considered before deciding on how to proceed with the next. This is in contrast to
the transfer function method and Taylor series method which both follow a structured
algorithm to obtain solutions.
For nonlinear systems we apply only the Taylor series and similarity transformation
methods, as the transfer function method is applicable to only linear systems. From the
Taylor series method, we are unable to determine what parameters are identifiable or
unidentifiable as the parameter combinations are long and algebraically complex. From
the similarity transformation method, we find some parameters to be identifiable, and
in fact if the observable function scalar can be predetermined, all parameters can be
theoretically identified. Although, we once again note that this is assuming noise-free
data. This is unlikely to be the case so issues of practical identifiability also need to be
taken into account. Though the method is not simple, and will be more difficult for larger
systems, it gives clear results. The Matlab [2] toolbox, STRIKE-GOLDD confirms the
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Figure 5.3.5: The STRIKE-GOLDD toolbox [129] confirms the identifiability of the pa-
rameters k+, k− and ψ−.
results of identifiable parameters but fails to return any parameter combinations.
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5.4 Identifiability with equilibrium, washout and mul-
tiple time courses
The results thus far have shown none of the models to be fully identifiable from a sin-
gle set of time course data. In this section we consider alternative ways in which full
identifiability can be established. As we discussed in Chapter 1, commonly performed
experiments for drug binding are equilibrium (or saturation) experiments. In these, for
each ligand concentration, the experiments are run until equilibrium is reached, then the
amount of ligand bound is observed. These experiments are often used to estimate equi-
librium constants KD = 1/KA and Rtot, for monomeric receptors [102]. For each model,
we aim to identify the model equilibrium parameters and then using time course data to
identify the remaining binding parameters.
Washout experiments can also be used to gain further insights into the binding ki-
netics of ligands and provide identifiability information. In these experiments the free
ligand is removed by repeated washing, ensuring that no further drug associates with
the receptors and the rate of decrease of effect is then observed. We use this type of
experimental data do determine the identifiability of the dissociation parameters before
then using association time course data to also determine identifiability of association
parameters.
Finally, we also consider multiple binding experiments, whereby each data set is col-
lected from experiments performed using different ligand concentrations. These data sets
are then used simultaneously, with a view to determine the minimum number of data sets
required to make the model globally identifiable. In each case, we choose the appropriate
identifiability method to apply.
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5.4.1 Monomer receptor binding with a single drug












We first attempt to identify equilibrium parameters. Note that, at equilibrium, we have
[AR] = KA[A][R], (5.168)






Taking two ligand concentrations, [A]1 and [A]2, and the corresponding output measure-













[A]1x2 − [A]2, x1
[A]1[A]2(x1 − x2)
(5.171)
and hence these are identifiable from a single dose response curve (in fact, only two points
from the curve). With these known, only a single parameter remains to be found from
time course data. This can be achieved using only one of the parameter combinations as
stated in equation (5.167), giving
ka−KA[A]Rtot = k̃a−KA[A]Rtot ⇒ ka− = k̃a−. (5.172)
Hence, we conclude that, using equilibrium data together with a single set of time course
data, it is possible to identify all model parameters.
Washout experiments
We also consider using washout experiment data to identify dissociation parameters. In
a washout experiment, the drug is removed from the system (usually once equilibrium
has been reached), hence, we set [A] = 0 in the model given in equations (5.23). This
gives
[R]′ = ka−[AR], (5.173a)
[AR]′ = −ka−[AR]. (5.173b)
We note that, it is clearly possible to solve the ODE for [AR], so it is possible to deter-
mine identifiability directly from this. However, we will continue to use a method that is
applicable to any system in order to highlight the process.
As the concentrations of each species is unknown at the start point of washout, the
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initial conditions are therefore
[R](0) = Rtot − x1, [AR](0) = x1, (5.173c)
while the output remains unchanged
y = [AR]. (5.173d)
The unknown parameters in the model in this form are ka−, Rtot and x1, although as we are
only interested in identifying the parameters in the overall system (as stated in equation
5.23), it is not necessary to determine identifibility of x1. Reducing the system using
conservation still leads to a zero force term, so we instead use the Taylor series method.
We have nx = 2 so calculate a maximum of three Taylor coefficients. Calculating the first
of these coefficient gives
y = AR, ⇒ y0 = x1, (5.174)
which clearly gives no information about ka−, but does (unnecessarily in this case) show
x1 to be identifiable. The second coefficient is
y(1) = AR′ = −ka−[AR], ⇒ y(1)0 = a1 = −ka−x1, (5.175)
and so we find ka− to be identifiable. The final coefficient is calculated as
y
(2)




and so gives no further information, hence, only ka− is identifiable from washout, disso-
ciation data.
Returning to the association coefficients, as ka− is now known we have p = (ka+, Rtot)
as the remaining unknown parameters. Taking the coefficients in equation (5.167) and
solving ζ(p) = ζ(p̃) for p confirms these parameters as also now identifiable.
Multiple time courses
We consider multiple sets of time course data, each with a different drug concentration.
Each of these will give the identifiable parameters, as stated in equation (5.50) for their





for i = 1, 2, ...k, where k is the number of time courses being considered. As fitting is
performed to all sets simultaneously, we solve the system as one also. For example, for








Setting ζ(p)2 = ζ(p̃)2 results in all parameters being successfully identified. Hence we
conclude that the model is fully identifiable from just two time courses.
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5.4.2 Monomeric receptor two drug competition binding
The model for a monomer binding with two ligands in a competition binding scenario is








Identifiability analysis from a single time course resulted in the parameter kb− being




ka+[A] + kb+[B] + ka−,
ka+kb−[A] + ka−kb+[B] + ka−kb−.
 (5.179)
Saturation curves
At equilibrium, we have the relations
[AR] = KA[A][R], [BR] = KB[B][R], (5.180)
where KA = ka+/ka− and KB = kb+/kb−. Taking this, together with the conservation
law
[R] + [AR] + [BR] = Rtot, (5.181)






Taking two points from the dose response curve (with [A] being the varied parameter and




for i = 1, 2, and solving for KA and Rtot gives the solutions
KA =






Considering further points on the curve gives no extra information, hence from a single
dose response curve the only identifiable parameter is Rtot, as the solution for KA still
depends the unknown parameter KB.
We then look again to time course data to identify remaining parameters. Assuming



























and so we find that only ka+ and kb− are identifiable. As we have two possible solutions
for ka− and kb+ these can be described as locally identifiable and as such there is no way
of knowing whether the estimated parameters are accurate or not. However, if k̃b− > k̃a−,
then the first solution set contains a negative value which makes this solution set invalid,
and therefore, all the parameters are identifiable.
We also consider using a second dose response curve, with an alternative concentration
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of the competitor drug B (as in the work done by Motulsky and Mahan [95]), giving the

















x3([B]1 − [B]2)([A]1x2 − [A]2x1)
[A]1([A]1[B]1x2(x1 − x3)− [A]2[B]1x1(x2 − x3)− [A]2[B]2x3(x1 − x2))
,
KB =
x3([A]1 − [A]2)(x1 − x3)
[A]1[B]1x2(x1 − x3)− [A]2[B]1x1(x2 − x3)− [A]2[B]2x3(x1 − x2)
, (5.187)
and so all equilibrium parameters are determined to be identifiable. Remaining parame-
ters are then all identifiable from time course data, hence, the model is fully identifiable.
Washout experiments
To determine identifiability using washout experiment data we set [A] = 0 in equation
5.45 to give the model with only dissociation terms as
[R]′ = ka−[AR] + kb−[BR], (5.188a)
[AR]′ = −ka−[AR], (5.188b)
[BR]′ = −kb−[BR], (5.188c)
initial conditions are unknown so we have
[R](0) = Rtot − x1 − x2, [AR](0) = x1, [BR](0) = x2. (5.188d)
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The only measured quantity is [AR] and so the output is
y = [AR]. (5.188e)
We have unknown parameters p = (ka−, kb−, Rtot, x1, x2), although we note that we will
be unable to identify Rtot as [R] does not appear in any of the model equations, and it is
not necessary to find estimates for x1 and x2 for the overall system to be identifiable. We
again use the Taylor series method as reducing the system results in a zero force term
(that is G = 0). We calculate the first Taylor coefficient as
y = AR, ⇒ y0 = x1, (5.189)
and so x1 is identifiable. The second coefficient is calculated as
y′ = AR′ = −ka−[AR], ⇒ y′0 = −ka−x1, (5.190)
giving ka− as also being identifiable. Further coefficients give no new information,
and so only ka− is identifiable from dissociation data. This leaves parameters p =
(ka+, kb+, kb−, Rtot) to be identified from association data. Using the coefficients in equa-
tion (5.179), we find all remaining parameters to be identifiable.
Multiple time courses
There are two ways in which we can consider using multiple time course data to determine
identifiability of this model. Taking the coefficients as stated in equation (5.179) we can
look at time courses with either multiple concentrations of A or multiple concentrations
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ka+[A]i + kb+[B] + ka−
ka+kb−[A]i + ka−kb+[B] + ka−kb−
 or ζ(p)i =

ka+Rtot
ka+[A] + kb+[B]i + ka−
ka+kb−[A] + ka−kb+[B]i + ka−kb−

(5.191)
for i = 1, 2.... If we first look to the first case, having multiple A concentrations, and


























from two sets of time course data, and so we once again have ka+, kb− and Rtot identifiable,
but two possible solutions for ka− and kb+, unless k̃b− > k̃a−. Further data sets with a
third concentration of A yields no further information. If we instead consider having time
courses for multiple [B], solving ζ(p)i = ζ(p̃)i gives all parameters as being identifiable
from just two time courses.
5.4.3 Pre-formed homodimer binding with a single drug









and we saw in the previous section (section 5.3.3) that we have no identifiable parameters,














We take the expression for the concentration of ligand bound at equilibrium, as stated in






1 +KA[A] + αK2A[A]
2
Rtot. (5.194)
where KA = ka+/ka− and α = α+/α−. Taking three drug concentrations [A]i and the






1 +KA[A]i + αK2A[A]
2
i
Rtot = xi, i = 1, 2, 3, (5.195)
for p = (KA, α, Rtot). This is simple to solve in a symbolic equation solver, using soft-
ware such as Matlab [2] or Mathematica [58], where we find that all three equilibrium
parameters are identifiable from a single dose-response curve. However, the expressions
are extremely lengthy and so impractical to write down, and so we refrain from doing so
here. The dynamic parameters can be then identified from a single time course, and can
be seen by solving ζ(p) = ζ(p̃), where ζ(p) is defined as in equation (5.193).
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Washout experiments
Again we consider washout experimental data to aid in identifiability, which is represented










The initial conditions for each species are now unknown and will instead have to be
determined through fitting. Also using conservation of receptors, we have the initial
conditions as
[R](0) = Rtot − x1 − x2, [AR](0) = x1, [ARA](0) = x2, (5.196d)
while the output remains as
y = [AR] + 2[ARA] (5.196e)
We have p = (α−, ka−, Rtot, x1, x2) as the vector of unknown parameters, though again
it is not necessary to identify x1 and x2 for the system to be identifiable. We again use
the Taylor series method to determine identifiability in this section. Through repeated







k2a−(x1 + (α− − 1)α−x2),
−k3a−(x1 + (α2− − α− − 1)α−x2),
 (5.197)


























x̃1 + 2(α̃− − 1)x̃2
2α̃− − 1




and so we find that all parameters are locally identifiable. In terms of fitting, this means
estimates will tend to one of these solution sets. However, when running fitting we impose
the restriction that all parameters can only take positive values. Hence with this we find
that the second solution set can only be obtained if
x̃1 + 2(α̃− − 1)x̃2
2α̃− − 1
> 0, and
(α̃− − 1)x̃1 + α̃−x̃2
2α̃− − 1
> 0. (5.199)
If the estimated parameters do not fall within these ranges then the only solution is that
the parameters are identifiable and as such the estimates are accurate for all parameters.
We use time course data to then identify the remaining parameters. Setting ζ(p) = ζ(p̃)
in equations (5.95) and solving for p = (ka+, α+, Rtot) confirms these as identifiable.
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Multiple experiments
To determine the minimum number of concentrations needed to ensure full identifiability,
we assume multiple experiments, each with a different ligand concentration. Each of
these have identifiable parameter combinations, as defined in (5.193), with [A]i as the














To determine identifiability we again set ζ(p)i = ζ(p̃)i, however, when solving we solve
the systems for i = 1, 2... simultaneously. From this we can conclude that only two data
sets are required to ensure all parameters are identifiable.
5.4.4 Ligand induced dimerisation with a single drug
In section 5.3.4 we saw that, from a single time course, the parameters
k+, k−, ψ−, (5.201)





In Chapter 4, we used this model to fit to experimental data and estimate the model
parameters. In this, we had three sets of experiments, each with a different VEGF
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isoform. Within each of these sets, the experiments are repeated with five concentrations
of VEGF. The quantity Rtot and scaler a are the same in all experiment sets (as the cell
membranes and measuring techniques are the same for each), while all other parameters
are unique. If we consider ζ(p) as above, we note that [A] does not appear in any of the
identifiable combinations, hence, multiple concentrations of drug for the same experiment
does not make further any parameters identifiable. However, as ψ− is different for each







where ψ̂+ indicates that it is a different value to ψ+. In this, we see that there are no
further identifiable parameters. This will also be the case for more than two sets of
experiments. Thus we can conclude that, although the model gives a good fit to the
data, the parameters a, Rtot and ψ+ are not identifiable and cannot be taken as accurate
estimates. For the model to be fully identifiable, prior knowledge of either a or Rtot is
needed. The consequence of these parameters not being identifiable is that we cannot
evaluate the cooperativity.
5.5 Conclusions
In this chapter, we have used well-established SIA techniques to determine model iden-
tifiability for a number of standard ligand-receptor binding models, followed then by our
own dimer models. The models we consider are: monomer binding with a single ligand,
monomer competition binding, GPCR dimer binding and VEGF dimer binding. Analysis
such as this is not typically undertaken for pharmacodynamics models, and parameter es-
timates obtained from fitting to real, experimental data are accepted without knowledge
of their accuracy or uniqueness. As a consequence, incorrect characteristics of ligands are
assumed. Furthermore, when we consider that data is rarely noise-free, practical identi-
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fiability issues compound these inaccuracies which can lead to unsuitable models being
used and further experiment designs may be flawed. As such, SIA should be undertaken
at an early stage. To aid with this, we have taken a tutorial style approach to approaching
the SIA for each of the models.
We used three methods to determine identifiability for each model (where applicable),
namely, the transfer function method based on the Laplace transform, the Taylor series
method and the similarity tranform method. In each case, we demonstrate the necessary
steps taken to perform identifiability, for each method. We compare the methods, high-
lighting the method that is best suited to each model. In this, we find that the transfer
function is best for linear models due to its simplicity. The Taylor series and similarity
transformation methods, while give the same end results, require more calculation and
are more algebraically complex. For nonlinear problems we again find that the Taylor
series method results in expressions that are too lengthy and complex to be practically
useful. We instead use the similarity transformation method to determine identifiability
for the nonlinear, VEGF model. For all models, we find them to be unidentifiable overall,
though we point out that the VEGF model would be identifiable if the output scaler is
known. In each case, we highlight which parameters are identifiable and also give identi-
fiable parameter combinations.
Following this we consider the possibilities for making the models fully identifiable.
For this we also look at dose-response data, washout experiments and multiple sets of
time course data. For the monomer, single ligand binding model, we find that the model
is fully identifiable from either dose-response or washout data, together with a single set
of time course data, or just two sets of time course data. For the monomer competition
binding model, we find that using dose response data, with a single concentration of the
unlabelled ligand, together with the time course data gives the system as locally iden-
tifiable. That is, we have two possible solutions, either the estimates will be accurate
(theoretically), or they will tend to a second solution. To ensure full identifiability, a
second dose-response curve, with a different concentration of unlabelled ligand can be
used. Using washout data will provide full identifiability also. When using multiple time
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courses, only local identifiability can be established when using differing concentrations
of labelled ligand, regardless of how many time courses are used, however, the system
is fully identifiable when the time courses have different concentration of the unlabelled
ligand for only two data sets. For the GPCR dimer binding model, full identifiability
can be obtained from using dose-response data, or from two sets of time course data,
however, only local identifiability can be established from washout data.
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Chapter 6
Conclusions and future work
6.1 Results summary
In this thesis, we have developed a number of models that describe ligand binding and
receptor activation to dimerised and dimerising. The central theme of the thesis is co-
operativity across the dimer, which we focus on analysing the effects of, for each model.
We have used a range of mathematical methods and techniques to analyse the different
problems. Here we detail the main results of the thesis.
In Chapter 2, we develop models for ligand binding to pre-dimerised GPCRs. We
consider both a single ligand and two ligand competition binding to a homodimer and
also a single ligand binding to a heterodimer. In these, we study the effects of binding
cooperativity, which is defined as the effect one protomer being bound by a ligand has
on the binding of a second ligand molecule to the other protomer in the dimer. For
single ligand models cooperativity is a single parameter, while the competition binding
model requires three cooperativity factors to fully describe all ligand-receptor interac-
tions. In each case, we first look at equilibrium results where we see extra inflections in
the logDR curves. LogDR curves for monomeric receptors are typically Hill curves and
have a sigmoidal shape. We find that, biphasic curves such as the ones seen in Chapter
2 are indicative of dimerised receptors and were seen for all models presented. For each
model, we use analytical expressions to analyse the curves and give conditions upon the
parameters for exactly when the extra inflections occur. For the single ligand homodimer
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binding model, this condition depends only on the cooperativity factor, where we find
that the extra inflections appear when cooperativity is particularly low. Also in Chapter
2, explore time course binding. For the single ligand homodimer binding model we give
analytical solutions to the ODE system. These are of practical use to pharmacologists
due to the ease at which they can be implemented and interpreted.
In Chapter 3, we see how extending the GPCR dimer model to include receptor acti-
vation leads to a wide range of equilibrium signal logDR curves (we note that, unlike the
other chapters, we only look at equilibrium results). There are four cooperativity factors
to explore. The parameter α represents ligand binding cooperativity, and is defined the
same as in Chapter 2. We also have activation cooperativity factor λ, which describes the
effect one protomer being active has on the activation of the other protomer. Finally, ν
and ξ are efficacy parameters and represent the change in propensity for activation when
ligand bound and the change in affinity for active protomers over inactive protomers.
Specifically, ν accounts for when binding and activation occur on the same protomer,
while ξ accounts for when these occur on opposite protomers. A neutral curve (where
all cooperativity factors are equal to one) shows a small peak in an otherwise constant
signal. Varying each cooperativity factor individually, shows how each alters the curve
from the neutral. Overall, we have three potential effects. Varying α alters the peak
height of the curve. We also see how an increased peak relates to the extra inflections
in the logDR binding curves. Increasing λ causes and upward shift in the whole curve,
although there is little change for lower values of λ. Varying either ν or ξ individually
cause the curves to show agonist or antagonist behaviour. When varying multiple cooper-
ativity factors these effects combine and can result in signal curves that show a biphasic
shape (symmetrical as in Chapter 2 or non-symmetrical) or curves that overshoot the
saturation signal. This work is still ongoing and requires both further exploration into
possible equilibrium effects as well as time course dynamics.
In Chapter 4 we follow the framework that we outlined in Chapter 2, by first analysing
equilibrium logDR curves and then considering time course dynamics, but we instead ap-
ply it to the growth factor, VEGF system (although the model can be applied to most
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growth factor systems). As the growth factor family is known to dimerise in response to
ligand binding, we develop a ligand induced model. This results in a nonlinear system
which is a key difference from all previous models. We again give analytical expressions
for equilibrium concentrations, and use these to explain the shifts in the signal curve,
although an important point to note is that there are no extra inflections in this case.
When investigating the time course dynamics of the system, we notice some interest-
ing behaviours such as peaks in the curves and curves which evolve on multiple time
scales. Using asymptotic analysis we find that, when dissociation cooperativity is low,
that is a slow dimer dissociation, we have peaks in the concentrations of bound monomers.
Conversely, when this is instead high, we have multiple time scales contributing the con-
centrations of bound dimers. If instead, we have either high forward cooperativity or
a high receptor to ligand ratio, we observe multiple time scales in the bound monomer
curves. The model is validated by fitting to published data, where we see an excellent
fit across multiple time courses, when fitting to datasets with five concentrations of three
VEGF isoforms simultaneously.
In Chapter 5 we use structural identifiability analysis to determine whether param-
eters returned from data fitting can be relied upon to be accurate. This is something
that is often overlooked in systems biology. Thus, we present this chapter as a tutorial
for determining identifiability to some classical monomeric binding models, before then
analysing the dimer binding models presented throughout this thesis. When applying
the techniques, we find that, using only a single set of time course data results in a non-
identifiable model, for all models. We are, however, able to find parameter combinations
that can be identified successfully. For linear models, we apply three methods, using
transfer functions, Taylor series and similarity transformations. We find that all meth-
ods give the same results, though there are advantages and disadvantages to each. For
nonlinear problems both the Taylor series method, and similarity transformation meth-
ods are applicable, however, we show how, even for a small problem, the Taylor series
method is problematic. An important point to note on this problem, is that, the model
is only unidentifiable as the measured output is scaled. If this scalar is known then the
model is fully identifiable. We also consider ways in which the models can be made fully
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identifiable. We use equilibrium data or washout experiment data together with the set
of time course data to ensure identifiability, as well as multiple sets of time course data.
6.2 Future work
6.2.1 G proteins
In Chapter 3, we highlighted the importance of looking beyond ligand binding to dimerised
receptors, and considering the signalling implications of including the full G protein cycle.
We took first steps towards this goal by developing a model that included receptor acti-
vation. So far, we looked at the equilibrium effects of binding and activation. However,
we are yet to explore the possible time course dynamics of the system. As time course
data is becoming more readily available, considering these effects is the logical next thing
to examine.
Following this, extending the model to include G protein binding, and eventually
downstream pathways, is necessary and essential to fully understand the signalling im-
plications for drug discovery and development. To achieve this, a second layer would be
added to the current, spherical schematic. The current schematic would sit inside, and
link to, a larger sphere, that contains reactions involving the attachment of G proteins.
This will result in a large model involving many species and reactions, however, would
provide a full insight into the consequences of dimerisation for GPCRs.
6.2.2 Receptor internalisation
Another potential area way in which the models we have developed thus far, would
be to include receptor internalisation (or endocytosis), which plays a key role in cell
signaling. Once a receptor becomes activated, and a signal has been transmitted, the
receptor moves from the plasma membrane towards the endosomal compartment where
they are recycled to the cell membrane or degraded [16, 114]. This process is known as
receptor internalisation. Initially it was thought that the primary implication of receptor
internalisation was signal desensitisation, that is, the decreased responsiveness to a ligand
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[16]. However, while the full implications for internalisation remain unknown, recent
research is showing that an internalised receptor can continue to signal [18, 114] from the
endosome. Furthermore, a signal initiated from the cell surface may produce a different
signal from an intracellular one [17, 18, 16, 114]. The ligand induced model in-particular
would benefit from including receptor internalisation. In the work by Peach et al [101],
it was found that internalisation has an effect on the binding of VEGF on longer time
scales.
6.2.3 Allosteric modulators
While GPCRs are targets for approximately 50% of all current drugs [13], only a small
fraction of these receptors have been exploited [121]. One reason for this seems to be
an issue with traditional agonists and antagonists, that bind to the orthosteric site, pro-
ducing unwanted side effects [98]. The configuration of the orthosteric site is similar for
several receptors, which lowers the specificity of the drug for the required receptor [50].
This means ligands must have a high affinity for the receptor, in order to produce an effect
with minimal side effects. Allosteric ligands bind at a site other than the orthosteric site
and can modulate a receptor’s signalling pathways, and the ligands’ effects [84]. These
ligands work by causing a conformation change in the receptor, and often a change in
the orthosteric site. This in turn may cause an increase in efficacy of the ligand bound
to the orthosteric site, thus reducing the required dose, and in turn, the level of side effects.
A receptor can (and often does) have multiple allosteric sites, hence, in developing new
drugs, it is possible to find a site that it more unique, causing the ligand to act with an
increased specificity, thus making it more safe [50]. Furthermore, many orthosteric drugs
work as antagonists, blocking the natural ligand from binding. Allosteric modulators can
reduce the activity of a ligand without blocking it entirely, and so is less disruptive [98].
Although there is already a rise in drugs targeting the allosteric sites of GPCRs [50],




In this section, we give details of the parameters used for plots in Chapters 2 - 4. There
are three sections that make up Chapter 2 (with a model in each section), and we give the
parameters for each of these sections individually, although we note that some parameters
appear in all of the models. In Table A.1, we have parameters for the single ligand, GPCR
binding model given in Section 2.1, while parameters for the competition binding model
presented in Section 2.2 are given in Table A.2, and the heterodimer binding model, as
given in Section 2.3, are detailed in Table A.3. All parameter values in this chapter are
taken from [83] and [138], and references within.
Parameter Rtot ka+ ka− KA
Value 10−10M 107M−1s−1 0.1s−1 108M−1
Table A.1: Values used for the single ligand, GPCR homodimer binding model, as pre-
sented in Section 2.1.
Parameter Rtot ka+ ka− KA kb+ kb− KB
Value 10−10M 107M−1s−1 0.1s−1 108M−1 106M−1s−1 0.5s−1 107M−1
Table A.2: Values used for the two ligand, GPCR homodimer, competition binding model,
as presented in Section 2.2.
In Table A.4 we have the parameter values used for all plots in Chapter 3, describing
the binding and activation of a single ligand with GPCRs. These values are taken from
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Parameter Rtot ka1+ ka1− KA1 ka2+ ka2− KA2
Value 10−10M 107M−1s−1 0.1s−1 108M−1 106M−1s−1 0.001s−1 106M−1
Table A.3: Values used for the single ligand, GPCR heterodimer binding model, as
presented in Section 2.3.
[137] and [138]. We note that, analysis was undertaken for the model at equilibrium only,
hence we have only equilibrium parameters.
Parameter Rtot KA Kact
Value 10−10M 2.3× 108M−1 10−3
Table A.4: Values used for the single ligand, GPCR homodimer, binding and activation
model, as presented in Chapter 3.
Finally, in Table A.5, we give figures used in the VEGF-VEGFR dimer binding model
presented in Chapter 4. The parameter values in this chapter are taken from [80] (and
references within), though we note that we have taken a slightly higher receptor total
concentration for simplicity and continuity in the analysis. The value taken still falls into
reported ranges.
Parameter Rtot k+ k− KA
Value 2× 10−10M 4.4× 107M−1s−1 1.32× 10−3s−1 3.3× 1010M−1
Table A.5: Values used for the single ligand, VEGFR homodimer binding model, as
presented in Chapter 4.
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Appendix B
Inflections in the GPCR logDR
curves
In Chapter 2 we saw how extra inflections appear in many of the logDR curves. In
this appendix, we investigate these inflections and derive conditions upon when they
appear. We begin by stating a general form, that applies to all models presented, of the
concentration of ligand bound as
Abound =
aX + 2bX2
c+ aX + bX2
Rtot. (B.1)





X(log 10)2(c− bX2)(abX2 + (8bc− a2)X + ac)
(c+ aX + bX2)3
Rtot (B.2)
To find the inflection points, we set this equal to zero and solve for X. Clearly we have
the trivial root at X = 0 as well as a root when
c− bX2 = 0. (B.3)
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We also get extra roots when
abX2 + (8bc− a2)X + ac = 0, (B.5)









(a2 − 16bc)(a2 − 4bc)
2ab
. (B.6)
We see that we get a single, real root when
(a2 − 16bc)(a2 − 4bc) = 0, (B.7)
that is when a2 = 16bc or a2 = 4bc. However we see that, if a2 = 4bc then X = −2c/a,
hence a negative root. Whereas if a2 = 16bc then X = 4c/a, so we have a positive root.
Thus we can conclude that we have a possible inflection at X = 4c/a under the condition
of a2 = 16bc.
Finally we have two real distinct roots when
(a2 − 16bc)(a2 − 4bc) > 0. (B.8)
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As a2 − 16bc < a2 − 4bc then this holds if either a2 > 16bc or a2 < 4bc. To confirm
whether these conditions give positive or negative roots we first note that
(a2 − 8bc)2 − 4a2bc > 0
⇒ (a2 − 8bc)2 > 4a2bc
⇒
√
(a2 − 8bc)2 − 4a2bc < a2 − 8bc. (B.9)
Using this we can state that, if a2 > 16bc then a2− 8bc > 16bc− 8bc = 8bc > 0, hence we
have two positive roots. Conversely, if a2 < 4bc, then a2 − 8bc < 4bc − 8bc = −4bc < 0,
hence both roots are negative. Thus we can conclude that we get two positive roots, and
possible inflection points, under the condition
a2 > 16bc. (B.10)
To confirm that these are in fact inflection points, we first confirm that X− < Xc <
X+. First noting that a
2 − 16bc < a2 − 4bc ⇒ (a2 − 16bc)2 < (a2 − 16bc)(a2 − 4bc) ⇒
a2 − 16bc <
√




(a2 − 16bc)(a2 − 4bc)
2ab
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hence confirming that Xc < X+. We now use the second derivative to confirm there is a
sign change at each of the points. We can see asX → 0+, we have d2Abound/d log10X2 > 0.










thus we can confirm there is an inflection point at X− with the curve changing from
convex to concave. Taking X̂+ = (a








(a2 − 8bc)((a2 − 8bc)2 − 4a2bc)2
32a4b3
> 0, (B.14)
hence there is a sign change at the point Xc with the curve changing from convex to
concave. Finally taking the limit as X → ∞, we see that d2Abound/d log10X2 < 0, thus
we have a third inflection point with the curve changing from convex to concave. So to
conclude, under the conditions 16bc < a2, we have three inflection points.
226
Appendix C
Definitions and theorems for SIA
C.1 The Lie bracket
The controllability matrix, as discussed in Section 5.2.3, is constructed by use of the Lie
bracket. We define this, as in [134]
Definition C.1.1 The Lie bracket is an algebraic operation on two vector fields f(x), g(x) ∈
Rnx that creates a third vector field F(x), which when taken with g as the input control
vector together with u ∈ Rnu defines an embedding in Rnx that maps the input to states.
It is given as






with higher order brackets being calculated recursively as











C.2 The Lie derivative
To construct the observability matrix, as discussed in Section 5.2.3, we use the Lie bracket,
which we define as in [129]:
















To determine identifiability of a linear ODE system, we use the algebraic equivalence
theorem [46, 112], which states that
Theorem C.3.1 (F,G,H) is algebraically equivalent to (F̃ , G̃, H̃) if and only if there
exists a continuously differentiable matrix T : Rnx → Rnx, such that
(i) detT 6= 0, (C.5a)
(ii) T x̃0 = x0, (C.5b)
(iii) T F̃ = FT, (C.5c)
TG̃ = G, (C.5d)
H̃ = HT, (C.5e)
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where F̃ = F (p̃), G̃ = G(p̃) and H̃ = H(p̃).
C.4 Nonlinear equivalence
Identifiability of a nonlinear ODE system is determined via the local state isomorphism
theorem, given as (as in [24, 28, 123]):
Theorem C.4.1 Assume that the model of (5.1) is locally reduced at x(p) for all p ∈ Ω.
Consider the parameter values p, p̃ ∈ Ω, an open neighbourhood V of x0(p̃) in M, and






= nx, ∀x̃ ∈ V, (C.6a)









h(λ(x̃),p) = h(x̃, p̃), (C.6e)
for all x̃ ∈ V . Then the system in (5.1) is globally identifiable at p if and only if (5.22a)-
(5.22e) implies p̃ = p.
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induced coupling versus receptor pre-association: cellular automaton simulations
of fgf-2 binding. Journal of theoretical biology, 227(2):239–251, 2004.
[48] AN Gorban. Detailed balance in micro-and macrokinetics and micro-
distinguishability of macro-processes. Results in Physics, 4:142–147, 2014.
[49] M Grewal and Keith Glover. Identifiability of linear and nonlinear dynamical sys-
tems. IEEE Transactions on automatic control, 21(6):833–837, 1976.
[50] Ashok Kumar Grover. Use of allosteric targets in the discovery of safer drugs.
Medical Principles and Practice, 22(5):418–426, 2013.
[51] Dong Guo, Julia M Hillger, Adriaan P IJzerman, and Laura H Heitman. Drug-
target residence time—a case for g protein-coupled receptors. Medicinal research
reviews, 34(4):856–892, 2014.
[52] Caitlin D Hanlon and Deborah J Andrew. Outside-in signaling–a brief review of
gpcr signaling with a focus on the drosophila gpcr family. Journal of cell science,
128(19):3533–3542, 2015.
[53] Robert Hermann and Arthur Krener. Nonlinear controllability and observability.
IEEE Transactions on automatic control, 22(5):728–740, 1977.
[54] Samuel RJ Hoare, Nicolas Pierre, Arturo Gonzalez Moya, and Brad Larson. Ki-
netic operational models of agonism for g-protein-coupled receptors. Journal of
theoretical biology, 446:168–204, 2018.
235
[55] Stefan Hoops, Sven Sahle, Ralph Gauges, Christine Lee, Jürgen Pahle, Natalia
Simus, Mudita Singhal, Liang Xu, Pedro Mendes, and Ursula Kummer. Copasi—a
complex pathway simulator. Bioinformatics, 22(24):3067–3074, 2006.
[56] Xiang-Qun Hu and Robert W Peoples. The 5-ht3b subunit confers spontaneous
channel opening and altered ligand properties of the 5-ht3 receptor. Journal of
Biological Chemistry, 283(11):6826–6831, 2008.
[57] Edward C Hulme and Mike A Trevethick. Ligand binding assays at equilibrium:
validation and interpretation. British journal of pharmacology, 161(6):1219–1237,
2010.
[58] Wolfram Research, Inc. Mathematica, Version 11.1. Champaign, IL, 2017.
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